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ABSTRACT 
During early stages of infection, HIV-1 and other lentiviruses progress 
through a series of cytoplasmic events that include capsid uncoating, reverse 
transcription and formation of the preintegration complex (PIC). In certain 
primates, the intrinsic immune factor TRIM5cc can bind to lentiviral capsids and 
disrupt this program. Neither TRIM5oc restriction nor early retroviral replication is 
understood in mechanistic detail and both were therefore the targets of 
investigation for research described in this dissertation. 
Chapter 2 describes a system for producing multimilligram quantities of an 
active TRIM5oc variant, termed TRIM5-21R. TRIM5-21R is a chimeric protein 
composed primarily of the TRIM5a from rhesus (rh) monkeys, except for the N-
terminal RING domain, which comes from the human TRIM21 protein. 
Recombinant TRIM5-21R was functional, as judged by its ability to 
autoubiquitylate in reconstituted ubiquitin transfer reactions and to bind 
specifically to HIV and EIAV capsid assemblies. Gel filtration and analytical 
ultracentrifugation experiments demonstrated that TRIM5-21R formed stable 
dimers, and chemical crosslinking experiments showed that TRIM5cc proteins 
expressed in mammalian cells are also predominantly dimeric. We anticipate that 
this system for producing pure recombinant TRIM5-21R will facilitate future 
studies of the biochemistry, mechanism, and structural biology of this important 
class of antiretroviral proteins. 
Research described in the remaining chapters of this thesis characterized 
the requirement for the ESCRT-II complex in HIV budding and endosomal protein 
sorting (Chapter 4), structural and biochemical properties of the ubiquitin-binding 
EAP45 GLUE domain (Chapter 5), the molecular mechanism of (ESCRT-II 
involvement in) Hepcidin-mediated Ferroportin down-regulation (Chapter 6) and 
self-assembly of pure recombinant ESCRT-III proteins into helical tubes (Chapter 
7). 
v 




1. INTRODUCTION 1 
HIV-1 Organization 2 
General Lifecycle Overview 4 
Core Uncoating 7 
Reverse Transcription and Preintegration Complex (PIC) 
Formation 8 
PIC Transport, Nuclear Import and Additional Early Lifecycle 
Events 9 
Summary of Early Events 9 
Host Cell Factors That Restrict Early Stages of HIV-1 
Replication 10 
TRIM5cc 11 
Assays to Examine Early Retroviral Replication and TRIM5a 
Restriction 15 
Research Overview: Retroviral Replication and TRIM5oc 
Restriction 17 
References 19 
2. BIOCHEMICAL CHARACTERIZATION OF A RECOMBINANT TRIM5a 
PROTEIN THAT RESTRICTS HUMAN IMMUNODEFICIENCY VIRUS 
TYPE1 REPLICATION 29 
Abstract 30 
Introduction 30 





3. HUMAN ESCRT-II COMPLEX AND ITS ROLE IN HUMAN 
IMMUNODEFICIENCY VIRUS TYPE 1 RELEASE 43 
Abstract 44 
Introduction 44 





4. STRUCTURAL BASIS FOR UBIQUITIN RECOGNITION BY THE HUMAN 





5. THE MOLECULAR MECHANISM OF HEPCIDIN-MEDIATED 
FERROPORTIN DOWN REGULATION 63 
Abstract 64 
Introduction 64 












7. CONCLUSIONS AND FUTURE DIRECTIONS 85 
TRIM5oc Restriction 85 
Early Events in Lentiviral Replication and the Development of Cell-




I would like to thank several people who helped greatly during this 
process. First, I want to thank my parents and grandparents for their support. I 
would like to thank Wes Sundquist, my advisor, for providing a model of 
excellence both as a scientist and as a human being. I would like to thank Terri 
for her support, love, and adventurous spirit. Finally, I would like to thank the 
members of the Sundquist, Hill, Kay, and Kaplan labs for their collegiality, 
contributions, and discussions that made this work possible. 
CHAPTER 1 
INTRODUCTION 
Retroviruses have played a decisive role in the survival and demise of 
vertebrates throughout their natural history. Human Immunodeficiency Virus-1 
(HIV-1) has been the most destructive of the known human retroviruses and has 
caused more than 25 million deaths and a profound degree of suffering during 
the past 25 years (86). In the most heavily affected countries, HIV-1 has 
reduced life expectancy by more than 20 years, slowed economic growth, and 
deepened household poverty (96). In sub-Saharan Africa alone, the epidemic 
has orphaned nearly 12 million children. According to the United Nations 
Development Programme (UNDP), HIV-1 has inflicted the "single greatest 
reversal in human development" in modern history. 
The magnitude of the global AIDS pandemic provides strong impetus for 
scientific investigation of retroviral pathogenesis and has driven worldwide 
research efforts aimed at understanding the molecular and structural biology of 
HIV-1. The dissertation research described here was undertaken as part of 
these efforts. Specifically, we have examined host/pathogen interactions in both 
early and late stages of HIV-1 replication, with a principal focus on the early 
events in replication and the antiviral intrinsic immunity protein, TRIM5a. 
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HIV-1 Organization 
HIV-1, like all retroviruses, uses the enzyme reverse transcriptase (RT) to 
convert a single stranded RNA genome into double stranded DNA that integrates 
into a host cell chromosome (19). HIV-1 is subclassified in the genus lentiviridae 
due to its: 1) characteristic latent replication profile, 2) complex genome that 
encodes additional accessory proteins not found in all retroviruses, 3) ability to 
infect both dividing and nondividing cells, and 4) distinct conical capsid (18). 
Retroviral genomes contain three basic genes: gag, which encodes structural 
proteins; pol, which encodes viral enzymes necessary for replication; and env, 
which encodes the viral envelope protein (19). 
The mature HIV-1 virion is surrounded by a lipid membrane studded with 
hetero-trimeric gylcoprotein spikes of the envelope (ENV) protein. Each Env 
protein is composed of three copies of the gp120/SU and three copies of 
gp41/TM (Figure 1.1). A layer of MA protein (the "matrix") is located beneath the 
lipid bilayer. Inside the matrix is a conical ribonucleoprotein complex called the 
core. The outer shell of the core is called the capsid, and is comprised of CA 
protein subunits. The capsid encloses two copies of the RNA genome, annealed 
tRNALys3 primers, reverse transcriptase/RNaseH (RT), integrase (IN), 
nucleocapsid (NC), protease (PR), and other accessory proteins (Figure 1.1). All 
retroviral capsids are composed of hexameric arrays of the CA protein, as well as 
12 CA pentamers, which introduce the declination necessary to close the 
hexameric lattice (35). Capsid morphologies vary owing to different distributions 




Figure 1.1. Structural features and protein components of the 
mature HIV-1 virion. An outer lipid envelope contains ENV 
glycoprotein spikes composed of SU and TM subunits. The 
envelope surrounds a matrix shell comprised of MA proteins, which 
in turn encloses the viral core particle. The outer capsid shell of the 
core particle is comprised of hexameric CA protein building blocks 
(yellow, with expanded view showing CA monomers in different 
colors) and is closed by the introduction of 12 pentameric defects. 
The capsid encloses two copies of the RNA genome, annealed 
tRNA primers, reverse transcriptase/RNaseH (RT), integrase (IN), 
nucleocapsid (NC), protease (PR) and other accessory proteins. 
Figure adapted from: (36, 37). 
HIV-1 Capsid 
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cones, rods and rounded particles. The capsids of lentiviruses, like HIV-1 and 
equine infectious anemia virus (EIAV), predominantly form geometric objects 
called fullerene cones, with five CA pentamers at the narrow end of the cone and 
seven CA pentamers at the wide end (Figure 1.1) (12, 35-37, 45, 50). 
General Lifecvcle Overview 
Retroviral replication can be categorized into early and late events (Figure 
1.2). Early events encompass the lifecycle stages that occur prior to transcription 
of viral genes (Figure 1.2). Replication begins when ENV interacts with the CD4 
receptor and either the CXCR4 or the CCR5 co-receptors at the host cell 
membrane (1,21, 53, 76). Receptor binding induces dramatic conformational 
changes in ENV that lead to fusion of viral and host cell membranes, releasing 
the viral core particle into the cytoplasm (27, 28, 81). Within the cytoplasm, 
uncoating of the viral core takes place in a manner that allows for reverse 
transcription of the viral RNA genome to produce a dsDNA product that 
integrates into the host cell genome. The early cytoplasmic replication steps are 
described in greater detail below. 
Late replication events begin with RNA polymerase ll-mediated 
transcription of the integrated provirus. This process is greatly enhanced by the 
HIV-1 transcriptional activating protein, Tat, which interacts with cellular 
transcription factors in a manner that enhances RNA Pol II processivity and 
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Figure 1.2. The HIV-1 lifecycle. Early stages of retroviral 
replication (left half of diagram) include fusion, entry, uncoating, 
reverse transcription, pre integration complex (PIC) formation, 
nuclear entry and integration. The late stages of replication 
(right side of diagram) include transcription, nuclear export, 
translation, assembly, budding and maturation. 
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increases transcript production by several orders of magnitude (41). The viral 
protein Rev mediates export of partially spliced and unspliced viral mRNAs out of 
the nucleus to the cytoplasm where translation of viral proteins takes place (19). 
The Gag polyprotein is translated on free ribosomes and acquires an N-terminal 
myristyl group co-translationally. Transcripts containing the Envgene, in 
contrast, are targeted to Endoplasmic Reticulum (ER)-associated ribosomes for 
translation, glycosylation, and subsequent trafficking to the plasma membrane 
(19,30). 
Following translation, Gag is targeted to the plasma membrane through a 
bipartite signal composed of the myristly group together with PI(4,5)P2 binding 
sites in the MA domain (33). Gag multimerization and assembly are coupled with 
NC-mediated genome encapsidation, and prior to cellular egress immature 
particles bud through limiting membranes of the host cell (11, 32). This process 
depends upon Gag recruitment of the ESCRT-I complex through direct 
interactions with its TSG101 subunit. The ESCRT complexes comprise an 
endogenous cellular pathway that normally functions in both vesicle formation at 
the multivesicular body and in cytokinesis (64,100, 104). HIV-1 usurps much of 
the ESCRT machinery, with the exception of ESCRT-II and some ESCRT-III 
subunits, to catalyze final abscission of the vesicle/budding virion and possibly 
also to deform the host cell's limiting membrane and sort cargo/Gag into forming 
vesicles (87, 97, 102). 
Before the infectious lifecycle is complete, a final maturation step takes 
place during which Gag is cleaved by the viral protease into three structural 
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proteins, MA, CA, and NC, resulting in a dramatic rearrangement of the virion 
(30, 104). In the mature virion, MA forms a matrix shell that is associated with 
the viral envelope, CA condenses to form the conical capsid shell of the core 
particle, and NC along with the genome and accessory proteins is encapsided 
within the core (30). Following maturation, the virion is competent to recognize a 
new host cell and begin subsequent rounds of infection. 
Core Uncoatinq 
In the cytoplasm, the outer capsid shell of the core particle is 
disassembled in a process termed "uncoating" (49, 69). Uncoating appears to be 
an essential process, as CA mutations that either destabilize or hyper-stabilize 
the viral capsid impair reverse transcription, nuclear import and ultimately viral 
replication (25, 31, 108). Lentiviruses are unique amongst retroviruses in their 
ability to infect nondividing cells, and proper uncoating is required to support this 
unique pathogenic characteristic. For example, HIV-1 capsids with core-stability 
altering mutations (that disrupt uncoating) lose their cell-cycle independence. 
Furthermore, HIV-1 particles with chimeric, non lentiviral capsids lose their ability 
to infect nondividing cells (107, 108). The exact location at which uncoating 
takes place within the cytoplasm is controversial, although several reports 
suggest that uncoating occurs en route to the nucleus in concert with reverse 
transcription and preintegration complex (PIC) formation (60, 65). In summary, 
uncoating is a critical, but poorly understood stage in the retroviral lifecycle. 
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Reverse Transcription and Preinteqration 
Complex (PIC) Formation 
Like uncoating, reverse transcription takes place in the cytoplasm and 
ultimately produces a dsDNA copy of the positive sense RNA genome through 
the action of the reverse transcriptase (RT) enzyme (5, 19). RT is located within 
a ribonucleoprotein complex termed the Reverse Transcription Complex (RTC) 
whose major components are genomic RNA and the nucleic acid binding protein, 
NC (29, 112). Reverse transcription requires a specific host cell derived 
tRNALys'3 primer that is annealed to the genome at the primer binding site (PBS) 
to initiate production of a negative sense DNA strand complementary to the 5' 
end of the RNA genome (65). The intrinsic RNAse H activity of RT then degrades 
the RNA component of this early transcript, allowing the newly synthesized 
strand to translocate onto the complementary long terminal repeat (LTR) at the 3' 
end of the genome and serve as a template for synthesis of full length minus 
strand DNA (19, 63). As the minus strand DNA is produced, the RNAse H 
activity of RT degrades most of the template RNA, except for a purine rich 
sequence termed the polypurine tract (PPT), which serves as a primer for 
synthesis of the positive strand DNA genome. Positive strand DNA synthesis 
also requires a second strand transfer event. The fully synthesized DNA genome 
then assembles into the pre integration complex (PIC) (69, 82). 
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PIC Transport. Nuclear Import and Additional 
Early Lifecycle Events 
PICs are large nucleoprotein complexes composed of reverse transcribed 
dsDNA, integrase (IN) and additional viral and host cell proteins including NC 
and Vpr (3, 16, 25). To access the nucleus, mature PICs navigate the 
cytoplasm via interactions with both microtubules and the actin cytoskeleton (3, 
66). Karyophilic signals within the PIC, in addition to the IN-binding host protein 
LEDGF/p75, help target the PIC to the nucleus (56, 57). PIC nuclear import is 
thought to take place via an ATP-dependent process that involves interactions 
with the nuclear pore complex (15, 34). Following import, IN catalyzes 
integration of the viral genome into host chromosomal DNA to form the provirus 
(10, 13, 14). The late stages of replication can then take place, which include 
transcription, translation, assembly of viral proteins, and budding through the 
host cell lipid membrane (69). 
Summary of Early Events 
The temporal relationship between uncoating, reverse transcription, PIC 
formation and nuclear transport are currently unclear. There are conflicting 
reports as to whether these events occur simultaneously or sequentially, and 
whether capsid structure is retained until nuclear import. Limited evidence 
suggests that reverse transcription may initiate within intact virions (80, 95, 99), 
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although it is more widely accepted that reverse transcription and uncoating are 
interdependent processes, and that expansion of the viral nucleic acid trapped 
within the core during reverse transcription may contribute to uncoating (3, 65, 
69, 83, 112). The events and factors that dictate uncoating and the temporally 
related processes of reverse transcription, PIC formation and nuclear trafficking 
are of considerable interest and also form the focus of some of the research 
described here. 
Host Cell Factors That Restrict Early 
Stages of HIV-1 Replication 
Successful completion of early retroviral replication depends upon host 
cell resources and adherence to the normal program of uncoating, replication, 
translocation, and integration. Thus, these early replication events represent 
exploitable targets for inhibiting viral infections. Indeed, it is now clear that host 
intrinsic immune systems employ a cadre of antiviral proteins, many of which 
specifically target and inhibit early stages of retroviral replication (9, 101). These 
proteins, termed restriction factors, presumably evolved owing to the strong 
evolutionary advantage conferred by an enhanced ability to resist retroviral 
invasion (9). 
Pioneering work on retroviral restriction utilized mouse genetics to identify 
the Fv1 gene as a locus that conferred resistance to the Friend Murine Leukemia 
Virus (MLV) (8, 54, 78, 79, 101). Two major Fv1 alleles were identified in 
laboratory mouse strains: Fv1b\n Balb/c mice and Fv1n in NIH Swiss mice. 
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These two alleles were found to confer resistance to N-tropic and B-tropic MLVs, 
respectively. Fv1 restriction occurs early in retroviral infection, prior to nuclear 
entry (46, 110). The viral capsid is the major determinant of Fv1 antiviral activity, 
and a single point mutation at CA residue 110 can switch allelic restriction 
susceptibility (46, 110). Furthermore, viruses deficient in replication, but with 
FW-sensitive capsids, can saturate Fv1 activity (a phenomenon termed 
abrogation), suggesting that Fv1 binds incoming capsids (6, 26). 
Cell lines from several primate species were subsequently found to 
possess retroviral restriction activities similar to those of Fv1. For example, 
human cell lines can restrict N-MLV infection and cells from other primates can 
restrict HIV-1 replication (39, 40, 88, 93). As with Fv1, restriction activity in 
primate cell lines is saturable, occurs prior to nuclear entry, and is dependent on 
the viral capsid (20, 38, 72). However, unlike Fv1 restriction, primate cell 
restriction typically blocks the accumulation of reverse transcripts (rather than 
blocking nuclear import). 
TRIM5a 
In 2004, Stremlau and colleagues identified TRIM5a as the key cellular 
factor responsible for HIV-1 restriction in rhesus macaque cells (90, 91). 
Subsequent work revealed that the orthologous human TRIM5a protein restricted 
N-tropic MLV replication and that a unique TRIM5-cyclophilin-A chimera was 
responsible for resistance to HIV-1 infection in owl monkeys (7, 75). It has since 
become apparent that TRIM5a is a principal determinant of retroviral species 
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tropism and that TRIM5a specificity can be attributed to sequence variations that 
result in differential abilities of TRIM5a homologs to recognize retroviral capsids 
(9, 68, 90, 94). Under normal restrictive conditions, TRIM5a blocks the 
accumulation of retroviral reverse transcripts, and accelerates the rate at which 
viral capsids dissociate from high molecular weight complexes into lower 
molecular weight subunits (Figure 1.3) (74, 90, 91). 
Like other tripartite motif (TRIM) family members, TRIM5a contains RING, 
B-box, coiled-coil, and B30.2/SPRY domains, each of which contributes to 
restriction activity (70). The RING domain of TRIM5a has intrinsic E3 ubiquitin 
ligase activity, which is important both for autoubiquitylation and for TRIM5a 
turnover in vivo (24, 43, 106, 109). The E3 ubiquitin ligase activity partially 
contributes to restriction (43, 73, 90), but the precise function of ubiquitylation is 
not yet fully understood. 
Proteasome activity is not strictly required forTRIM5a antiviral activity per 
se (24, 73), but proteasome inhibitors can alter the normal progression of 
TRIM5a restriction by allowing reverse transcripts to accumulate and by 
impairing accelerated dissociation of intact viral capsids (2, 22, 105). 
Furthermore, proteasome-dependent degradation of TRIM5a accompanies 
restriction of incoming capsids, which again supports the idea that the 
proteasome contributes to the mechanism of restriction. 
B-Box-2 domains are zinc coordinating motifs that are structurally related 
to RING domains and are unique to tripartite motif family proteins (51, 59, 61). 
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Figure 1.3. Possible mechanisms of TRIM5a restriction. Current 
models hold that TRIM5a restriction probably involves an initial 
capsid binding event that results in TRIM5a autoubiquitylation 
and subsequent proteasomal degradation, accelerated 
dissociation of the capsid into smaller subunits, and a block in 
reverse transcript production. In the presence of proteasome 
inhibitors, however, reverse transcripts are produced, the capsid 
does not prematurely dissociate, and restriction takes place at a 
later stage, prior to nuclear entry. 
TRIM proteins may be equipped with B-box-1, B-box-2 (two distict B-box 
variants) or tandem B-box domains. Assigned B-box functions include protein 
oligomerization, higher-order assembly, intracellular localization and protein-
protein interactions (61). The B-box-2 domain of TRIM5a plays an essential but 
still not well understood role in restriction activity, as mutations in this domain can 
abolish restriction, influence protein turnover, and affect subcellular localization 
(23). A recent report suggests that the B-box-2 domain contributes to the higher-
14 
order assembly of TRIM5 proteins, presumably on retroviral capsid templates, 
and that TRIM5a assembly is important for inducing premature capsid 
dissociation and inhibiting reverse transcript accumulation (51). 
The coiled-coil (CC) and adjacent linker 2 (L2) regions of TRIM5a 
contribute to protein oligomerization and are important for efficient capsid binding 
and restriction (44, 62). Early studies that examined the SDS-PAGE mobilities of 
crosslinked TRIM5a proteins suggested a trimeric oligomeric state (62). 
However, my subsequent studies of pure recombinant TRIM5 proteins using 
more rigorous biophysical techniques demonstrated that TRIM5a (and likely 
other TRIM proteins) are actually dimeric, but exhibit aberrant SDS-PAGE 
mobilities when crosslinked (Chapter 2) (47, 48). 
The C-terminal B30.2/SPRY domain of TRIM5a is essential for viral capsid 
recognition. This domain is predicted to share structural homology with 
immunoglobulin domains, and is the key determinant of antiviral specificity (42, 
70, 71, 73, 89-91, 103, 111). Several studies indicate that TRIM5a proteins 
recognize the hexameric lattice of the viral capsid rather than individual CA 
subunits (12, 35-37, 45, 50, 51). Several motifs within the SPRY domain exhibit 
evidence of strong positive selection and display pronounced variability between 
species, suggesting that they are key determinants of retroviral capsid 
recognition (55, 71, 84, 85, 89, 92). In particular, variable region 1 (V1: residues 
323-350 in rhesus TRIM5a) is critical both for efficient restriction and for capsid 
binding, and a single amino acid alteration at position 332 of the V1 loop allows 
human TRIM5a to bind HIV-1 capsids and inhibit HIV-1 replication (52, 89, 111). 
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Assays to Examine Early Retroviral 
Replication and TRIM5a Restriction 
The observations that TRIM5a binds the viral capsid and accelerates 
capsid dissociation suggest that uncoating is the stage of the viral lifecycle that is 
most likely disrupted during restriction. However, despite extensive work 
conducted since the discovery of TRIM5a, the mechanism by which initial capsid 
binding events ultimately inhibit reverse transcription is still not fully understood. 
The technical challenges involved in studying early stages of retroviral 
replication and TRIM5a restriction present a significant barrier to obtaining a 
comprehensive mechanistic understanding of these processes. One such 
challenge arises because, even at high multiplicities of infection (MOI), very few 
cores enter the host cell cytoplasm, and even fewer go on to complete successful 
replication (58). Moreover, most of the retroviral particles in a typical innoculum 
are noninfectious, and these particles can contribute substantial background in 
any bulk measurement of viral replication. Indeed, it has been estimated that 
only between 1 in 10 and 1 in 60,000 HIV-1 particles are capable of infection 
(69, 77). Finally, there are limitations in the available assays for probing the 
different stages early retroviral replication. For example, recently developed 
fluorescence live-cell microscopy assays represent a significant step forward, but 
are still in early stages of development and are limited by the availability of 
relevant fluorescent probes (17, 108). 
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Cell-free assays represent an alternative approach for dissecting the early 
events of retroviral replication and TRIM5a restriction, and have the potential to 
overcome some of the limitations of cell-based assays. The first such in vitro 
system was developed for the avian sarcoma and leukocytosis virus subgroup-A 
(ASLV-A) and was based on arresting pH-dependent virion fusion intermediates 
within endosomes, purifying the endosomes, adding them to cell-free extracts, 
and then restarting virion fusion by lowering the pH (67). This work 
demonstrated a requirement for cellular factors and ATP hydrolysis in retroviral 
DNA synthesis (67). A subsequent study utilized an alternative approach to 
demonstrate that soluble cell extracts from activated, but not quiescent CD4+ 
lymphocytes could induce the dissociation of membrane-stripped HIV-1 capsids 
and stimulate the formation of reverse-transcription products (4). More recently, 
an in vitro system used detergent-permeabilized HIV-1 virions to demonstrate 
that soluble factors present in extracts from a variety of human cell types 
modestly enhance the production of complete double-stranded DNA transcripts 
(98). Together, the above reports indicate that cell extracts can influence reverse 
transcript production and demonstrate the potential utility of in vitro assays for 
studying early lifecycle events and TRIM5a retroviral restriction. However, all of 
these assays utilized crude viral inputs and none has gained widespread usage. 
In Chapter 3, I describe the development of a novel in vitro assay 
designed to examine the early events of lentiviral replication and TRIM5a 
restriction. In this system, purified EIAV core particles are incubated with cell 
extracts, dNTPs, and an ATP regeneration system. Reverse transcript 
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production is then quantified by real-time PCR, while capsid 
uncoating/dissociation is monitored using ultracentrifugation to separate 
dissociated CA monomers from intact capsids. We have used this system to 
show that purified EIAV cores undergo ATP and extract-dependent reverse 
transcription and uncoating. In addition, we have extended our assay to examine 
TRIM5a restriction and demonstrate that in extracts, both cell-expressed and 
recombinant TRIM5a molecules are necessary and sufficient to recapitulate 
restriction in vitro. 
Research Overview: Retroviral Replication 
and TRIM5a Restriction 
TRIM5a restriction and early retroviral replication are essential 
components of HIV-1 pathogenesis and innate immune retroviral defense. 
Characterization of these processes offers the potential to both elucidate the 
mechanistic details of these fundamental events and benefit human health. 
The research described in this dissertation addresses both early and late 
stages of retroviral replication, but with a principal focus on TRIM5a restriction 
and other early events in HIV-1 replication. Chapter 2 reports the development 
of systems to express, purify and characterize recombinant TRIM5 proteins. 
Chapter 3 describes my work examining the role of the ESCRT-II complex in viral 
release and MVB vesicle formation. Chapter 4 describes a study in which I 
collaborated to examine the structure and function of a novel ubiquitin binding 
domain present in the ESCRT-II protein, EAP45. Chapter 5 describes a study in 
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which I collaborated to examine the role of the ESCRT machinery in the down 
regulation of the iron export protein, Ferroportin. Chapter 6 reports the structural 
basis for ESCRT-III protein autoinihibition, a study for which I performed electron 
microscopy-based analyses. Finally, Chapter 7 summarizes my research, 
discusses its relevance to the understanding retroviral replication, and reflects on 
future directions in the field. 
19 
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The rhesus monkey intrinsic immunity factor TRIM5arh recognizes incoming capsids from a variety of 
retroviruses, including human immunodeficiency virus type 1 (IirV-1) and equine infectious anemia virus 
(EIAV), and inhibits the accumulation of viral reverse transcripts. However, direct interactions between 
restricting TRIM5a proteins and retroviral capsids have not previously been demonstrated using pure recom-
binant proteins. To facilitate structural and mechanistic studies of retroviral restriction, we have developed 
methods for expressing and purifying an active chimeric TRIM5arh protein containing the RING domain from 
the related human TRIM21 protein. This recombinant TRIM5-21R protein was expressed in SF-21 insect cells 
and purified through three chromatographic steps. Two distinct TK1M5-21R species were purified and shown 
to correspond to monomers and dinters, as analyzed by analytical ultracentrifugation. Chemically cross-linked 
recombinant TRIM5-21R dimers and mammalian-expressed TRIM5-21R and TRIMSa proteins exhibited 
similar sodium dodecyl sulfate-polyacrylamide gel electrophoresis mobilities, indicating that mammalian 
TRIMSa proteins are predominantly dimeric. Purified TRIM5-21R had ubiquitin ligase activity and could 
autoubquitylate with different E2 ubiquitin conjugating enzymes in vitro. TRIM5-21R bound directly to 
synthetic capsids composed of recombinant HIV-1CA-NC proteins and to authentic EIAV core particles. HIV-1 
CA-NC assemblies bound dimeric TRIM5-21R better than either monomelic TRIM5-21R or TRIM5-21R 
constructs that lacked the SPRY domain or its VI loop. Thus, our studies indicate that TRIMSa proteins are 
dimeric ubiquitin E3 ligases that recognize retroviral capsids through direct interactions mediated by the 
SPRY domain and demonstrate that these activities can be recapitulated in vitro using pure recombinant 
proteins. 
Susceptibility to retroviral infections influences species sur-
vival and has driven the evolution of cellular restriction factors 
that inhibit retroviral replication. One important antiretroviral 
intrinsic immune response is mediated by TRIMSa, which can 
block early postentry steps in the replication of certain retro-
viruses in specific primate lineages (3, 37, 55, 58). Under nor-
mal restrictive conditions, TRIM5a proteins block accumula-
tion of retroviral reverse transcripts (55) and accelerate the 
rate at which viral capsids dissociate from high-molecular-
weight complexes into lower-molecular-weight subunits (42, 
56). The allelic specificity of TRIM5a restriction is illustrated 
by the fact that rhesus macaque TRIM5a potently inhibits 
human immunodeficiency virus type 1 (HIV-1) replication, 
whereas human TRIM5a instead exhibits restriction activity 
against N-tropic murine leukemia virus but not HIV-1 (23, 29, 
43, 55, 67). These differences can be attributed to the differ-
* Corresponding author. Mailing address: Department of Biochem-
istry, University of Utah, Salt Lake City, UT 84112-5650. Phone: (801) 
585-5402. Fax: (801) 581-7959. E-mail: wes@biochem.utah.edu. 
I Supplemental material for this article may be found at http://jvi 
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ential abilities of TRIM5ot proteins to interact with retroviral 
capsids after viral entry (34,42, 56). 
Like other tripartite (TRIM) family members, TRIM5a con-
tains RING, B-box, coiled-coil, and B30.2/SPRY domains, and 
each of these domains contributes to restriction activity. The 
RING domain of TRIM5a has intrinsic E3 ubiquitin ligase 
activity (63,64), which is important both for autoubiquitylation 
and for protein turnover in vivo (12, 26). The E3 ubiquitin 
ligase activity also contributes to restriction but is not abso-
lutely required (26, 41, 55), and the precise functions of ubiq-
uitylalion and the role of the ubiquitin/proteasome system in 
retroviral restriction are not yet fully understood. Specifically, 
proteasome activity is not required for TRIM5a antiviral ac-
tivity per se (12, 41), but proteasome inhibitors do alter the 
normal progression of TRIM5ot restriction, allowing reverse 
transcripts to accumulate and impairing the ability of TRIMSa 
to accelerate the dissociation of intact viral capsids (2,10,62). 
Moreover, the restriction of incoming capsids results in pro-
teasome-dependent degradation of TRIM5a (47), again sug-
gesting possible involvement of the proteasome in the normal 
stepwise progression of restriction. 
The B-box domain of TRIM5a plays an essential, but still 
11682 
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undefined role in restriction activity, and mutations in this 
domain can influence protein turnover, intracellular localiza-
tion, and restriction activity (11). The coiled-coil and ensuing 
linker 2 (L2) regions of TRIMSct also contribute to efficient 
capsid binding and restriction, and these elements appear to 
function primarily in protein oligomerization (27, 36). Cross-
linking studies have suggested that TRIM5a may function as a 
trimer, but trimerization has not been rigorously demonstrated 
by biophysical studies of pure TRIM5 proteins (36). Finally, 
the C-terminal B30.2/SPRY domain of TRIM5a is essential 
for viral capsid recognition and is the key determinant of an-
tiviral specificity (38,41, 54-56, 68). Several motifs within the 
SPRY domain have been subject to significant positive selec-
tion and exhibit pronounced variability between species (35, 
38,49,50,54,57). In particular, variable region 1 (VI, residues 
323 to 350 in rhesus TRIM5ot) is critical both for efficient 
restriction and for capsid binding, and a single amino acid 
alteration at position 332 of the VI loop allows human 
TRIMSa to bind HIV-1 capsids and inhibit HIV-1 replication 
(34,54,68). These and other observations show that the SPRY 
domain dictates retroviral capsid recognition, although direct 
binding interactions have not yet been demonstrated and char-
acterized using pure TRIM5ot proteins. 
TRIM5a proteins appear to recognize the outer shell of the 
retroviral core particle, which is called the capsid. Lentiviruses 
such as HIV-1 and equine infectious anemia virus (EIAV) 
have conical capsids composed of CA protein hexamers that 
form hexagonal assemblies called fullerene cones (4,19-21,28, 
32). Intact retroviral core particles can be isolated from mem-
brane-stripped retroviruses and purified by using sucrose-gra-
dient centrifugation, but these assemblies are rather unstable 
and typically disassemble spontaneously in buffer (1,17,30,46, 
60). Structural and biochemical studies of the HIV-1 capsid 
have therefore frequently used synthetic assemblies created 
from pure recombinant CA proteins (20). The assemblies 
formed by pure HIV-1 CA-NC proteins on DNA templates are 
particularly stable and can be formed under near physiological 
conditions (7, 21). These CA-NC/DNA assemblies are a mix-
ture of cylindrical and conical structures that recapitulate the 
hexagonal lattice of CA hexamers found in authentic viral 
capsids (4,21,32). Synthetic HIV-1 CA-NC/DNA assemblies, 
like membrane-stripped viral capsids, also bind exogenously 
expressed TRIM5a proteins present in crude cell lysates (51, 
56), indicating that the CA-NC/DNA assemblies recapitulate 
the key elements required for TRIM5ot recognition. 
In summary, it is now well established that capsid recogni-
tion dictates the allelic specificity of TRIM5ot restriction. How-
ever, direct interactions between pure TRIM5 proteins and 
retroviral capsids have not yet been demonstrated in vitro, 
largely owing to the technical challenges of creating suitable 
capsid targets and of expressing and purifying recombinant 
TRIM5a proteins. To date, soluble full-length TRIM5a pro-
teins have not been expressed successfully in Escherichia coli, 
and TRIM5a proteins tend to turnover rapidly and aggregate 
into cytoplasmic bodies when overexpressed in mammalian 
systems (6, 12, 53). However, replacing the TRIM5a RING 
domain with the RING domain from the homologous TRIM21 
protein reduces protein turnover without compromising HIV-1 
restriction substantially (12, 33). We have taken advantage of 
this observation to develop systems for expressing and purify-
ing chimeric TRIM5-21R proteins in quantities suitable for 
biochemical and biophysical characterization. 
MATERIALS AND METHODS 
Cell cultures. Human 293T and HeLa cells were maintained in Pulbecco 
modified Eagle medium supplemented with 10% fetal calf semm. HeLa cells 
stably expressing rhesus TRIM5a (TRJM5atb) (55) were maintained with an 
additional supplement of 1 u.g of puromycin/ml. 
Expression vectors. The pLPCX TRIM5-21R expression vector, encoding a 
hemagglutinin (HA)-lagged TR1M5-21R (12), was used as a PCR template to 
create a DNA fragment containing the TRIM5-21R gene with Kpnl and Xhol 
restriction sites. This fragment was ligated into the pCAG.OSFT (WISP-08-189) 
backbone, which itself was modified from the pCAG vector backbone (Addgene) 
to encode an N-terminal OneStrcp and Rag (OSF) epitope tag followed by a 
TEV protease cleavage site. The resulting vector, pCAG.OSFT-TRIM5-21R 
(W1SP-08-176), was used as a PCR template to amplify a DNA fragment with 
terminal attB sites to allow for recombination into tbe pDONR221 Gateway 
Entry Vector (Invilrogen) to create the pDONR221.0SFT-TRIM5-21R Entry 
Vector (WISP-08-177). This vector was used as a template for QuikChange 
site-directed mutagenesis (Stratagene) to create pD0NR221.OSFT-TRIM5-
21RAV1 (WISP-08-178) (deletion in the VI variable loop of the SPRY domain 
corresponding to TRIM5atb residues 332 to 344) and pDONR221.0SFT-
TRIM5-21R4SPRY (WISP-08-I79) (deletion of the entire SPRY domain and 
L2 element, TRIM5o,h residues 233 to 497). The pCAG.OSFT-TRIMSa,,, and 
pDONR221.0SFT-TRIM5,„ vectors (WISP-08-197 and -08-198) were con-
structed in an analogous fashion. Recombinant baculoviruses expressing TRIM5-
21R, TRIM5-21RAV1, and TRIM5-21RASPRY were prepared in situ by using 
the BaculoDirect system (Invilrogen). Equivalent mammalian cell expression 
constructs were generated in the Gateway pcDNA-DEST40 vector (WISP-08-
180, -181, -182, and -199, respectively). pET28-based plasmids for bacterial 
expression of UbcHS (WISP-08-190), UbcH6 (WISP-08-191), UbcH7 (WISP08-
192), and Ubal (VVISP-08-192) were generous gifts from Rachel Klevit (Univer-
sity of Washington) (5, 8), and the Ubal gene was originally a gift from Richard 
Vicrstra (University of Wisconsin) (22). 
Expression and purification of recombinant proteins, (i) TRIM5-21R. Two 
liters of SF-21 insect cells were grown to a density of 2 x 106 cells/ml in SF-900 
II media (Invilrogen), infected at a multiplicity of infection of 1.0 with recom-
binant baculoviruses encoding TRIM5-21R and variants, and the expressed pro-
teins were allowed to accumulate for 36 to 44 h (100 rpm shaking, 27°C). All 
subsequent steps were carried out at 4°C, except where noted. Cells were col-
lected by centrifugation at 500 x g for 8 min, resuspended in 1:25 (vol/vol) of lysis 
buffer (50 mM NaCl, 50 mM Tris [pH 8.0], 1.5% Triton X-100,1 mM TCEP, and 
mammalian protease inhibitor cocktail [Sigma] at 1:150 [vol/vol]), and lysed in a 
lOu-ml Dounce homogenizer (15 strokes). The iysate was clarified by ultracen-
trifugation (Beckman Ti 50.2 rotor, 45,000 rpm, 184,000 x g, 40 min), filtered 
(0.45 um), and loaded at 2 ml/min onto a 10-ml StrepTactin Superflow affinity 
column (1BA). The bound protein was washed with 50 ml of buffer (50 mM NaCl, 
50 mM Tris [pH 8.0], 1 mM TCEP) and eluted with wash buffer supplemented 
with 25 mM D-desthiobiotin. The eluate was loaded directly onto two 5-ml 
HiTrap O-Sepharose anion-exchange columns connected in series (GE Health-
care) and eluted with a NaCl gradient from 50 mM to 1 M over 200 in! of buffer 
(50 mM Tris [pH 8.0], 1 mM TCEP). Purified TRIM5-21R eluted in two peaks 
(see Fig. IB). Fractions containing the early eluting peak were pooled, concen-
trated to 2 ml (Vivaspin concentrator, Sartorius), and loaded onto a 120-ml 
Superose-6 gel filtration column. The later eluting protein fraction peak tended 
to aggregate under high-ionic-strcngth conditions and was therefore loaded 
directly ooto a Superose-6 column without concentration (4-ml fractions). Gel 
filtration chromatography was performed at 1 inl/min in 25 mM NaCl, 50 mM 
Tris (pH 8.0), 1 mM TCEP. The gel filtration column was calibrated by using the 
HMW standard gel filtration calibration kit (GE Healthcare), and the two 
TR1M5-21R species eluted with apparent molecular masses of 232 kDa (dimer, 
second anion exchange peak) and 70 kDa (monomer, first anion exchange peak). 
The purified monomer could be concentrated to 10 mgAnL whereas the dimer 
tended to precipitate at concentrations above 3 mg/ml. Concentrated proteins 
were stored at 4°C for short-term use but tended to precipitate when stored for 
multiple days. Alternatively, proteins were flash frozen in liquid nitrogen and 
retained CA-NC binding and autoubiquitylation activities when thawed. 
(11) Ublqultin-related proteins. Recombinant El and E2 proteins were ex-
pressed in BL21-Codon Plus (DE3)-RIPL bacteria (Stratagene) grown in LB 
media and purified as described previously (8). Briefly, human UbciISc, UbcH6, 
and UbcH7 were purified by cation-exchange chromatography (SP Sepharose) 
and eluted with a 0 to 0.5 M NaCl gradient in 30 mM MES (morpholineethane-
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TABLE 1. Posttranslational moderations of TRIM5-21R and 
TRIM5arh proteins 
No. of _ MASCOT score 
Cell type Protein peptides
 r *_„ (total protein 
identified" C o v e r a S e score) 
SF-21 TRIM5-21R IV 54 7365 
Ubiquitin 7t 79 138 
293T TRIM5oth-HA 42* 47 2162 
Ubiquitin 2 23 63 
" *,Two nested TRIM5-21R phosphopeptides were identified: 8ILREVKI.SP 
EEGQK" and "'EVKLSPEEGOK". t, One ubiquitvlaled ubiquitin peptide 
was identified: "UFAGKQLEDGR5'1. 
sulfonic acid)-l oiM EDTA (pH 6.0). E2-rieh fractions were pooled and purified 
further by size exclusion chromatography in 25 mM sodium phosphate (pH 
7.0J-150 mM NaCl. Wheat Hi^-Ubal (El) was purified by Ni2+-affinity chro-
matography, followed by size exclusion chromatography. Ubiquitin was purified 
as described previously (44). 
Mass spectrometry. Monomeric and dimeric TRIM5-21R proteins were de-
salted for electrospray ionization mass spectrometry using a CIS Ziptip (Milli-
pore) and analyzed on a Quattro-H mass spectrometer (Micromass, Inc.). The 
data were acquired with a cone voltage of 50 eV, a spray voltage of 2.8 kV, and 
scanning from 800 to 1,400 mlz in 4 s. Spectra were combined, and the multiply 
charged molecular ions were deconvolved into a molecular-mass spectrum by 
using MuxEnt software (Micromass, Inc.). 
Liquid chromatography tandem mass spectrometry experiments were used to 
examine posttranslational modiiications of both TRIM5atb expressed in 293T 
cells and TRIM5-21R expressed in SF-21 cells. TRIM5aA contained a C-termi-
nal HA tag (55) and was affinity purified from 293T cells by using a-HA-
conjugated Sepharose matrices as described below for cross-linking experiments. 
Dimeric TRIM5-21R was purified by anion-exchange chromatography, concen-
trated, and mixed with an equal volume of 2x sodium dodecyl sulfate (SDS) 
loading buffer. In both cases, samples were boiled, separated by SDS-4 to 
20%polyacrylamide gel electrophoresis (PAGE), and visualized using Coomassie 
blue staining. Major bands corresponding to each TRIM5 protein, as well as 
minor bands corresponding to higher-molecular-mass (modified) TRIM5 pro-
teins were excised, digested with TPCK (tolylsulfonyl phcnylalanyl chloromethyl 
ketone )-modificd trypsin (Promega) and introduced by nanoLC (Eksigent, Inc.) 
with nano-eleclrospray ionization (ThermoElectron Corp) into a LTQ-FThybrid 
mass spectrometer (ThermoElectron Corp). Peptide molecular masses were 
measured by Fourier transform ion cyclotron resonance, and peptide sequencing 
was performed by collision-induced dissociation in the linear ion trap of the 
instrument. Protein identification and posttranslational modifications (phosphor-
ylation and ubiquitylation) of peptides in tryptic digests were determined by 
using the MASCOT search engine (Matrix Science) and the NCBInt mammalian 
taxonomy database using a significance threshold of P < 0.05 and an ion score 
cutoff value of 20 (Table 1). 
Equilibrium sedimentation analyses. Equilibrium sedimentation of purified 
TRIM5-21R proteins was performed using Optima XL-I and XL-A centrifuges 
(Beckman) at protein subunit concentrations of 6.09,3.05, and 1.53 u,M (mono-
mer) or 6.0, 3.0, and 1.5 jiM (dimer) in 50 mM Tris-HCI (pH 8.0)-50 mM 
NaCl-1 mM p-mercaptoethanol (monomer) or in 25 mM Nad-50 mMTris-HCl 
(pH 8.0H mM TCEP (dimer). Centrifugation (4°C) was performed at two 
speeds: 14,000 and 18,000 rpm (monomer) and 14,000 and 16,000 rpm (dimer). 
The resulting six data sets for each oligomeric species were globally fit to single 
ideal species models with fixed or floating molecular masses using the nonlinear 
least-squares algorithms in the Heteroana lysis software (9). Solvent density and 
the partial specific volume of TRIM5-21R were calculated by using the program 
SEDNTERP (version 1.09) (31). 
Autoublqultylatlon activity assays. TRIM5-21R-directed ubiquitylation assays 
were carried out in 50-|iI reaction mixtures containing 1.0 p.M TRIM5-21R, 1.0 
u,M concentrations of the specified E2 enzyme, 20 u,M ubiquitin, and 0.5 p.M 
wheat Ubal. Reactions were incubated for 60 min with or without addition of 5 
mM ATP-10 mM MgCt2, and reaction products were analyzed by SDS-7.5% 
PAGE and Western blotting as described below. 
Cross-linking reactions, (i) Cross-finking of recombinant TR1M5-21R pro-
teins. Pure recombinant TRIM5-21R proteins were dialyzed overnight into phos-
phate-buffered saline (PBS; 1 mM KH2P04, 5.6 mM Na2HPO,„ 154 mM NaCl) 
plus 1 mM TCEP. Cross-linking reactions were then performed for 10 min at 
25°C in 30-p.l reaction volumes at final protein concentrations of 0.5 \±M, along 
with 0,0.1, OS, or 1 mM fresh EGS [ethylene glycol-bis(succinimidyl succinate)] 
cross-linker. Reactions were quenched by addition of 30 u,l of 0.1 M Tris-HCI 
(pH 7.5), and samples were mixed with SDS loading buffer plus 1.2% p-mer-
captoethanol, and analyzed by SDS-75% PAGE and Western blotting. For 
reactions performed in the presence of mammalian cell lysate, recombinant 
TRIM5-21R proteins in PBS plus 1 mM TCEP buffer were incubated in 30-u.l 
reactions containing final concentrations of 50% clarified lysate prepared from 
293T cells {see below), 0.25 ^M TR1M5-21R, and EGS at 0,0.1, OS, or I mM (20 
min, 25°C). Reactions were quenched by the addition of 30u.lof 0.1 M Tris-HCI 
(pH 75), diluted to 400 u,l with PBS plus 1 mM EDTA, and incubated with 30 
til of StrepTactin Sepharose (IBA) at 4°C for 2 h. The matrix was washed four 
times with PBS plus 0.5% NP-40 and resuspended in 30 u,l of SDS loading buffer 
plus 1.2% p-mercaptocthanol for Western blot analysis. 
(II) Cross-linking of TRIM proteins expressed In mammalian cells. For each 
cross-linking series (four samples), a 10-cm plate of confluent 293T cells express-
ing OSF-tagged TRIM5-21R or HA-tagged TRIM5n,h was rysed in 300 M.1 of 
PBS plus 0.5% NP-40 supplemented 1:150 with protease inhibitor cocktail 
(Sigma) for 15 min on ice. Lysates were clarified by centrifugation at 16,100 x g 
for 30 min, and the resulting supernatant was diluted to a final volume of 1.7 ml 
with PBS plus 1 mM EDTA. Then, 400-u,I aliquots of diluted h/satc were incu-
bated with 0,0.1, OS, or 1.0 mM EGS (20 min at 25°C). Reactions were quenched 
by the addition of 400 y.1 of 0.1 M Tris-HCI (pH 7.5), mixed with 30 p] of 
pre-equilibrated StrepTactin Sepharose (TRIM21-5R; IBA) or «-HA-conju-
gated Sepharose (TRIM5art; Sigma), and incubated for 2 h at 4°C Matrices 
were washed four times with PBS plus 0S% NP-40 and resuspended in 30 u.1 of 
SDS loading buffer plus 1.2% p-mercaploelhanol for Western blot analysis using 
SDS-7.5%- PAGE. 
Western blotting. Proteins were separated by SDS-PAGE, transferred to 
PVDF-FL membranes (Miflipore) in Tris-glycine-10% methanol buffer, blocked 
in 5% milk-Tris-buffered saline (20 min), and incubated with primary antibodies 
diluted in 5% nonfat milk-Tris-buffered saline plus 0.1% Tween 20 (16 h, 4°C). 
Blots were visualized by using an Odyssey infrared imaging system (Li-Cor, Inc.) 
to detect Alexa 680-nm (Molecular Probes; 1:10,000) or IRDye 800-nm (Rock-
land; 1:10,000) secondary antibodies. The primary antibodies and dilutions used 
were as follows: mouse anti-FLAG (Sigma) at 1:3,000 for OSF-TRIM5-21R (Fig. 
1, 3 to5, and 7), mouse anti-HA.ll (Sigma) at 1:1,000 for TRIMSo-HA (Fig. 3), 
rabbit anti-HIV-1 CA (UT415 made against purified NL4-3 CA protein and 
affinity purified) at 1:15,000 (Fig. 5), and rabbit anti-EIAV CA (UT418 made 
against purified EIAV CA protein and affinity-purified) at 15,000 (Fig. 7). 
Restriction assays. (1) HIV-1 restriction assays. The HIV-1 vector pCMVAR8.2, 
which expresses a lacZ reporter, was packaged into vesicular stomatitis virus G-
pseudotyped HIV-1 as described previously (48a, 59a). For restriction assays, 3 x 
104 HeLa-M cells were seeded in 24-well plates and transfected (Ijpofectainine 
2000) 24 h later with 1 u.g of the control pcDNA-DEST40 vector or with vectors 
expressing OSFT-TRIM5a„„ OSFT-TRIM5-21R, OSFT-TRIM5-21R4V1, or 
OSFT-TR1M5-21RASPRY. Cells were incubated for 24 h, washed with media, 
transduced for 24 h with various quantities of the HIV-1 vector, washed again, and 
the percentage of infected cells was determined by assaying for lacZ expression at 
48 h post infection. Equivalent expression levels of the different TRIM5 constructs 
were verified by Western blotting. 
(il) EIAV restriction assay. To assay for restriction, 293T cells were transfected 
in a 10-cm plate with the CeGFPW EIAV vector system as described below, and 
infectivity was subsequently assayed as previously described (48). Briefly, dilu-
tions of vector preparations were added to target cells (HeLa or HeLa-
TRIMSo^h, 2.0 x 105 cclls/weil, six-well plate) and incubated for 72 h at 37°C. 
Transduction efficiencies were determined from the percentage of GFP-positive 
cells measured by fluorescence-activated cell sorting. 
EIAV core Isolation. EIAV cores were prepared by using an adaptation of a 
method described previously (30). Briefly, EIAV virions were produced by co-
transfection of 293T cells (16 x 10-cm plates) with an EIAV vector system. 
Each 10-cm plate of cells was transfected (CalPhos mammalian transfection kit; 
Clontech) with 8.1 ng of pEV53 (EIAV structural proteins), 7.5 jig of 
pSIN6.1CeGFFW (packaged GFP expression vector), and 2.7 u,g of phCMV-
VSV-G (VSV-G envelope) (39, 69). After 36 h, the supernatants were removed, 
pooled (four plates/pool), filtered (0.45-um pore size), and pelleted through a 
4-ml 20% sucrose cushion in a Beckman SW-32Ti rotor (134,000 x g, 2 h, 4°C). 
Each set of pelleted virions was resuspended by gentle pipetting (4 h at 4°C) in 
400 pi of ST buffer (10 mM Tris-HCI [pH 7.4], 50 mM NaCl). Four 11.5-ml 
sucrose gradients (30 and 70% [wt/vol] sucrose in ST buffer) were prepared in 
14-by-89-mm lubes using a gradient mixer (Biocomp). The gradients were over-
laid with a 0.3-ml cushion of 15% sucrose containing 1% Triton X-100 and then 
with a 0.3-ml barrier layer of 7.5% sucrose in ST buffer. Each tube of concen-
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trated EIAV panicles was carefully layered on top of a gradient and centrifuged 
in a Beckman SW-41 rotor (210,000 x g, 16 h, 4°C). Twelve 1-nil fractions were 
collected from the bottom of each tube, and fraction densities were measured by 
using a digital refractometer (Lcica), and EIAV CA was assayed by Western 
blotting. Three 1-ml fractions of the correct density (1.22 to 1.26 g/tnl) contained 
intact EIAV core particles and were pooled, repcllcted by ccntrifugation in a 
Beckman SW-41 rotor (2,000 x g, 2 h, 4°C), and resuspended in 40 (il of ST 
buffer for binding assays. 
Capsld binding assays. Recombinant HIV-1 CA-NC was expressed and puri-
fied as described previously (21). Cylindrical and conical assemblies were created 
by coincubating 10 u.M CA-NC and 2 \iM d(TG)so oligonucleotide (15) in L ml 
of assembly buffer (50 mM Tris-HCl [pH 8.0), 500 mM NaCl) for 16 h at 4°C 
Assembled complexes were enriched by centrifugation at 10,000 rpm in a mi-
crocentrifuge (—9,000 x g) for 5 min, and pelleted assemblies were resuspended 
in 200 pA of supernatant. TRIM5-21R proteins were used at final concentrations 
of 5.0 ixM (for the experiments described in Pig. 5B and 6B comparing different 
TRIM5-21R constructs), 0.5 or 0.15 p,M (0.3x) (for the more stringent binding 
assays described in Fig. 5C), or 0.36 u.M (for the EIAV core binding assays 
described in Fig. 7B). TRIM5-21R proteins were mixed with 20 |j,l of concen-
trated CA-NC particles (see the figure legends for quantities) or with purified 
EIAV cores (-100 ng, -20 nM CA) in reaction volumes of 200 jtl, with a final 
buffer composition of 10 mM Tris, 2 mM KH3P04, II mM Na:HP04, and 280 
mM Nad (Fig. 5B), 308 mM NaQ (Fig. 5C, 1 x), 316 mM NaCJ (Fig. 5C, 0.3x ), 
or 250 mM NaCl (Fig. 7B). Reactions were incubated for 45 min at 25X (CA-NC 
binding assays) or 4"C (EIAV core assays) with gentle mixing at 10-min intervals. 
Prior to centrifugation, a 10-p.l sample was removed and mixed with SDS loading 
buffer (input). Binding reactions were layered onto a 4.2-mI cushion of 70% 
(CA-NC) or 57% (EIAV cores) sucrose (wt/vol; sucrose-PBS plus 1 mM TCEP) 
in 13-by-51-mm tubes and centrifuged in a Beckman SW-50.1 rotor (110,000 x 
gt 1 h, 4°C). Samples of the supernatant remaining above the sucrose cushion 
were saved (supernatant), the sucrose cushions were removed by aspiration, and 
the pellet was resuspended in 40 (xl of lx SDS loading buffer. Input, supernatant, 
and pellet samples were analyzed by Western blotting at concentrations in which 
the supernatant samples corresponded to 1.25% (CA-NC) and 2% (EIAV cores) 
of the total supernatant, and pellet samples corresponded to 80% of the total 
pellet. Under these conditions, —2S% of the input EIAV cores pelleted, and 
-1.6% (5.0 ^M input TRIM5-21R), 1.6% (0.5 uM input TRIM5-21R), and 
2.4% (0.15 jiM input TRIM5-21R) of the CA-NC assemblies pelleted. 
Transmission electron microscopy analyses of TRIM-bound CA-NC tubes. 
For transmission electron microscopy analyses, binding reactions containing 5-ul 
suspensions of CA-NC particles (prepared as described above) were incubated 
with final TRIM5-21R concentrations of 20 to 50 u.M (15-u.l total volumes, 25°C, 
45 min, with gentle mixing every 10 min). Carbon-coated grids were placed on 
aliquots of each reaction mixture (7 (j.1, 90 s), washed with 3 to 4 drops of 0.1 M 
KG, stained with 3 or 4 drops of 4% uranyl acetate, and air dried. Samples were 
imaged on Hitachi 7100 and Philips Tecnai 12 transmission electron microscopes 
at magnifications between x25,000 and X100.000. Each electron microscopic 
analysis was repeated at least three times with proteins from at least three 
separate purifications. 
RESULTS 
TRIM5-21R expression and purification. Wild-type rhesus 
TRIM5ot accumulates at low levels and tends to aggregate 
when overexpressed in mammalian and insect cells (12; data 
not shown). These properties have made it difficult to obtain 
sufficient quantities of pure recombinant TRIM5a proteins 
for biophysical and structural studies. Substitution of the 
TRlM5ari, RING domain with the RING domain of the ho-
mologous human TRIM21 protein (58% identity), however, 
generates a fusion protein (designated TRIM5-21R) that has a 
longer half-life and accumulates to higher levels in mammalian 
cells than does wild-type TRIM5a (12). Importantly, TRIM5-
21R restricts HIV-1 replication, although its activity is slightly 
reduced relative to wild-type TRIM5a (12; see also Fig. SlAin 
the supplemental material). TRIM5-21R was therefore an at-
tractive candidate for large-scale expression in insect cells. 
TRIM5-21R constructs with N-terminal OSF epitope tags 
were expressed in SF-21 cells using baculoviral expression sys-
tems. TRIM5-21R expression was detectable in Western blots 
of soluble lysates of infected SF-21 cells but not in control 
lysates (Fig. 1A, upper panel, compare lanes 1 and 2). The 
soluble TRIM5-21R protein was affinity purified on a Strep-
Tactin matrix, and elution with D-desthiobiotin yielded 
TRIM5-21R as essentially the only protein detectable by either 
Western blotting (upper panel, lane 3) or Coomassie blue 
staining (lower panel). The protein was further purified by 
anion-exchange chromatography, where it separated into two 
distinct species, both of which corresponded to TR1M5-21R 
(Fig. IB, upper panel, and Fig. 1A, lanes 4 and 5). The ratios 
of the two species varied between preparations, but it was 
common for the late-eluting species to predominate, as shown 
in Fig. IB. 
Gel filtration chromatography was used as a final step to 
purify the two distinct TRIM5-21R species. The two species 
again exhibited different chromatographic behavior, eluting 
with apparent molecular weights of 232 kDa (late-eluting an-
ion-exchange peak) and 77 kDa (early-eluting anion-exchange 
peak). The apparent size of the smaller protein suggested that 
it was likely to be a TRIM5-21R monomer, whereas the ap-
parent size of the larger protein suggested that it was probably 
either a trimer or a dimer with an extended Stokes radius. 
Typical yields were 150 u.g (larger species) and 200 u.g (smaller 
species) per liter of infected SF-21 cells. 
The identities of the two purified recombinant TRIM5-21R 
proteins were confirmed by electrospray mass spectrometric 
(ESI/MS) analyses of the intact proteins, and by liquid chro-
matography tandem mass spectrometric analyses of tryptic di-
gests. The mass of the intact smaller species corresponded to a 
TRIM5-21R protein that was missing the N-terminal methio-
nine and was acetylated at the N terminus (MWact„^ = 62,518 
g/mol, M W , l h 4 l B j = 62,520 g/mol), and the mass spectra 
revealed no evidence for posttranslational modifications. In 
contrast, the oligomeric species showed a protein of the same 
mass (MWacma, = 62,517 g/mol), as well as a second protein 
with a mass that corresponded to a singly phosphorylated pro-
tein ( M W „ t - = 62,596 g/mol, MWcaIC = 62,595; -30% of 
protein). Peptide mapping experiments were therefore per-
formed on TRIM5-21R proteins produced in both SF-21 (in-
sect) and 293T (mammalian) cells. These studies identified a 
single phosphoserine residue at position 87 within the LI 
linker between the RING and B-box domains in TRIM5-21R 
proteins isolated from both insect and human cells (Table 1, 
TRIM5ot,b numbering). Given its location, this phosphoryla-
tion site could, in principle, modulate a postulated interaction 
between the RING and adjacent LI elements (24). Ubiquitin-
derived peptides were also detected in trypsin digests of puri-
fied TRIM5-21R expressed in both insect and mammalian 
cells, indicating that the protein was also ubiquitylated at low 
levels. Interestingly, ubiquitin peptides with Lys-48 isopeptide 
linkages were also detected, indicating that TRIM5-21R could 
be poh/ubiquitylated with Lys-48 chains. 
In summary, we have developed methods that can be used to 
express and purify up to milligram quantities of two different 
TRIM5-21R oligomers, and the larger species can be phos-
phorylated and ubiquitylated in human and in insect cells. 
Recombinant TRIM5-21R proteins are monomers and dimers. 
Equilibrium sedimentation centrifugation experiments can 
provide shape-independent measures of protein solution mass, 
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156kOa 44kDa FIG. 1. TRIM5-21R expression and purification. (A) Western blot (upper, anti-FLAG) and Coomassie blue-stained SDS-PAGE gei (lower) 
showing the stepwise purification of recombinant TRIM5-21R proteins. Lane 1, soluble lysate from control SF-21 cells: lane 2, lysate from SF-21 
cells infected with baculovirus expressing TRIM5-21R; lane 3, StrepTactin affinity-purified TRIM5-21R; lanes 4 and 5, monomeric (M, early 
eluting peak) and dimeric (D, late eluting peak) TR1M5-21R proteins purified by anion-exchange chromatography; lanes 6 and 7, monomeric (Mf 
late eluting peak) and dimeric (D, early eluting peak) TR1M5-21R proteins purified by gel filtration chromatography. (B) Anion-exchange (upper) 
and gel filtration (lower) chroraatographs showing the elution profiles of monomeric (M) and dimeric (D) TRIM5-21R proteins. Inset (upper 
panel) shows a Coomassie blue-stained SDS-PAGE analysis of the designated fractions. Elution positions of control molecular mass standards are 
shown below the gel filtration chromatograph for reference, and estimated molecular masses are given above the peaks of monomeric and dimeric 
TRIM5-21R. 
and this approach was therefore used to determine the oligo-
meric state of each TRIM5-21R species. Sedimentation data 
were collected at three different protein concentrations and 
two rotor speeds, yielding a total of six data sets for each 
TRIM5-21R species. These six data sets were globally fit to 
single species models in which the molecular weight was al-
lowed to float and also to monomer, dimer, and trimer models 
with fixed molecular weights. As illustrated in Fig. 2A, the 
distribution of the smaller TRIM5-21R species fit a protein 
with a predicted mass of 59,305 g/mol, which matched the mass 
expected for a TRIM5-21R monomer (62,520 g/mol, M^J 
Mcalc = 0.95). The data for three initial concentrations of 
TRIM5-21R centrifuged at 14,000 rpm are shown together 
with the global fits (Fig. 2A, upper panel), and the small, 
random residuals indicate that the data were satisfactorily fit by 
a simple single species model (lower panels). Global fits to the 
three data sets collected at 18,000 rpm were also satisfactory 
(data not shown). Similarly, when fixed monomer, dimer, or 
trimer molecular weights were used during the global fitting 
procedure, the monomer model was clearly the best fit to the 
data (see Fig. S2A in the supplemental material). 
In contrast, equilibrium distributions of the larger TRIM5-
21R species indicated that this TRIM5-21R protein was a 
dimer. As shown in Fig. 2B, data fit with a floating molecular 
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FIG. 2. Recombinant TRIM5-21R proteins are monomers and dimers. Equilibrium sedimentation distributions of purified monomelic (A) and 
dimeric (B) TRIM5-21R proteins (upper panels), and residual differences between the data and the single species models (lower panels). The data 
are shown for initial subunit protein concentrations of 6.09, 3.05, and 1.53 u.M (monomer), and 6.0, 3.0, and 1.5 u,M (dimer) at rotor speeds of 
14,000 rpm. The data sets were also collected at 18,000 rpm (monomer) and 16,000 (dimer), and all of the data were globally lit to a single species 
model in which the molecular weight was allowed to float during the refinement. The data points are shown in open symbols, and the best-fit curves 
are shown as solid lines. Estimated molecular weights were as follows: TRIM5-21R monomer, 59,305 g/mol (MWmononler = 62,520 g/mol, 
M„h/M^ = 0.95); and TRIM5-21R dimer, 123,825 g/mol (MWdi,„„ = 125,040 g/mol, M J M . „ _ „ = 1.98). 
weight gave an estimated mass of 123,825 g/mol, which 
matched the molecular weight expected for a TRIM5-21R 
dimer (125,040 g/mol, Mobs/Mmo„om<!r = 1.98), and the global 
(its again exhibited small, random residuals (Fig. 213 and data 
not shown). The dimer model was also clearly best when the 
data were globally fit to fixed TRIM5-21R monomer, dimer, or 
trimer models (see Fig. S2B in the supplemental material). We 
therefore conclude that the smaller TRIM5-21R species is a 
monomer and that the larger species is a dimer. 
Recombinant TRIM5-21R dimers and mammalian TRIM5-
21R and TRIM5ct proteins exhibit similar cross-linking pat-
terns. The observation that recombinant TRIM5-21R formed 
monomers and dimers was somewhat surprising because pre-
vious studies had suggested that TRIM5ot proteins might be 
trimers (36). This conclusion was based upon the SDS-PAGE 
electrophoretic mobilities of chemically cross-linked, mamma-
lian-expressed TRIMBa proteins, whose mobilities appeared 
to correspond to trimers (-150 kDa). To reconcile these ob-
servations, we tested whether chemically cross-linked TRIM5 
dimers exhibited anomalously slow SDS-PAGE electro-
phoretic mobilities. Our first set of experiments examined 
the mobilities of pure recombinant monomeric and dimeric 
TRIM5-21R proteins cross-linked with EGS. The monomeric 
protein was used as a control to ensure that protein and cross-
linker concentrations were sufficiently low to prevent nonspe-
cific intermolecular cross-linking of nonassociated proteins. As 
shown in Fig. 3A, TRIM5-21R dimers formed intermolecular 
cross-links efficiently, whereas TRIM5-21R monomers did not. 
The major cross-linked species for the TRIM5-21R dimer mi-
grated at an apparent molecular mass of -160 kDa on a 
SDS-7.5% PAGE gel, and a species migrating at -125 kDa 
was also observed at trace levels. Thus, the major cross-linked 
form of the TRIM5-21R dimer exhibits anomalously slow 
SDS-PAGE mobility. 
In a second set of experiments, we tested whether the oligo-
meric state or cross-linking properties of TRIM5oc proteins 
could be altered by cross-linking in crude lysates, by expression 
in human versus insect cells, or by the non-native N-terminal 
OSF lag or RING domain of the TRIM5-21R construct. As 
shown in the first panel of Fig. 3B, the cross-linking pattern did 
not change significantly when the pure recombinant TRIM5-
21R dimers were cross-linked either in a buffer solution or in 
a soluble mammalian cell extract, indicating that TRIM5-21R 
dimer does not appreciably cross-link with extract proteins 
under these conditions (compare the first panel of Fig. 3B to 
Fig. 3A). A very similar cross-linking pattern was also seen 
when TRIM5-21R proteins were expressed in human 293T 
cells and cross-linked directly in their soluble extracts (com-
pare Fig. 3B, second and third panels), although in this case 
the minor, faster-migrating cross-linked species was more ev-
ident. This experiment indicates that TRIM5-21R forms sim-
ilar dimers when expressed in human or insect cells. Finally, we 
examined the cross-linking of an authentic TRIMSot protein 
expressed in 293T cells. Although the C-terminally HA-tagged 
TRIM5a had a slightly lower molecular weight than TRIM5-
21R, the cross-linking pattern of the authentic TRIM5a-HA 
protein expressed in human 293T cells was again very similar to 
those seen for the various TRIM5-21R proteins. Thus, TRIM5-21R 
and TRIM5a proteins are predominantly dimeric when ex-
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FIG. 3. Recombinant TR1M5-21R dimers and mammalian-expressed TRIM5-21R and TRIM5a proteins exhibit similar cross-linking patterns. 
(A) Western blot (anti-FLAG) showing purified monomelic (M) and dimeric (D) proteins cross-linked with increasing concentrations of EGS 
(lanes 3 to 8) or controls without EGS (lanes 1 and 2). (B) Western blots (anti-FLAG) showing purified recombinant TRIM5-21R dimer added 
to 293T cell lysate and cross-linked in the presence of increasing concentrations of EGS (first panel); TRIM5-21R expressed in 293T cells, 
cross-linked directly in the lysate, and concentrated by StrepTactin affinity purification (second panel); and TRlM5a expressed in 293T cells, 
cross-linked directly in the lysate, and concentrated by a-HA affinity purification (third panel). Lanes 1, 5, and ° show controls in the absence of 
EGS, and the asterisk denotes contaminating immunoglobulin G heavy chain eluted from the HA-Sepharose beads. Note that all of the samples 
were run on the same gel, and migration positions can therefore be compared directly. 
pressed in human or insect cells, but the cross-linked dimers 
exhibit anomalously slow electrophoretic mobilities. 
Autoubiquitylation of recombinant TRIMS-21R proteins. 
TRIM5a exhibits ubiquitin E3 ligase activity (63, 64), and a 
recent study showed that a partially purified, recombinant 
MBP-TRIM5a fusion protein could pair with the UbcH5b E2 
enzyme and exhibit ubiquitin E3 ligase activity in vitro (64). 
We also tested whether our purified TRIM5-21R proteins 
were active for autoubiquitylation in vitro, using three different 
pure E2 enzymes. As shown in Fig. 4, both monomeric and 
dimeric TRIM5-21R proteins paired successfully with UbcH5c 
and UbcH6, but not with UbcH7 in our in vitro autoubiquity-
lation assays. Ubiquitylation was particularly efficient in the 
Monomer Dimer 
E 2 : UbcHS UbcHS UbcH7 UbcH5 UbcH6 UbcH7 
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FIG. 4. TRIM5-21R proteins can be autoubiquityiated in vitro. Pu-
rified monomeric (lanes 1 to 6) and dimeric (lanes 7 to 12) TRIM5-
21R proteins were incubated with the wheat Ubal El enzyme, ubiq-
uitin, and one of three ubiquitin E2-conjugating enzymes—UbcH5c, 
UbcH6, or UbcH7—in the presence or absence of ATP. Reactions 
were terminated after 60 nun, and TRIM5-21R reaction products were 
analyzed by Western blotting (a-FLAG). 
UbcH5 reactions, where most of the TRIM5-21R dimer was 
modified with ubiquitin (compare lanes 8 and 9). Control re-
actions behaved as expected in that ubiquitylated products 
were not observed in the absence of ATP (compare even and 
odd lanes). 
Interestingly, UbcH5 and UbcH6 produced dramatically dif-
ferent product distributions, with UbcH5 catalyzing polyubiq-
uitylation (or possibly multimonoubiquitylation) and UbcH6 
catalyzing only monoubiquitylation of TRIM5-21R. These re-
sults demonstrate that the purified TRIM5-21R protein is an 
active ubiquitin E3 ligase and are in good agreement with the 
report of Yamauchi et al. (64), who found that MBP-TRIM5a 
was active with UbcH5B but not with UbcH7 (UbcH6 was not 
tested). Our results are also consistent with the observations 
that TRIM5a, TRIM21, and TRIM5-21R can self-ubiquitylate 
to form polyubiquitin chains in vivo, which can contain Lys-48 
linkages (64; the present study). Finally, our experiments raise 
the possibility that TRIM5a and TRIM21 may exhibit different 
product distributions when paired with different E2 ubiquitin-
conjugating enzymes in vivo. Such behavior has been seen 
previously for other RING and U-box E3 ligases (e.g., BRCA1 
and CHIP, respectively) (8, 72) but remains to be confirmed 
with in vivo studies of nonchimeric TRIM5oc and TRIM21 
proteins. 
Recombinant TRIM5-21R proteins bind HIV-1 CA-NC as-
semblies. Although numerous studies have established that the 
B30.2/SPRY domains of TRIM5a proteins dictate the speci-
ficity of retroviral capsid recognition (34, 38, 41, 54-56, 68), 
direct binding of TRIM5ot proteins to retroviral CA protein 
assemblies has not yet been demonstrated. We therefore tested 
whether pure recombinant TRIM5-21R proteins could bind 
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the tubular and conical assemblies formed in vitro by pure 
recombinant H1V-1 CA-NC proteins on DNA templates. Pre-
vious studies have shown that these CA-NC/DNA assemblies 
form the same hexagonal surface lattices as authentic HIV-1 
capsids and should therefore present native-like capsid sur-
faces for TRIM5-21R recognition. Our binding studies took 
advantage of the observation that CA-NC/DNA assemblies 
can be separated from free proteins by centrifugation through 
sucrose cushions (56). TRIM5-21R proteins therefore re-
mained in the supernatants above the cushion, unless they 
bound and copelleted with the CA-NC/DNA assemblies. 
Our studies used both monomeric and dimeric wild-type 
TRIM5-21R proteins, as well as two mutant TRIM5-21R pro-
teins used as specificity controls (Fig. 5A). The first specificity 
control (denoted TRIM5-21RAV1) lacked 13 residues from 
the middle of the VI recognition loop of the SPRY domain 
(10). This loop is required for efficient HIV-1 capsid binding 
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and restriction, although the TRIM5-21RAV1 protein does 
.  retain modest residual HIV-1 restriction activity (10; see Fig. 
l S1A in the supplemental material). The recombinant TRIM5-
I 21RAV1 protein behaved like wild-type TRIM5-21R in that it 
I  formed both monomers and dimers, and the purified TRIM5-
21RAV1 dimer was used in our studies. The second specificity 
l control (denoted TRIM5-21RASPRY) lacked the entire 
SPRY domain and the preceding L2 linker. This control was 
c  used because TRLM5 constructs lacking SPRY domains can-
not bind HIV-1 capsid in extracts or restrict HIV-1 replication 
in vivo (56). This construct differed from wild-type TRIM5-
21R in that it was exclusively monomeric (data not shown), and 
.  the purified monomer was therefore used in our studies, 
if As shown in Fig. 5B, CA-NC/DNA proteins formed a mix-
 ture of assembled tubes and cones, which pelleted to the bot-
torn of the sucrose cushion, and disassembled proteins, which 
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FIG. 5. TRIM5-21R binds CA-NC assemblies. (A) Schematic summary (above) and SDS-PAGE/Coomassie blue analyses (below) of purified 
full-length dimeric TRIM5-21R (lane 3, denoted WT), a dimeric TRIM5-21R construct missing part of the VI loop (lane 2, denoted AVI), and 
a monomeric TRIM5-21R construct missing the entire SPRY domain (lane 1, denoted ASPRY). (B) TRIM5-21R protein binding to CA-NC/DNA 
assemblies. Monomeric (M) or dimeric (D) TR1M5-21R (WT, lanes 3 and 4 and lanes 7 and 8), TRIM5-21RAV1 (AVI, lanes 2 and 6), or 
TRIM5-21RASPRY (ASPRY, lanes I and 5) proteins were incubated alone (lanes I to 4) or with CA-NC/DNA assemblies (lanes 5 to 8) and then 
centrifuged through a 70% sucrose cushion to separate CA-NC assemblies and bound proteins (pellet) from unbound and lower-molecular-weight 
proteins (supernatant). Western blots show the distribution of TRIM (a-FLAG, first, third, and fifth panels) and CA-NC (a-CA, second, fourth, 
and sixth panels). Note that CA-NC assemblies bound full-length TRIM5-21R constructs better than either TRIM5-21RAV1 or TRIM5-
21RASPRY. Ratios of bound CA-NC and TRIM5-21R proteins were obtained by combining known input protein concentrations, quantification 
of bound CA-NC levels using a standard curve of known CA-NC protein concentrations, and quantification of Western blot band intensities. 
Estimated bound ratios were as follows: CA-NC/TRIM5-21R dimer •= 1.1, CA-NC/TRIM5-21R monomer = 0.8, and CA-NQTRIM5-21RAV = 
0.18. (C) CA-NC/DNA assemblies bind better to dimeric TRIM5-21R proteins than to monomeric proteins under stringent conditions. Monomeric 
(lanes 2, 4, and 6) or dimeric (lanes 1, 3, and 5) proteins were incubated alone (lanes 1 and 2) or with CA-NC/DNA assemblies (lanes 3 to 6) and 
then centrifuged through a 70% sucrose cushion to separate CA-NC assemblies and bound proteins (pellet) from unbound and lower molecular 
weight proteins (supernatant). Western blots show the distribution of TRIM5-21R (a-FLAG, TRIM panels) and CA-NC (a-CA, CA-NC panels). 
The concentrations of TRIM5-21R proteins in lanes 5 and 6 were 3.33-fold higher than in lanes 3 and 4, and all binding assays were performed 
at lower protein concentrations than those shown in part (B) (see Materials and Methods). Note that under these conditions, CA-NC assemblies 
bound dimeric TRIM5-21R better than monomeric TRIM5-21R. The estimated ratios of bound proteins were as follows: CA-NC/TRIM5-21R 
dimer (0.15 fiM input) = 0.025; CA-NC/TRIM5-21R monomer (0.15 p.M input) = 0.01, CA-NC/TRIM5-21R dimer (0.5 M-M input) = 0.068; and 
CA-NOTRIM5-21R monomer (0.5 JJLM input) = 0.028. 
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TRIM5-21R proteins remained exclusively in the supernatant 
in the absence of CA-NC/DNA assemblies (lanes 1 to 4, com-
pare panels 3 and 5). In the presence of CA-NC/DNA as-
semblies, however, both monomeric and dimeric wild-type 
TRIM5-21R proteins partitioned between the supernatant and 
pellet fractions, indicating that both TRIM5-21R proteins 
could bind CA-NC/DNA assemblies (compare lanes 7 and 8 to 
lanes 3 and 4 in the sixth panel). The TRIM5-21RAV1 protein 
also bound detectably to CA-NC/DNA assemblies (compare 
lane 6 to lane 3), but at much lower levels than either of the 
two wild-type TRIM5-21R proteins (compare lane 6 to lanes 7 
and 8). A deletion in the SPRY domain VI loop therefore 
reduced, but did not entirely eliminate, CA-NC/DNA binding. 
The TRIM5-21RASPRY protein did not bind CA-NC/DNA 
assemblies detectably in this assay, indicating that the SPRY 
domain was required for CA-NC/DNA binding (compare lane 
5 to lanes 7 and 8). These experiments demonstrate that pure 
recombinant TRIM5-21R proteins bind directly to CA-NC/ 
DNA assemblies and show that efficient binding requires the 
SPRY domain and its VI loop. 
Although our binding experiments were not performed un-
der equilibrium conditions, we have nevertheless estimated the 
concentrations and stoichiometrics of the binding reaction 
components in an initial effort to define the parameters that 
govern the TRIM5-CA interaction. CA-NC tubes and cones 
can assemble and disassemble reversibly, and we therefore 
estimated the concentration of CA-NC protein in the pellet-
able assemblies by quantifying Western blot band intensities 
and comparing them to a standard curve of known CA-NC 
concentrations. Analyzed in this fashion, the pelletable CA-NC 
protein in each experiment shown in Fig. 5B corresponded to 
11 pmol (corresponding to an initial concentration of 55 nM). 
The initial concentration of TRIM5-21R subunits in each re-
action mixture was 5 u.M, and the quantity of pelleted TRIM5-
21R dimer corresponded to 12 pmol of protein. Thus, in this 
experiment, the binding reaction was performed with substan-
tial excess of TRIM5-21R dimer over assembled CA-NC pro-
tein (~100-fold), and under these conditions the ratio of 
bound TRIM5-21 to CA-NC was approximately 1:1. The 
TRIM5-21RAV1 protein bound less well in this experiment, at 
a TR1M5-21AV1/CA-NC ratio of 0.18:1. Although these esti-
mated values neglect several potential complications, including 
possible incomplete CA-NC tube pelleting efficiency and dis-
sociation of CA-NC assemblies during the assay, the data nev-
ertheless imply that TRIM5-21R can bind assembled CA-NC 
lattices at nearly stoichiometric levels. 
CA-NC/DNA assemblies bind TRIM5-21R dimcrs more ef-
ficiently than monomers. TRIM5a protein oligomerization has 
been shown to enhance retroviral capsid binding owing to 
avidity effects (27), and it was therefore surprising that CA-
NC/DNA assemblies bound equivalent levels of TRIM5-21R 
monomers and dimers in the previous assay. We therefore 
tested whether more stringent binding conditions might reveal 
differential CA-NC binding of TRIM5-21R monomers and 
dimers. The stringency was increased by reducing the TRIM5-
21R concentration, and under these conditions CA-NC/DNA 
assemblies bound TRIM5-21R dimers better than monomers. 
This effect is illustrated in Fig. 5C, which shows that TRIM5-
21R dimers bound better at two different initial TR1M5-21R 
concentrations (0.5 and 0.15 (iM, compare lanes 3 and 4 to 
lanes 5 and 6 in the bottom panel). Under these more stringent 
conditions, the quantity of pelletable CA-NC protein did not 
change, but the ratios of pelletable CA-NC to bound TRIM5-
21R proteins were substantially lower, demonstrating that the 
binding conditions were indeed more stringent (see the caption 
to Fig. 5C). These data suggest that although TRIM5-21R 
monomers and dimers can both bind CA-NC/DNA assemblies, 
TRIM5-21R dimerization enhances the efficiency of binding 
under more stringent conditions, in agreement with the obser-
vation that disruption of the coiled-coil oligomerization motif 
of TRIM5a inhibits restriction (27). 
Electron microscopic analyses of TRIM5-21R-dccorated 
CA-NC tubes. The effects of TRIM5-21R binding to CA-NC 
tubes were visualized by using transmission electron micros-
copy of negatively stained CA-NC/DNA assemblies incubated 
with a 10- to 50-fold excess of TRIM5-21R prior to imaging. As 
shown in Fig. 6, TRIM5-21R binding did not dramatically alter 
the appearance of CA-NC/DNA tubes, but two effects were 
evident. First, CA-NC/DNA tubes incubated with excess 
TRIM5-21R consistently exhibited increased exterior stain 
deposition compared to tubes incubated with control TRIM5-
21RAV1 or TRIM5-2IRASPRY proteins. The simplest expla-
nation for this effect is that it reflects formation of TRIM5-21R 
coats on the CA-NC/DNA tube exteriors. This effect was 
sometimes subtle and difficult to discern, but in extreme cases 
resulted in a thick, dark irregular coat on tube exteriors, as 
though the TRIM5-21R were aggregating about the tube (Fig. 
6, panel 8). Second, CA-NC/DNA tubes decorated with 
TRIM5-21R frequently appeared more broken and irregular 
than their counterparts incubated with control TRLM5-
21RAV1 or TRIM5-21RASPRY proteins (tube breaks are 
highlighted by arrows in Fig. 6, panels 5 to 8). This observation 
suggests that high levels of TR1M5-21R destabilized the lubes 
and increased their fragmentation, although the effect was 
modest, and most tubes remained intact. Overall, our electron 
microscopic data indicate that TRIM5-21R can coat and de-
stabilize CA-NC/DNA assemblies, but both effects were subtle. 
Higher-resolution cryo-electron microscopic analyses will be 
required to determine the density and location of TRIM5-21 
binding sites on the CA-NC/DNA assemblies. 
EIAV core binding assays. Retroviral cores are the actual 
targets of TRIM5o restriction, and we therefore tested 
whether TRIM5-21R could bind authentic, purified core par-
ticles. Cores isolated from EIAV vectors were used in these 
experiments because TRIM5arh restricts EIAV (10,23,71; see 
Fig. SIB in the supplemental material) and because we are 
able to purify cores from membrane-stripped EIAV virions 
more reproducibly and in higher yields than HIV-1 cores. 
EIAV cores were membrane stripped with a brief Triton X-100 
detergent treatment (30) and then purified on a sucrose gra-
dient where they concentrated at the expected density of —1.24 
g/ml (Fig. 7A). 
Purified EIAV cores were incubated with a — 16-fold excess 
of pure recombinant TRIM5-21R or control AVI or ASPRY 
variants. As in the CA-NC/DNA binding assay, high-molecu-
lar-weight EIAV cores were pelleted by centrifugation through 
a sucrose cushion (Fig. 7B, lanes 4 to 6 in the sixth panel). 
Wild-type dimeric TRIM5-21R protein bound and copelleted 
with the EIAV cores but did not pellet in the absence of cores 
(compare lanes 3 and 6, fifth panel). In contrast, much lower 
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FIG. 6. Electron microscopic images of CA-NC assemblies incubated 
with full-length TR1M5-21R or deletion mutants. Negatively stained, 
transmission electron microscopic images of CA-NC assemblies incu-
bated with monomeric TRIM5-21RASPRY (panels 1 and 2), dimeric 
TRIM5-21RAV1 (panels 3 and 4), or full-length dimeric TRIM5-21R 
(panels 5 to 8). Note that CA-NC/DNA assemblies incubated with 
TRIM5-21R show enhanced exterior staining and more frequent breaks 
(arrows) compared to the TRIM5-21RAV1 or TRIM5-21RASPRY con-
trols. TRIM5-21R-induced breaks were quantified by scoring randomly 
selected electron microscopic images of CA-NC/DNA tubes for the pres-
ence of discontinuities (see arrows), with the following results: TRIM5-
21RASPRY-treated tubes (0% broken, 0 total breaks, n = 26 tubes), 
TRIM5-21RAVl-treated tubes (4% broken, 2 total breaks, n = 50), and 
TRIM5-21R-treated tubes (42% broken, 55 total breaks, n = 50). 
levels of the control TRIM5-21R AVI protein copelleted with 
the EIAV cores (compare lanes 5 and 6), and no detectable 
TRIM5-21R ASPRY protein copelleted with the cores (com-
pare lanes 4 and 6). We therefore conclude that TRIM5-21R 
binds and copellets with authentic EIAV core particles and 
that this interaction is specific because the wild-type TRIM5-
21R protein binds much better than control proteins lacking 
part of the VI loop or the entire SPRY domain. 
B 
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FIG. 7. TRIM5-21R binds EIAV cores. (A) Sucrose gradient pu-
rification of membrane-stripped cores produced by an EIAV vector. 
The Western blot (a-CA) shows the distribution of EIAV CA protein 
across a sucrose density gradient (with fraction densities shown). The 
CA distribution is quantified below, and the CA protein in fractions 10 
to 12 corresponds to core particles. (B) TRIM5-21R protein binding to 
purified EIAV cores. Dimeric TRIM5-21R (WT, lanes 3 and 6), di-
meric TRIM5-21RAV1 (AVI, lanes 2 and 5), or monomeric TRIM5-
21RASPRY (ASPRY, lanes 1 and 4) proteins were incubated alone 
(lanes 1 to 3) or with purified EIAV cores (lanes 4 to 6) and then 
centrifugcd through a 57% sucrose cushion to separate EIAV cores 
and bound proteins (pellet) from unbound and lower-molecular-
weight proteins (supernatant). Western blots show the distribution of 
TRIM (a-FLAG, TRIM panels) and EIAV CA (a-CA, CA panels). 
Note that the pelleted EIAV cores bound full-length TR1M5-21R 
better than either TRIM5-21RAV1 or TRIM5-21RASPRY. 
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DISCUSSION 
We have described the expression, purification, and charac-
terization of TRIM5-21R, which represents the first study of a 
pure recombinant TRIMSa protein capable of restricting 
HIV-1 replication. Our experiments provide direct experimen-
tal support for the importance of both TRIM5a protein oligo-
merization and the B30.2/SPRY domain in retroviral capsid 
recognition. Specifically, we found that deletion of the SPRY 
domain eliminates binding to both HIV-1 CA-NC assemblies 
and EIAV cores, that a deletion in the VI loop reduces binding 
significantly, and that TRIM5-21R dimerization enhances 
binding to HIV-1 CA-NC assemblies under stringent binding 
conditions. These in vitro binding activities correlate well with 
restriction activities in vivo, indicating that our in vitro exper-
iments accurately recapitulate interactions between capsids 
and TRIM5 proteins during retroviral restriction. 
Our experiments indicate that restricting TRIM5a proteins, 
including TRIM5a itself, are dimers. Previous studies had 
established that TRIM5a proteins oligomerize and that the 
oligomeric state might be trimeric (27, 36). We now show, 
however, that TRIM5-21R forms dimers but that chemically 
cross-linked TRIM5-21R dimers exhibit anomalously slow 
electropnoretic mobility, causing them to appear trimeric. 
Cross-linked TRIM5a proteins expressed in mammalian 
cells exhibit very similar mobilities, implying that authentic 
TRIM5a proteins are also dimeric. It will be of interest to 
determine whether other members of the TRIM protein family 
are also dimers. In this regard, we note that others have re-
ported that the related TRIM21 protein forms trimers (45). 
This conclusion was again based upon the electrophoretic mo-
bility of chemically cross-linked TRIM21 proteins, however, 
which may be subject to the same uncertainties as cross-linked 
TRIMSa proteins. Moreover, another group has reported that 
the TRIM21/SS-A/Ro52 protein may instead be dimeric, based 
on its gel filtration mobility (59), and two groups have reported 
that the isolated coiled-coil region of TRIM21 forms dimers 
rather than trimers (27, 40). We therefore speculate that 
dimerization may be a common property of many members of 
the tripartite motif protein family. If so, there are several 
intriguing similarities between TRIM proteins and immuno-
globulin G proteins, since both types of protein can dimerizc to 
display a pair of terminal immunoglobulin-like domains that 
can recognize antigens, including repeating motifs on viral 
capsid surfaces. 
Once formed, TRIM5-21R dimers are stable and can be 
purified without appreciable dissociation. Similarly, we saw no 
evidence of monomer accumulation in equilibrium distribu-
tions of TRIM5-21R dimers across a range of micromolar 
concentrations, again indicating that assembled TRIM5-21R 
dimers are highly stable (or kinetically inert). Nevertheless, 
monomeric TRIM5-21R proteins were produced in our bacu-
loviral expression system. These TRIM5-21R monomers did 
not exhibit a propensity to dimerize, suggesting that they may 
be kinetically "trapped," perhaps owing to misfolding of the 
coiled-coil motif. Not surprisingly, a TRIM5-21R construct 
missing the SPRY domain and preceding L2 linker was exclu-
sively monomeric, a finding consistent with previous experi-
ments showing that the TRIM5a L2 region is required for 
oligomerizalion (40). 
SPRY domains of TRIM proteins, presumably including 
TRIM5a, adopt immunoglobulin-like folds consisting of two 
antiparallel 0-sheets. The ligand binding surface is located at 
one end of the (3-sandwich and is composed of six extended 
loops and two pockets (25, 61). The loops, which are hyper-
variable in both amino acid composition and length, share 
homology with the complementarity-determining region loops 
of immunoglobulins and account for the species specificity of 
restriction. In particular, the variable region 1 loop of 
TRIM5arh is a critical determinant of capsid binding and an-
tiviral activity, and a deletion within the VI loop also reduced 
capsid recognition by TRIM5-21R in our in vitro binding as-
says. Our results are therefore in good agreement with the 
prevailing model that retroviral capsid recognition is mediated 
by the variable loops of the SPRY domain of TRIMSa (34,54, 
68). Furthermore, our experiments demonstrate that this in-
teraction is direct and can be highly efficient. Indeed, under 
some conditions we observed essentially stoichiometric binding 
of TRIM5-21R to CA-NC assemblies. Electron microscopic 
images of CA-NC tubes decorated with TRIM5-21R proteins 
also suggest that TRIM5-21R can "coat" the CA-NC surface, 
although higher-resolution studies will be necessary to confirm 
and extend this finding. 
TRIM5a restriction represents a very intriguing problem in 
molecular recognition because specific TRIM5a alleles are 
able to recognize a remarkable variety of different retroviral 
capsids, despite their substantial variation in amino acid se-
quence and surface topology. This attribute is exemplified by 
TRIM50,,,, which is able to recognize both EIAV and HIV-1 
capsids even though the HIV-1 and EIAV CA proteins share 
only - 2 5 % sequence identity. Retroviral capsids do share a 
common organization, however, since all capsids are assem-
bled on a hexagonal surface lattice composed of CA hexamers. 
It is therefore likely that both reading heads of the dimeric 
TRIM5a protein engage similar sites on the capsid surface, 
and this is most easily accomplished by binding across a local 
twofold symmetry axis on the capsid lattice (although asym-
metric binding is also a formal possibility). Hexagonal HIV-1 
CA arrays exhibit two distinct types of local twofold symmetry, 
one of which is colinear with the local sixfold axes and the 
other of which connects adjacent hexamers. These two sites 
have different subunit orientations and spacing, and it is there-
fore likely that only one of these sites is the preferred TRIM5a 
binding site. 
In solution, HIV-1 CA forms dimers that correspond to the 
twofold symmetric interactions between adjacent hexamers in 
the assembled hexagonal lattice. Expression of HIV-1 CA 
alone does not abrogate restriction, however, indicating that 
the CA dimer alone probably does not create a high-affinity 
TRIM5a binding site (14, 16, 51, 52). It is possible that CA 
alone cannot abrogate restriction because the CA solution 
dimer is not the preferred TRIM5a binding site or because this 
CA dimer is weak and/or inherently flexible. However, an 
interesting alternative is that isolated SPRY domains, and even 
isolated TRIM5a dimers, may have weak intrinsic capsid bind-
ing energies and that high-affinity binding is achieved through 
the cooperative formation of even higher-order TRIM5a as-
semblies. This model would be consistent with the observation 
that TRIM5a proteins are highly susceptible to aggregation or 
assembly in vitro and in vivo. Indeed, fluorescence images 
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indicate that at least in some cases, large numbers of TRIMSa 
proteins can assemble on HIV-1 capsids in vivo (6). This model 
could also help explain how individual TRIM5 alleles can bind 
such a variety of different retroviral capsid surfaces because 
direct TRIM5ot-CA interfaces would not need to form a large 
number of favorable interactions but rather could utilize just a 
few specific interactions and then be stabilized by the cooper-
ative formation of multiple TRIM5a-CA and TRIM5ot-
TRIM5a interfaces. In contrast, isolated TRIM-Cyp proteins, 
in which a cyclophilin A domain replaces the SPRY domain, 
may bind specific retroviral capsids with higher affinities be-
cause the cyclophilin A domain can make specific interactions 
with individual HIV-1 CA subunits (18, 70). This "high-affin-
ity" recognition mechanism could explain why the upstream 
RING and B-box domains play less important roles in TRIM-
Cyp restriction activity (10,13,65,66) but may come at the cost 
of reducing the ability of TRIM-Cyp restriction factors to rec-
ognize as broad a variety of different retroviral capsids as 
canonical TRIM5a alleles. 
Our electron microscopic analyses also indicated that high-
level TRIM5-21R binding destabilizes the CA-NC lattice to 
some degree because TRIM5-21R induced many more breaks 
in CA-NC/DNA lubes than did nonbinding control TRIM5-
21R constructs. Destabilization of the CA-NC lattice could 
reflect steric hindrance upon saturation binding of TRIM5-
21R and/or mismatches in the symmetry or spacing between 
the CA-NC lattice and putative higher-order TRIM5-21R as-
semblies. We emphasize, however, that the capsid destabiliza-
tion induced by TRIM5-21R binding was a relatively minor 
effect because most CA-NC assemblies remained largely in-
tact, even in the presence of a large excess of TRIM5-21R. 
Similarly, F.IAV cores remained pelletable in the presence of 
excess TRIM5-21R. Thus, the dramatic destabilization of ret-
roviral capsids observed under restrictive conditions in vivo 
does not appear to be a direct consequence of TRIMSa bind-
ing. Rather, it appears that capsid recognition by TRIM5ot and 
subsequent destabilization/restriction are largely separable 
events. This idea is consistent with a series of other observa-
tions, including the fact that mutations in the B-box region of 
TRIM5ot can abrogate restriction without apparently affecting 
capsid recognition (11), and that capsid destabilization is ab-
rogated upon inhibition of the proteasome (6,10). 
In summary, our biochemical and biophysical studies have 
established that purified recombinant TRIM5-21R forms sta-
ble dimers that can bind specifically to higher-order HIV-1 
CA-NC assemblies and to authentic E1AV core particles. It 
will be important to ascertain precisely how TRIM5a binds the 
capsid lattice and to determine the minimal CA assembly re-
quired for high-affinity binding, and we anticipate that the 
availability of recombinant TRIM5-21R protein will facilitate 
such studies. 
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The budding of many enveloped RNA viruses, including human immunodeficiency virus type 1 (HIV-1), 
requires some of the same cellular machinery as vesicle formation at the multivesicular body (MVB). In 
Saccharomyces cerevisiae, the ESCRT-II complex performs a central role in MVB protein sorting and vesicle 
formation, as it is recruited by the upstream ESCRT-I complex and nucleates assembly of the downstream 
ESCRT-III complex. Here, we report that the three subunits of human ESCRT-II, EAP20, EAP30, and EAP45, 
have a number of properties in common with their yeast orthologs. Specifically, EAP45 bound ubiquitin via its 
N-terminal GRAM-like ubiquitin-binding in EAP4S (GLUE) domain, both EAP45 and EAP30 bound the 
C-terminal domain of TSG101/ESCRT-I, and EAP20 bound the N-terminal half of CHMP6/ESCRT-III. 
Consistent with its expected role in MVB vesicle formation, (i) human ESCRT-II localized to endosomal 
membranes in a VPS4-dependent fashion and <ii) depletion of EAP20/ESCRT-II and CHMP6/ESCRT-III 
inhibited lysosomal targeting and downrcgulation of the epidermal growth factor receptor, albeit to a lesser 
extent than depletion of TSG101/ESCKT-I. Nevertheless, HIV-1 release and infectivity were not reduced by 
efficient small interfering RNA depletion of EAP20/ESCRT-H or CHMP6/ESCRT-III. These observations 
indicate that there are probably multiple pathways for protein sorting/MVB vesicle formation in human cells 
and that HIV-1 does not utilize an ESCRT-II-dcpcndent pathway to leave the cell. 
Enveloped RNA viruses like human immunodeficiency virus 
(HIV) acquire lipid bilayers and exit infected cells by budding 
through limiting membranes. The process of HIV budding 
shares a number of similarities with the cellular process of 
vesicle formation at the multivesicular body (MVB) (reviewed 
in references 2, 14, 25, 26, 33, 40, and 51). MVB vesicles and 
HIV virions both bud away from the cytoplasm (58) and share 
the following mechanistic similarities: (i) a requirement for 
ubiquitin (Ub) in formation and cargo incorporation (reviewed 
in references 40 and 81), (ii) recruitment and utilization of the 
cellular ESCRT-I complex (6,15,19,22,47,48,52,70,79), and 
(iii) a requirement for ESCRT-III, LIP5, and VPS4 ATPase 
activities (22, 46, 69, 83, 85). In spite of these similarities, 
however, MVB biogenesis and viral budding ultimately create 
different vesicles, and it is therefore of interest to determine 
the precise relationship between the two processes. 
Genetic screens in Saccharomyces cerevisiae defined the ba-
sic machinery of MVB vesicle formation and identified 17 
soluble yeast proteins that are essential for MVB biogenesis 
(the "class E" proteins) (40, 59). Complementary biochemical 
analyses revealed that MVB vesicle formation proceeds through 
an ordered pathway in which a series of soluble class E complexes, 
termed ESCRT-I (39), ESCRT-II (4), and ESCRT-III (3), are 
sequentially recruited to endosomal membranes, where they 
function in vesicle formation (Fig. 1A). Although the processes of 
vesicle formation and cargo incorporation are not yet understood 
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in mechanistic detail, ESCRT-I and -II appear to function pri-
marily as adaptors that recognize protein cargoes and help recruit 
ESCRT-III, which in turn appears to function more directly in 
protein sorting and vesicle formation. 
As the central complex in the yeast ESCRT pathway, 
ESCRT-II bridges ESCRT-I and ESCRT-III and also interacts 
with ubiquitylated cargoes. As shown in Fig. IB, crystal struc-
tures of the yeast ESCRT-II core (30, 74) have revealed that 
the yeast ESCRT-II complex contains two copies of Vps25p 
(EAP20) that bind asymmetrically to single copies of Vps22p 
(EAP30) and Vps36p (EAP45) (human protein names are 
provided in parentheses for reference). The two Vps25p 
(EAP20) proteins project away from the Vps22p-Vps36p 
dimer, so that the overall complex assumes a trilobed "Y" 
shape. The three ESCRT-II subunits are related structurally, 
as each contains two copies of the winged-helix (WH) protein 
motif. Two of the proteins also contain N-terminal extensions: 
Vps22p (EAP30) has an extended helix (Fig. IB), and Vps36p 
(EAP45) contains a linker and an N-terminal GRAM-like 
ubiquitin-binding in EAP45 (GLUE) domain (not present in 
the core structure). Structural and biochemical analyses of the 
Vps36p GLUE domain have shown that it is a split PH domain 
that binds phosphatidylinositol phosphates, particularly PI(3)P 
(67,73). An extended insert within the GLUE domain contains 
two Npl4 zinc fingers (NZF), which are small globular zinc 
binding modules that mediate protein-protein interactions 
(49). The first, NZF-N, binds Vps28p (ESCRT-I) and helps 
recruit ESCRT-II to the endosomal membrane (73), whereas 
the second, NZF-C, binds ubiquitin and is required for efficient 
sorting of ubiquitylated cargoes (1). 
The human and yeast ESCRT-II complexes are likely to be 
related structurally, because mammalian ESCRT-II can be iso-
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FIG. 1. ESCRT-H structure and interactions. (A) Schematic model summarizing the protein interactions of the human ESCRT-II complex (see 
the text for details). Note that the stoichiometrics and compositions of the ESCRT-I and ESCRT-III complexes have not yet been denned 
unambiguously. The complexes are therefore simply shown with all possible subunhs. (B) Three-dimensional structure of the yeast ESCRT-II 
complex. The structure of the ESCRT-II core was determined by X-ray crystallography (30, 74). The N-terminal region of Vps36 (EAP45) (shown 
schematically) has not yet been determined but contains two NZF domains (1) embedded within a GLUE domain (67). The structural 
elements/domains correspond approximately lo the following residues (human homologs are in parentheses): for Vps36p (EAP45), GLUE domain, 
1 to 285 (1 to 135); NZF-1,177 to 205; NZF-2, 242 to 259 (neither NZF motif is present in EAP45); linker domain, 286 to 404 (136 to 238); WH-1, 
405 to 491 (239 to 316); and WH-2, 492 to 566 (317 to 386); for Vps22p (EAP30), helix 1 (HI), 1 to 51 (1 to 55); WH-1, 90 to 165 (95 to 176); 
and WH-2, 166 to 233 (177 to 258); for Vps25p (EAP20), WH-1, 19 to 127 (22 to 103), and WH-2, 128 to 200 (104 to 176). (C) Summary of the 
positive yeast two-hybrid interactions between ESCRT-II proteins and all known human class E proteins. The right array shows doubly transformed 
yeast replica plated on minus Leu, minus Trp, minus His, minus Ade selection media, where successful growth represents a positive protein 
interaction. The left array shows replica-plated yeast on minus Leu, minus Trp media (a control for equivalent transformation and yeast growth). 
The indicated constructs were fused to DBDs (rows) or ADs (columns). Unfused DBD and AD constructs are shown as negative controls. Note 
that the interaction between DBD-EAP30 and AD-CHMP6 was judged to be negative because it was very weak and was not detected in the 
reciprocal direction. Analogous data were summarized previously in reference 83. 
lated as a stable, soluble complex composed of three proteins 
that share 19 to 36% pairwise identity with their S. cerevisiae 
homologs (excluding the N-terminal region of Vps36p/EAP45) 
(37,61). We have therefore used the crystal structure of the S. 
cerevisiae ESCRT-H core as a working model for the human 
ESCRT-II complex (Fig. IB) (see Materials and Methods). 
Mammalian ESCRT-II functions are less well studied than 
those of the yeast complex, but the mammalian EAP20 and 
EAP45 proteins do colocalize with ESCRT-III components 
and with ubiquitylated proteins on endosomal membranes (67, 
88). Like their yeast counterparts, EAP20 can bind the 
ESCRT-III protein, CHMP6 (46, 83, 88), and the N-terminal 
GLUE domain of murine EAP45 was recently shown to bind 
ubiquitin (67). These observations all support the idea that the 
mammalian and S. cerevisiae ESCRT-II complexes are func-
tional homologs. Nevertheless, there must also be important 
differences between human and yeast ESCRT-II proteins. For 
example, the mammalian complex lacks both NZF domains 
and therefore must interact differently with both ESCRT-I and 
ubiquitin. Moreover, ESCRT-II and CHMP6 overexpression 
does not inhibit HIV type 1 (HIV-1) budding (46), and it was 
recently reported that ESCRT-II is not required for lysosomal 
degradation of major histocompatibility complex I (MHC-I) or 
epidermal growth factor receptor (EGFR), indicating that the 
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complex is not absolutely required for membrane protein sort-
ing or MVB vesicle formation (11). Indeed, several groups 
have proposed that ESCRT-II complexes in other species may 
perform functions that appear to be unrelated to MVB protein 
sorting. These include a role for mammalian ESCRT-II in 
transcriptional elongation (37,61,65) and a role for the Schizo-
saccharomyces pombe ESCRT-II protein EAP30 in meiotic 
spindle pole body amplification (35). The relationship between 
MVB protein sorting and these other putative ESCRT-II ac-
tivities, if any, is not yet clear. 
During HIV-1 assembly, human class E proteins are re-
cruited by two short sequence motifs (termed "late domains") 
within the C-termina! p6 region of the Gag poiyprotein (re-
viewed in references 15,19,22,47,48, 52, 70, and 79). The first 
p6s<*s late domain is a PTAP tetrapeplide motif that binds and 
recruits TSG101 (mmor susceptibility gene 101; yeast Vps23p). 
TSG101 is the central protein of the human ESCRT-I com-
plex, and there is good evidence that the entire ESCRT-I 
complex functions directly in HIV-1 release (15,19,22,24,48). 
The second late domain within pCF*8 is a YPX,,L motif (where 
X„ can vary in identity and length) that binds and recruits 
ALIX/AIP1 (yeast Brolp) (69, 80). AUX functions late in 
MVB biogenesis (56) and binds both ESCRT-I (83) and 
ESCRT-III (41) proteins but is not a permanent subunit of any 
of the three discrete ESCRT complexes. Like TSG101, ALIX 
functions directly in virus release, although disruptions of the 
PTAP-TSG101 interaction generally inhibit HIV-1 budding to 
a greater degree than do disruptions of the ALIX-YPX^., 
interaction (16,46). As noted above, there are also indications 
that HIV-1 budding requires the activities of the late-acting 
ESCRT-III, LIP5, and VPS4 class E proteins (22, 46, 69, 83, 
85). Specifically, HIV-1 release is dominantly inhibited by 
overexpression of VPS4 ATPase mutants and ESCRT-III pro-
teins with large N- or C-terminal extensions (22, 46, 69, 83). 
HIV-1 release is also impaired by small interfering RNA 
(siRNA) depletion of the VPS4 binding protein LIPS (85). It is 
important to note, however, that these experiments do not 
definitively establish a direct role for these proteins in HIV-1 
budding, because the inhibitory effects could also arise from 
sequestration of the entire ESCRT machinery at aberrant en-
dosomal compartments (called "class E" compartments). 
In summary, HIV-1 uses the ESCRT-I complex to bud from 
cells and also requires the activities of downstream ESCRT-III 
and VPS4-LIP5 complexes. In 5. cerevisiae, ESCRT-II physi-
cally bridges the ESCRT-I and ESCRT-III complexes and is 
essential for MVB protein sorting and vesicle formation (4). 
The mammalian ESCRT-II function appears to be more com-
plex, however, and we therefore undertook this study with the 
goals of characterizing the biochemical properties of human 
ESCRT-II and testing its role in HIV release. 
MATERIALS AND METHODS 
ESCRT-U homology modeling. A working model for the human ESCRT-II 
core was created as follows. Protein Data Bank (PDB) coordinates from a yeast 
ESCRT-II crystal structure (PDB accession no. 1U5T) were utilized to create a 
consensus template using Swiss-PdbViewer (http://www.expasy.org/spdbv/). The 
human and yeast ESCRT-II sequences were then aligned within Swiss-
PdbViewer, the alignment was used to thread the human sequence onto the yeast 
ESCRT-II template, and the model was energy minimized within Swiss-
PdbViewer. 
Plasmlds. Genes for human EAP20, EAP30, EAP45, and CHMP6 used in 
yeast two-hybrid and biochemical experiments were amplified from expressed 
sequence tag clones as described previously (83). A complete list of all constructs 
used in this study is provided in Table SI in the supplemental material. Genes 
and fragments for yeast two-hybrid experiments were cloned into pGADT7 
(activation domain) and pGBKT7 (binding domain) vectors (Clontech) using 5' 
Ndel and 3' BamHI or Bgill cloning sites. Recombinant proteins used in bio-
chemical experiments were expressed as glutathione S-transferase (GST) C-
tenninal fusions from a modified pGEX vector (GE Bioscicnces). This vector 
(pGEX2T-TEV) contained a tobacco etch virus (TEV) protease cleavage site 
and 5' Ndel and 3' BamHI or Bglll cloning sites following the GST gene. 
Expression constructs for deletion mutants were created by amplifying and sub-
cloning the desired fragments or by introducing a stop codon using Quickchange 
mutagenesis (Stratagene). For mammalian expression, ESCRT genes were 
cloned as EcoRI-BamHI fragments into pcDNA3.1(-)MycHis in frame with the 
C-terminal Myc lag, and with a Kozak sequence, ACC, inserted between the 
EcoRI site and the ATG start codon. 
Preparation of recombinant EAP20. GST-EAP20 was expressed in Escherichia 
colt BL21(DE3) transformed with WISP05-68 (see Table SI in the supplemental 
material) by induction in mid-log phase (0.4 mM IPTG [isopropyl-fi-D-thiogalacto-
pyranosidej) and allowing the protein to accumulate for 4 hours at 23°G The 
cells were lysed by lysozyme treatment (2.5 lng/ml) in 50 mM Tris, pH 8.0, 300 
mM NaCl, 10% glycerol, 1 mM dithiothreitot (DTT), followed by sonication and 
centrifugation (at 27,000 x g for 45 min) to remove cell debris. Soluble GST-
EAP20 was bound to a glutathione-Sepharose affinity matrix (GSTPrep FF; GE 
Healthcare), washed, and eluted with a step gradient of 20 mM glutathione. 
Protein fractions were dialyzed into 25 inM Tris (pH 8.0), 150 mM NaCt, and 1 
mM DTT), and the fusion protein was cleaved during dialysis with 1 mg TEV 
protease per 100 mg protein (24 h; 23°C). The TEV cleavage reaction mixture 
was adjusted to 25 mM Tris (pH 8.0), 300 mM NaO, 10% glycerol, 1 inM DTI", 
and free EAP20 was separated from GST and GST-EAP20 by size exclusion 
chromatography (Superdex 200; GE Healthcare). This purification method typ-
ically yielded —1.5 mg of pure protein per liter of starting culture. 
Preparation of recombinant CHMP6 proteins. GST-CHMP6 expression, affinity 
purification, and TEV cleavage were carried out as described for GST-EAP20. 
Following TEV cleavage, free GST was removed by glutathione-Sepharose affinity 
chromatography. The solution was then diluted six-fold to reduce the salt in the 
buffer to 50 mM NaCl, and the CHMP6 protein was purified to homogeneity by 
anion-exchange chromatography on immobilized Q-Sepharose (GE Biosciences). 
CHMP6 eluted at -400 mM NaCl from a linear gradient of 50 mM to 1 M NaCl in 
25 mM Tris (pH 8.0), 10% glycerol, 1 mM DTT. 
GST pull-down assays. GST and GST-CHMP6 fusion proteins were expressed 
in E. coli BL21(DE3) and induced at mid-log phase with 0.4 mM IPTG. Ten-
milliliter cultures of cells expressing GST-CHMP6 were pelleted; resuspended in 
2 ml of 300 mM NaO, 0.1% NP-40,10% glycerol, I mM DTT, 50 mM Tris (pH 
8.0); and lysed by lysozyme treatment and sonication. Soluble GST-CI-IMP6 was 
incubated with 100 u,l glutathione-Sepharose resin. Approximately 30 |xM puri-
fied recombinant EAP20 was added to 2 \tM (equivalent) of immobilized GST-
CHMP6 and incubated for 30 min at 4°C in resuspension buffer. Unbound 
EAP20 was removed by washing with lysis buffer, and bound proteins were 
released from the resin by boiling it in sodium dodecyl sulfate-polyacryiamide gel 
electrophoresis (SDS-PAGE) loading buffer and were analyzed on Coomassie-
stained 4 to 20% SDS-PAGE gradient gels. 
Yeast two-hybrid binding assays. Directed yeast two-hybrid assays were per-
formed using the Matchmaker GAL4 Yeast Two Hybrid 3 system (Clontech). 
Briefly, Sacchammyces cerevisiae AH-109 was cotransformed with pGADT? or 
pGBKT7 cloning vector (Clontech) containing the inserts of interest. The trans-
formed yeast colonies were grown for 3 days at 30°C on yeast extract-peptone-
dextrose plates with minus Leu, minus Trp selection. Ten to 100 colonies were 
pooled, resuspended in a liquid culture of Sabourand dextrose broth (minus Leu, 
minus Trp), selected on Sabourand dextrose broth (minus Leu, minus Trp, minus 
Ade, minus His) plates, and allowed to grow for 3 days. 
Antibody production. Antibodies against the purified recombinant proteins 
EAP20 (UT461 and -462) and CHMP6 (UT463 and -464) were raised in rabbits 
by Covance Inc., following their 87-day protocol (http://abservices.crpinc.com/ab 
_sampleProtocots.aspx). UT461 and UT463 were affinity purified with the re-
spective proteins, as described previously (83). 
Biosensor binding experiments. EAP45-ubiquitin bioseasor binding experi-
ments were performed at 20°C using a BIACORE 2000 (Biacore AB, Uppsala, 
Sweden) equipped with a research grade CM4 sensor chip. Approximately 5,000 
response units (RU) anti-GST antibody was immobilized on all four Mow cells 
using amine-coupling chemistry (36). GST-EAP451_329, GST-EAP45W39, or 
recombinant GST alone from soluble E. coli lysates was diluted in running buffer 
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(20 mM Tris, pH 8.0, 100 mM NaCt, 1 mM DTT, 0.2 mg/ml bovine serum 
albumin [BSA], and 0.005% P20) and captured on the antibody surfaces at 
densities of —0.5 kRU. Pure GST alone was also captured as a blank reference. 
Ubiquitin was purified (84), diluted in running buffer, and injected in duplicate 
or triplicate over the four flow cells at concentrations of 0 to 1,250 M-M. Re-
sponses were collected at a rate of 2 Hz during the 30-s association and disso-
ciation phases. Binding isotherms from the equilibrium phases were fitted to 
simple 1:1 binding models to determine the dissociation constant and statistical 
fitting errors (see Fig. 4) (53). To obtain more accurate estimates for the disso-
ciation constant and standard errors, the interaction between GST-EAP451_u9 
and ubiquitin was measured in six independent experiments, yielding values of 
410 ± 90 u.M. Biosensor binding experiments for EAP20 and GST-CHMP6 were 
performed as described for the EAP45-ubiquitin interaction, except that a BIA-
CORE 3000 instrument was used and binding was examined in a buffer contain-
ing 50 mM Tris, pH 8.0, 300 mM NaCI, 10% glycerol, 1 mM DTT, 0.2 mg/ml 
BSA, and 0.005% P20. Anti-GST antibody was immobilized over all four flow 
cells (-13,000 RU/cell), and CHMP6, CHMP6,_i00, and CHMP61()I„2M were 
captured to densities of —2,700 RU. Purified EAP20 was diluted in running buffer 
and injected in triplicate at 0.03 to 560 u-M concentrations. 
Immunofluorescence. COS-7 cells grown on collagen-coated glass coverslips in 
12-wel! plates were transfected with 0.5 p.g of pEGFP-VPS4A-KQ DNA and, in 
some experiments, 0.5 jig pcDNA3.1-EAP20-myc DNA or pcDNA3.1-EAP30-
myc DNA, using 2 u.1 Lipofectaminc 2000 (Invitrogen) following the manufac-
turer's instructions. The cells were fixed 24 h posttransfection in 4% paraform-
aldehyde-phosphate-buffered saline (PBS), blocked in 10% fetal calf serum 
(FCS) in PBS containing 0.1% Triton X-100, and incubated at room temperature 
with murine monoclonal anti-Myc (9E10; Covance Inc.) to detect transfected 
Myc-tagged ESCRT-II proteins or with anti-EAP20 UT461 (1:1,000) or anti-
CHMP6 UT463 (1:1,000) antibody to detect endogenous ESCRT proteins. Sec-
ondary antibodies were anti-mouse Alexa 594- or anti-rabbit Alexa 594-conju-
gated antibodies (Molecular Probes; 1:1,000). Images of 0.5*u-m-thick Z sections 
were collected as single wavelengths on an Olympus FV300 confocal fluores-
cence microscope, using Fluoview 2.0.39 software. 
Viral Infecdvtty assays. EAP20 and CHMP6 were silenced by transfecting 5 p.1 
of 20 fiM annealed siRNAs, together with 1 jxg of pSLl 180 (carrier DNA) and 
9 M-1 Lipofectamine 2000, into 293T cells in six-well plates (22). The sense strands 
of the siRNAs were as follows (lowercase letters denote RNA, and uppercase 
letters denote DNA nucleotides [nt]): EAP20 (start site, nt 218), cgauccagauug 
uauuagaTT; CHMP6-1 (start site, nt 257), ccaugguucagaguauugaTT; and 
CHMP6-2 (start site, nt 284), agaucgaaaugaaagugauTT. TSG101 and INV 
(TSG101) siRNA constructs have been described previously (22). The levels of 
protein depletion were estimated by quantifying the intensities of bands in 
Western blots using NIH ImageJ software. 
Viral-particle production was initiated during a second siRNA transfection 
(/ = 24 h) by replacing the 1-^ ig carrier DNA either with an HIV-1 vector system 
or with an infectious R9 HIV-1 NL4-3 plasmid. Virus was harvested 24 h after 
the second transfection, and the titers were measured using single-cycle MAGIC 
assays (70). Tlie HIV-1 vector system contained 0.38 u.g pCMVAR8.2 (54), 0.12 
u.g pRSV-Rev (18), 0.12 |xg pMD.G (57), and 0.38 u-g pWPTS-nlsLacZ (all 
generous gifts from D. Trono, Swiss Federal Institute of Technology). HIV-
packaged lacZ vectors were harvested 48 h later and titered on HeLaM cells as 
described previously (85). 
Western blotting. Viral supernatants and cellular proteins from transfected 
293T cells were prepared using standard procedures (82). For Western blots, 
virions or cytoplasmic proteins were separated by 12% SDS-PAGE, transferred 
to nitrocellulose (TSG101) or potyvinylidene difluoride (all others) membranes 
in Tris-gh/cine-10% MetOH buffer, blocked in 1% (TSG101) or 5% milk, and 
incubated with antibodies diluted in Tris-buffered sa!ine-0.1% Tween 20 buffer 
(anti-TSGlOl), or in 1% BSA or 5% nonfat milk in Tris-buffered saline-0.1% 
Tween 20. Proteins were detected by enhanced chemiluminescence (Pierce) or 
by imaging Alexa 680-nm (Molecular Probes; 1:10,000) or IRDye 800-nm (Rock-
land; 1:20,000) secondary antibody on an Odyssey scanner (U-Cor Inc.). The 
primary antibodies used were rabbit anti-HIV CA (UT415 made against purified 
NL4-3 CA protein and affinity-purified; 1:15,000); rabbit anti-HIV MA from 
Didier Trono, Swiss Institute of Technology (1:25,000); rabbit anti-EAP20 
UT461 (1:1,000); rabbit anti-CHMP6 UT463 or UT464 (1:1,000); and mouse 
anti-TSGlOl (GeneTcx; 1:1,000). 
EGFR degradation assays. 2931' or He La cells were plated on duplicate 
six-well plates in Dulbecco's modified Eagle's medium-10% fetal bovine serum, 
and transfected with either oligofectamine or Lipofectamine 2000 and specific 
siRNAs (see above). During the second siRNA transfection (r = 24 h), 1 u,g R9 
HIV plasmid was added to one set of cells (to control for knockdown efficiency 
and viral production), together with the second aliquot of 5 u.1 siRNA. In this 
case, virus and cells were harvested 48 h later (t = 72 h) and analyzed by Western 
blotting and MAGIC infectivity assays. The other set of cells, used in EGFR 
assays, was transfected a second time with siRNA-oltgofectamine alone. Twenty-
four hours after the second transfection (t •= 48 h), the cells were resceded on 
polylysinc (Sigma)-coated coverslips and the next day were incubated in serum-
free medium for 18 h. The cells were then incubated in the presence of 1 jig/ml 
human EGF (Molecular Probes/Invitrogen) for 1 h (HeLa) or 2 h (293T cells); 
fixed in 3.7% formaldefayde-PBS, pH 7.2, at room temperature for 20 min; and 
incubated with mouse anti-human EGFR (1:100; Neomarkers) in 0.1 % saponin-1 % 
bovine serum albumin-PBS, pH 7.2, at room temperature for 60 min. The cells 
were washed extensively and incubated in Alexa 488-conjugated goat anti-mouse 
immunoglobulin G (1:750) (Molecular Probes/Invitrogen). The cells were im-
aged using an epifluorescence microscope with MagnaFire software or an Olym-
pus FV300 confocal fluorescence microscope with Fluoview 2.0.3.9 software 
using 0_5-|j,m sections. The fluorescence intensities were quantified using NIH 
ImageJ software. 
EGF-lysosome colocallzation assays. HeLa cells were plated on duplicate 
six-well plates in Dulbecco's modified Eagle's medium-10% fetal bovine serum 
and transfected twice with either oligofectamine or Lipofectamine 2000 (( = 0 
and t = 24 h) with the siRNA oligonucleotides listed above and with EAP20-2 
(start site, nt 477; gcacaaggccgagaucaucTT). At t = 48 h, the cells were reseeded 
on polylysine (Sigma)-coated coverslips, and at ( = 72 h, the cells were switched 
to serum-free media for 18 more hours while being incubated with 0.1 mg/ml 
Alexa 488-conjugated dextran (molecular weight, 10,000). The cells were then 
washed extensively in growth medium followed by a 4-h chase in dexiran-free/ 
serum-free medium, placed at 0°C, incubated with 1 ng/ml EGF-Alexa Fluor 
555-streptavidui complex (Molecular Probes/Invitrogen) for 60 min, and washed 
extensively in growth medium. Finally, the cells were incubated for 30 min at 
37°C to allow time for EGF internalization and trafficking. Fluorescent images 
were captured with an Olympus FV300 confocal fluorescence microscope with 
Fluoview 2.0.3.9 software using 0.5-u.m sections and analyzed using NIH ImageJ 
software. Three to seven fields of cells were analyzed for each sample, and the 
EGF-lysosome localization was scored manually, with a positive score given to 
any cell showing significant colocalization of the EGF and dextran markers. 
KK3-mediated MHC-1 downregulatlon. EAP20 and CHMP6were silenced as 
described above with the addition of either 2 u,g of pTRACER-K3 or pTRACER 
empty control plasmid transfected at 24 and 48 h. Thirty-six hours after the 
second transfection, 5 x 10s cells were incubated in suspension with anti-human 
HLA-ABC antibody (1 u.g/u,l; eBiosctence) for 1 h at 4°C in a solution of 10% 
FCS in PBS. The cells were washed once with 1 ml of PBS and then incubated 
with phycoerythrin-labeled goat anti-mouse immunoglobulin (1 u,g/'fi,l; BD Bio-
sciences) in 10% FCS-PBS, followed by an additional wash with PBS. The cells 
were pelleted by centrifugation and resuspended in 1 ml PBS, and surface 
HLA-ABC levels were analyzed using the FACScan system (BD Biosciences). 
RESULTS 
Protein interactions within the ESCRT-II complex. To sur-
vey the protein interactions of human ESCRT-II, we tested for 
yeast two-hybrid interactions between each of the three human 
ESCRT-II proteins and all known human class E proteins (83). 
As shown in Fig. 1C, the following positive interactions were 
observed: EAP2OEAP30, EAP20-EAP45, EAP20-CHMP6, 
EAP30-EAP30, EAP30-EAP45, EAP30-TSG101, and EAP45-
TSG101 (andTSGlOl-TSGlOl). All of these interactions were 
positive in both directions, and none of the ESCRT-II proteins 
interacted with control DNA binding domain (DBD) or acti-
vation domain (AD) constructs (Fig. 1C) or with any other 
class E proteins (data not shown). As noted above, ESCRT-II 
contains two copies of EAP20 and single copies of EAP30 and 
EAP45. Hence, all of the expected heteromeric interactions 
within the human ESCRT-II complex were observed, because 
EAP20, EAP30, and EAP45 all interacted with one another. 
The absence of EAP20 and EAP45 bomomeric interactions 
can also be rationalized, because there is only a single copy of 
EAP45 in the complex and the two copies of EAP20 within 
ESCRT-II do not contact one another directly (30, 74). The 
observed homomeric EAP30-EAP30 interaction was unex-
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FIG. 2. Yeast two-hybrid mapping of the interaction sites between 
TSG101 and the EAP30 and EAP45 proteins. (A) Fragments of 
TSGIOI binding to full-length EAP30 (left) and EAP45 (right). Selec-
tion media in the right and left arrays of each pair are the same as in 
Fig. 1C. (B) Full-length TSGIOI binding to fragments of EAP45 (left) 
and EAP30 (right). (C) Schematic summary of fragment maps and 
interaction sites of TSGIOI, EAP30, and EAP45. 
pected, however, and may have arisen because EAP30 was 
overexpressed in the absence of its other ESCRT-II binding 
partners. Alternatively, the interaction may reflect a natural 
tendency for ESCRT-II oligomerization (either directly or via 
bridging yeast proteins). In summary, all observed heteromeric 
intra-ESCRT-II interactions were consistent with structural 
models for the yeast and human ESCRT-II complexes, but the 
homomeric EAP30 interaction was not readily explained by 
the structure of isolated ESCRT-II. 
ESCRT-I-ESCRT-I1 interactions. Two ESCRT-II proteins, 
EAP30 and EAP45, also interacted with TSGIOI, the central 
component of the ESCRT-I complex. Further mapping studies 
revealed that a fragment corresponding to the C-terminal re-
gion of TSGIOI (termed the steadiness box [20, 42, 73]), was 
necessary and sufficient for both ESCRT-II protein interac-
tions (Fig. 2A). Conversely, full-length TSGIOI interacted with 
EAP30,_17, and EAP45U4_229, but not with fragments outside 
of these regions (Fig. 2B). Thus, the TSGIOI interaction site 
on EAP45 maps to the linker region between the GLUE do-
main and the first WH repeat. The TSGIOI interaction site on 
EAP30 spans both the long N-terminal helical extension and 
the WH repeat. TSGIOI also interacted, albeit less robustly, 
with an EAP30 fragment missing the first 40 amino acids that 
form the segment of the N-terminal helix that extends beyond 
the globular body of EAP30. Hence, the full EAP30 N-termi-
nal helical extension is not strictly required for TSGIOI bind-
ing, although this helix may contribute to the interaction, par-
ticularly as the full helix is predicted to extend to EAP30 
residue 55. 
As noted above, interactions between ESCRT-I and 
ESCRT-II must differ in the human and yeast systems, because 
the GLUE domain of human EAP45/ESCRT-II lacks the N-
terminal NZF motif that forms the ESCRT-II interface in the 
yeast Vps28p/ESCRT-I-Vps36p/ESCRT-II complex (73). 
Nevertheless, we observed two-hybrid interactions for both 
EAP45/ESCRT-II and EAP30/ESCRT-H with human TSG101/ 
ESCRT-I, indicating that the human ESCRT-I and ESCRT-II 
complexes can still interact, albeit via different ESCRT-I binding 
partners. Furthermore, the overall orientation of the ESCRT-I-
ESCRT-H interaction may also be conserved, because the C-
terminal region of TSGIOI forms an extended interlace with 
VPS28 (9,42,48,73) and the TSGIOI binding site on EAP45 lies 
immediately downstream (or at the very C-terminal end) of the 
GLUE domain. Thus, interactions between ESCRT-I and 
ESCRT-II appear to be retained in higher eukaryoles, al-
though more detailed analyses of binding sites and energetics 
must await the production of pure recombinant human 
ESCRT complexes. 
ESCRT-II-ESCRT-IH interactions. In yeast, ESCRT-II re-
cruits the downstream ESCRT-III complex through direct in-
teractions between the ESCRT-II protein Vps25p (EAP20) 
and the ESCRT-III component Vps20p (CHMP6) (human 
homologs are in parentheses) (3, 74). Similarly, the human 
EAP20 and CHMP6 proteins also interacted in our two-hybrid 
survey of human class E proteins (Fig. 1C and 3A). Yeast 
two-hybrid mapping studies revealed that this interaction was 
mediated by the N-terminal half of CHMP6 binding to the 
C-terminal half of EAP20 (Fig. 3A), consistent with earlier 
reports (74, 88). The two C-terminal domains of EAP20 are 
exposed at the ends of the Y-shaped ESCRT-II complex, 
where they would be ideally positioned to nucleate ESCRT-III 
deposition through bivalent binding interactions (Fig. IB). 
GST pull-down and biosensor binding experiments with pu-
rified recombinant EAP20 and CHMP6 proteins demonstrated 
that the EAP20-CHMP6 interaction was direct, and these ex-
periments again confirmed that EAP20 bound to the N-termi-
nal half of CHMP6 (Fig. 3B and 4). As shown in Fig. 4A and 
B, the equilibrium binding isotherm for EAP20 binding to the 
full-length CHMP6 proteins fitted a simple 1:1 binding model 
with a dissociation constant of 5.3 i 0.2 u,M. Interestingly, 
EAP20 bound even more tightly to the N-lerminal half of 
CHMP6 alone (residues 1 to 100) (equilibrium dissociation 
constant [KD] = 601 ± 9 nM), and the increased affinity pri-
marily reflected a significantly lower rate of EAP20 dissocia-
tion from the truncated CHMP6 fragment. This observation 
demonstrates that C-terminal sequences in CHMP6 reduce the 
EAP20 binding affinity, providing direct physical evidence for 
the proposal that isolated full-length ESCRT-III proteins can 
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FIG. 3. Interactions between EAP20 and CHMP6. (A) Yeast two-hybrid mapping of the interaction sites between EAP20 and CIIMP6. 
(B) GST pull-down experiment showing a direct interaction between EAP20 and the N-terminal half of CHMP6. The proteins present in each 
incubation mixture are given above lanes 2 to 5. Pure recombinant EAP20 is shown in lane 1 for reference. MW, molecular weight. 
adopt autoinhibited "foldback" conformations (45). In this re-
gard, it is interesting that several different CHMP proteins can 
be posttranslationally modified and that the unmodified 
CHMP proteins preferentially localize to the cytoplasm (68, 
83). The posltranslational modifications might therefore desta-
bilize autoinhibitory conformations, thereby enhancing the 
protein-protein interactions that help dictate ESCRT-III pro-
tein localization. 
EAP45-uhiquitin interactions. The yeast ESCRT-II complex 
helps sort ubiquitylated protein cargoes and binds ubiquitin 
through the second NZF motif (NZF-C) within the N-terminal 
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FIG. 4. Biosensor quantification of EAP20 binding to full-length and truncated CHMP6 proteins. (A) Sensorgrams showing different concen-
trations of EAP20 binding to full-length, immobilized GST-CHMP6. The inset shows EAP20 binding to a control GST surface. (B) Binding 
isotherms for EAP20 binding to full-length GST-CHMP6 (KD = 5.3 ± 0.2 |iM) and GST-CHMP100_M, (KD > 1 mM). Dissociation constants and 
errors were derived by fitting simple 1:1 models to the equilibrium binding data (panel A and data not shown). (C) Sensorgrams showing different 
concentrations of EAP20 binding to GST-CHMP6I..10o. The association and dissociation phases were globally fitted to simple 1:1 interaction 
models. The light-gray lines show global fits with the following parameters: association rate constant^ :,, = (1.46 ± 0.04) X 105 M-1 s~l, dissociation rate 
constant kd = 0.088 ± 0.003 s"', and KD = 601 ± 9 nM. (D) Schematic summary of the interaction sites between EAP20 and CHMP6. The arrow 
with the question mark illustrates a possible "autoinhibitory" interaction between the N- and C-terminal regions of CHMP6. 
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FIG. 5. Biosensor binding analyses of EAP45t„229-ubiquitin inter-
actions. Binding isotherms for wild-type Ub (circles) (KD = 210 ± 10 
M.M), F4A Ub (squares) (KD = 170 ± 10 u,M), and I44A Ub (dia-
monds) (KD > 1 mM) binding to immobilized GST-EAP45K229. The 
error bars represent standard deviations. 
lack NZF motifs, however, and it has therefore been unclear 
whether they could still interact with ubiquitylated protein 
cargoes. This puzzle has recently been resolved by Slagsvold 
and colleagues, who showed that a minimal N-terminal frag-
ment of murine EAP45 spanning residues 1 to 139 binds di-
rectly to ubiquitin (KD = 460 |iM) and also binds phospho-
inositides (67). 
We independently tested for ubiquitin binding activity in the 
human EAP45 protein using the entire region of human 
EAP45 that is missing from the crystal structure of yeast 
Vps36p (EAP45,_229). Biosensor binding analyses revealed 
that ubiquitin bound specifically to GST-EAP451„229, with an 
estimated dissociation constant of 210 ± 10 (iM in the exper-
iment shown in Fig. 5. EAP45,_22s binding was strongly inhib-
ited by the Ub I44A mutation, but not by a F4A mutation, 
demonstrating that the exposed hydrophobic Ub 144 surface 
forms at least part of the EAP45 binding site. This same bind-
ing surface is also recognized by nearly all of the other ubiq-
uitin binding proteins characterized to date (29). Ubiquitin 
also bound with a similar affinity to a minimal EAP45i_,3<, 
construct (KB = 410 ± 90 u,M; n = 6), indicating that the 
ubiquitin binding site is located within the N-terminal GLUE 
domain. These data are all in excellent agreement with recent 
analyses of ubiquitin binding to the murine EAP45 GLUE 
domain (67). 
EAP20 and CHMP6 accumulate on aberrant cndosomal 
class E compartments in the absence of VPS4 ATPase activity. 
Under steady-state conditions, all three ESCRT complexes are 
predominantly cytoplasmic but assemble transiently on the en-
dosomal membrane to participate in vesicle formation. The 
assembled ESCRT complexes are then recycled off the endo-
somal membrane by the action of the VPS4 AAA ATPases (5). 
Inhibition of human and yeast VPS4 ATPase activity therefore 
traps class E proteins, including the VPS4 proteins themselves, 
on aberrant endosomal class E compartments (3-5, 8, 21, 83, 
89). 
To test whether human ESCRT-II associated with endosomal 
membranes in a VPS4-dependent fashion, we examined the 
localization of two different ESCRT-II components, EAP20 
and EAP30, in the presence of a mutant VPS4A protein (green 
fluorescent protein [GFP]-VPS4AK173Q) previously shown to 
block ATP binding and to dominantly inhibit VPS4 activity in 
cells (8). As shown in Fig. 6A and B, antibodies against EAP20 
detected endogenous EAP20 in COS-7 cells, albeit weakly. 
These antibodies also cross-reacted with a second protein of 
—36 kDa (data not shown). We therefore also examined the 
localization of exogenous, Myc-tagged EAP20 to take advan-
tage of the enhanced immunofluorescence signal of the tagged, 
overexpressed protein (Fig. 6C). In both cases, EAP20 local-
ized to the enlarged endosomes induced by GFP-VPS4AK173Q 
overexpression. In the absence of GFP-VPS4AKJ73Q, both en-
dogenous and overexpressed EAP20 were distributed through-
out the cytoplasm, as has been seen for other ESCRT com-
plexes (Fig. 6B and D). To confirm that these results accurately 
represented the distribution of the entire ESCRT-II complex, 
the localization of a second ESCRT-II component, EAP30, 
was also examined. Once again, the overexpressed, Myc-tagged 
EAP30 protein was seen throughout the cell, but it became 
trapped on the class E compartments induced by dominant-neg-
ative GFP-VPS4AK173Q (compare Fig. 6E and F). Hence, 
ESCRT-II was recruited to class E compartments, where it be-
came trapped in the absence of VPS4 ATPase activity. Localiza-
tion of the endogenous ESCRT-III protein, CHMP6, was also 
examined, and this protein was also strongly recruited to aberrant 
class E compartments (Fig. 6G and H and data not shown). 
Similar results were obtained using the other dominant-
negative ATPase constructs, GFP-VPS4AEa28Q, DsRed-
VPS4BKJSOQ, and DsRed-VPS4B,,235Q (22, 83), and with hu-
man osteosarcoma cells (data not shown). These data are all 
consistent with the idea that human EAP20/ESCRT-II, 
EAP30/ESCRT-II, and CHMP6/ESCRT-III function in vesicle 
formation and cargo sorting at the MVB. 
HIV-1 particles are released efficiently from cells depleted of 
EAP20. To test whether ESCRT-II is required for efficient 
HIV-1 budding, we measured the levels of HIV-1 vector and 
virus production following siRNA depletion of EAP20 or 
TSG101 (positive control). As shown in Fig. 7A and C, both 
EAP20 and TSG101 were successfully depleted to nearly un-
detectable levels, as determined by quantification of Western 
blots of cellular extracts (Fig. 7A and C, "Cells," top two rows). 
Importantly, intracellular Gag expression levels were not sig-
nificantly altered by depletion of either protein ("Cells," bot-
tom rows). As expected, the release of virions was dramatically 
reduced upon TSG101 depletion (Fig. 7A and C, "Virions," 
lanes "TSG101"), and the infectious titers were reduced ~20-
fold (Fig. 7B and D). Surprisingly, however, depletion of 
EAP20 did not significantly affect viral release as measured in 
Western blot assays (Fig. 7A and C, "Virions", lanes 
"EAP20"), and actually increased vector titers slightly at the 
24-h time point (Fig. 7B and D, bars 4), although at a later lime 
point (48 h), HIV-1 titers were reduced twofold (data not 
shown). We therefore conclude that efficient depletion of 
EAP20 does not significantly inhibit the release or infectivity of 
HIV-1. 
HIV-1 particles are also efficiently released from cells de-
pleted of CHMP6. The efficient release of HIV-1 from EAP20-
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FIG. 6. Localization of ESCRT-II and ESCRT-IH proteins by immunofluorescence. COS7 cells expressing fluorescent, exogenous, dominant-
ocgative GFP-VPS4AKI73Q (denoted GFP-VPS4A-KQ) were cotransfected and/or costained to detect the following proteins: (A) endogenous (endog) EAP20 protein (antibody UT461), (C) exogenous EAP20-Myc (anti-Myc antibody), (E) exogenous EAP30-myc (anti-Myc), and (G) en-
dogenous CHMP6 (UT463). Column 1 (from left), ESCRT proteins alone (red); column 2, GFP-VPS4A-KQ proteins alone (green); column 3, 
overlaid (merged) images (colocalization on class E compartments is in yellow); column 4, differential interference contrast (Die) images. Panels 
B, D, F, and H show the protein distributions in the absence of dominant-negative VPS4. Scale bars, 20 M-m. Note that our two EAP20 antibodies 
also stained COS7 and human osteosarcoma cell centrosomes and spindles (Fig. 6B), and one of our two CHMP6 antibodies, UT 464, exhibited 
a punctate nuclear staining pattern in addition to staining class E membranes (not shown). 
depleted cells was unexpected, and the implications of this 
observation were examined further by testing the requirement 
for CHMP6/ESCRT-HI in virus release. CHMP6 was selected 
for study because it binds EAP20, forms the only known con-
nection between ESCRT-II and ESCRT-III, is the only myris-
toylated CHMP protein (3, 88), and appears to initiate 
ESCRT-III assembly in yeast (3). 
The effects of CHMP6 depletion on the release and infec-
tivity of HIV-1 vectors and virus are shown in Fig. 8. As 
expected, virus release and infectivity were again substantially 
reduced upon siRNA depletion of TSG101 (Fig. 8A to D, lanes 
"TSG101" and bars 2), whereas treatment with an inverted 
control siRNA had no significant effect on virus release (de-
fined as 100% infectivity; lanes "INV" and bars 3). Two dif-
ferent siRNAs were used to knock down CHMP6 (designated 
CHMP6-1 and CHMP6-2), and both siRNAs decreased 
CHMP6 levels very significantly (Fig. 8A and C, "Cells," sec-
ond row) without affecting Gag protein expression or process-
ing (third row). As with EAP20 depletion, CHMP6 depletion 
again failed to reduce HIV-l release or infectivity substantially 
(Fig. 8Aand 8C, "Virions," and B and D). Although there was 
some variability in multiple repetitions of this experiment, the 
average viral titers nevertheless fell within 40% of control 
levels following treatment with both CHMP6-1 and CHMP6-2 
(Fig. 8B and D). At a later time point (48 h), viral infectivities 
were reduced four- to fivefold, possibly owing to secondary 
effects on general protein trafficking. We therefore conclude 
that normal cellular levels of CHMP6 are not required for 
efficient HIV-1 release or infectivity. 
EAP20 and CHMP6 are required for efficient downregula-
tion of the EGF receptor. The EGFR is normally present on 
the cell surface, where it can bind EGF and transmit growth 
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FIG. 7. siRNA depletion of EAP20 does not diminish HIV-1 vector telease or transduction efficiency. (A) Western blot analysis of 293T cell 
extracts showing the efficiency of siRNA depletion of TSG101 (positive control, lane TSG101 in top gel) or EAP20 (lane EAP20 in second gel from 
top) and the effects on Gag protein expression (third gel from top) and virus-like particle release (virions, bottom gel) from a cotransfected HIV-1 
vector system. Lanes Mock and INV are negative controls showing cells that were mock transfected without the HIV-1 vector or cotransfected with 
an inverted siRNA against TSG101 (INV), respectively. Cellular Gag, CA and MA levels were monitored to ensure equal transfection and protein 
expression levels. Extracellular CA and MA levels reflect the relative efficiencies of virus-like particle release. The TSG10I signal intensity for 
TSGlOl-depleted cells was 1% of that of the control, and the EAP20 signal intensity for EAP20-depIeted cells was 2% of that of the control. 
Quantification of at least three repetitions of this experiment showed the following levels of MA and CA release: TSG101 siRNA, 9% ± 2% of 
the control; inverted siRNA, 100% (defined as the control); EAP20, 108% ± 12%. The data were collected 48 h after the second siRNA 
transfection. (B) HIV-1 viral-vector titers produced by cells depleted of EAP20 or TSG101 (positive control). Vector transduction levels were 
normalized to the negative control (INV) and averaged from six independent experiments. Control vector titers were 2,5 X 105 to 3.2 X lO^ml. 
The data were collected 48 h after the second siRNA transfection. (C) Western blot analysis showing the efficiency and effects of siRNA-mediated 
silencing of EAP20 in unalogous experiments with wild-type (wt) HIV-1NW.3 virus. The experiment was similar to that shown in panels A and B, 
except that wt HIV-lp,,^, virus was utilized. Quantification of at least three repetitions of this experiment showed tile following levels of MA and 
CA release: TSG101 siRNA 12% ± 9% of the control: inverted siRNA, 100% (denned as the control); EAP20, 75% ± 4%. The data were 
collected 26 h after the second siRNA transfection. (D) HIV-1 titers produced by cells depleted of EAP20 or TSG101 (positive control). Control 
viral titers were 0.9 X 106 to 4 X 106/ml of supernatant. The values represent the average and standard error of eight independent experiments. 
The data were collected 24 to 26 h after the second siRNA transfection. 
signals. Following high levels of EGF stimulation, the receptor 
is internalized, trafficked through the MVB pathway, and de-
graded in the lysosome, thereby attenuating the growth signal 
(32,43). The lack of a requirement for EAP20 and CHMP6 in 
HIV-1 budding was surprising, and we therefore tested 
whether depletion of these proteins altered EGFR downregu-
lation, as would be expected for proteins that function in MVB 
vesicle formation and protein sorting. These experiments also 
served as controls for our ability to deplete TSG101, EAP20, 
and CHMP6 to functionally significant levels. 
As shown in Fig. 9, depletion of TSG101/ESCRT-I, EAP20/ 
ESCRT-II, and CHMP6/ESCRT-IH significantly reduced the 
efficiency of EGFR degradation in response to EGF stimula-
tion, although the block was not complete and was somewhat 
greater for TSG101/ESCRT-I than for EAP20/ESCRT-II and 
CHMP6/ESCRT-III. Total cellular EGFR protein levels and 
localization were assayed by immunofluorescence, using an 
anti-EGFR antibody. In the absence of EGF stimulation, 
EGFR was located almost exclusively on the surfaces of 293T 
cells (Fig. 9A, column 1 [from left] and inset). Following EGF 





* - fM 
*- <£, <o 
5 Q. n. 
» S I x 
I- 2 o o 
HIV + 
siRNA: 
— -» .— - » TSG101 
* » » » 4 ^ . - -
Ceils 






Cells i. " _ _^ 






1 2 3 4 5 1 2 3 4 5 
FIG. 8. HIV release and infectivity are minimally affected by CHMP6 depletion. (A) Western blot analysis of 293T cell extracts showing the 
efficiency of siRNA depletion of TSG101 (positive control; lane TSGiOl in the top gel) or CHMP6 (lanes CHMP6-1 and -2 in the second gel from 
the top) and the effects on Gag protein expression (third gel from the top) and virus-like particle release (virions; bottom gel) from a cotransfected 
HlV-i vector system. CHMP6 was depleted using two different siRNAs (denoted CHMP6-1 and CHMP6-2). Lanes Mock and INV are negative 
controls showing cells that were mock transfected without the HIV-1 vector or cotransfected with an inverted siRNA against TSG101 (INV), 
respectively. Cellular Gag, CA, and MA levels were monitored to ensure equal transfection and protein expression levels. The extracellular CA 
and MA levels reflect the relative efficiencies of virus-like particle release. The TSG101 signal intensity for TSG101 -depleted cells was 2% of that 
of the control, and the CHMP6 signal intensities for CHMP-6-depleted cells were 12% (CHMP6-1) and 3% (CHMP6-2) relative to the control. 
Quantification of at least three repetitions of this experiment showed the following levels of MA and CA release: inverted siRNA, 100% (defined 
as the control); CHMP6-1, 133% ± 14%; and CHMP6-2, 105% ± 35%. The data were collected 48 h after the second siRNA transfection. 
(B) HIV-1 viral-vector titers produced by cells depleted of CHMP6 Of TSG101 (positive control). Vector transduction levels were normalized to 
the negative control (INV) and averaged from four independent experiments. The data were collected 48 h after the second siRNA transfection. 
(C) Western blot analysis showing the efficiency and effects of siRNA-mediated silencing of the CHMP6 protein. The experiment was similar to 
that shown in panel A except that wild-type HIV-lNl4.3 virus was used. Quantification of at least three repetitions of this experiment showed the 
following levels of MA and CA release: inverted siRNA, 100% (defined as the control); CHMP6-1,109% ± 22%; and CHMP6-2, 94% i 38%. 
The data were collected 26 b after the second siRNA transfection. (D) HIV-1 titers produced by cells depleted of CHMP6 or TSG101 (positive 
control). Viral transduction levels were normalized to the negative control (INV) and averaged from eight independent experiments. The data were 
collected 26 h after the second siRNA transfection. The error bars represent standard deviations. 
stimulation for 2 h, >90% of the EGFR was internalized and 
degraded (column 2). Importantly, EGFR degradation was 
significantly reduced by treatment with siRNAs against 
TSG101 (column 4), EAP20 (column 5), and CHMP6 (column 
6), but not by treatment with a control siRNA (column 3). 
Depletion of the three ESCRT components did not affect 
receptor internalization but rather induced intracellular accu-
mulation of internalized receptors, consistent with a defect in 
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FIG. 9. EGF receplor downregulation is inhibited by depletion of TSG101, EAP20, and CHMP6. (A) 293T cells treated with siRNA were 
serum starved and then incubated in the presence or absence of EGF. Fixed and permeabilized cells were visualized by differential interference 
contrast (Nomarski) microscopy (top row) or by immunofluorescence to determine EGFR levels and localization (bottom row). Stacked whole-cell 
images are shown in all cases, with a central confocal slice (inset) also shown in the first image in the bottom row to demonstrate that the EGFR 
is located on the cell surface prior to EGF stimulation. (B) Quantification of the total levels of EGFR in 293T cells under the different conditions 
described for panel A. Each bar in the histogram represents the average fluorescence of individual cells as measured in three different images 
containing two to five cells per image. The error bars show the standard errors of the mean. The data were collected 91 h after the second siRNA 
transfection. (C) Quantification of total levels of EGFR in HeLa cells under the conditions described for panel A. The data were collected 92 h 
after the second siRNA transfection. 
MVB trafficking. We note that treatment with siRNAs against 
TSG101 resulted in the accumulation of EGFR in larger class 
E compartments (17) than were seen in cells treated with 
siRNAs against EA1S20 or CHMP6. The EGFR trafficking 
defects seen in the absence of ESCRT activities were similar in 
293T and HeLa cells, as shown quantitatively in Fig. 9B and C. 
The efficiencies of protein depletion and virus release were 
monitored in parallel experiments that confirmed that the tar-
geted proteins were depleted as expected and that HIV-1 re-
lease was significantly reduced by TSG101 depletion, but not 
by depletion of EAP20 or CHMP6 (data not shown). 
Bowers et al. recently reported that siRNA depletion of 
EAP20 did not measurably inhibit the lysosomal degradation 
of MHC-I and EGF-EGFR complexes (11). This differs from 
our conclusion that EAP20 depletion reduced the efficiency of 
EGFR degradation, and we therefore investigated the issue 
further by testing the effects of depleting TSG101/ESCRT-I, 
EAP20/ESCRT-II, and CHMP6/ESCRT-III on (i) MHC-I 
degradation and (ii) movement of fluorescent EGF to the 
lysosome. In the former experiments, we found that depletion 
of TSG101/ESCRT-I reduced the stimulation of MHC-I re-
ceptor degradation by the Kaposi's sarcoma-associated herpes-
virus ubiquitin ligase KK3 (13, 28), whereas depletion of 
EAP20/ESCRT-II and CHMP6/ESCRT-III did not (data not 
shown). These results are in excellent agreement with those of 
Bowers et al. (11), and we therefore conclude that efficient 
MHC-I downregulation requires TSG101/ESCRT-I but not 
EAP20/ESCRT-II or CHMP6/ESCRT-III. Thus, the ESCRT 
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FIG. 10. Colocalizatioil of EOF and lysosomal fluid phase markers upon depletion of TSG101, EAP20, and CHMP6. (A) HeLa cells were 
treated with the designated siRNA, Alexa 488-dextran (green), and EGF-Alexa Fluor 555 streptavidin (red) as described in Materials and 
Methods. (B) Quantification of the fractions of cells showing some colocalization of Alexa 488-dextran and EGF-Alexa Fluor 555 streptavidin 
under the different conditions described for panel A. The quantification of EGF (red) coincident with lysosome dextran (green) was performed 
in single-plane overlay analyses using the Olympus Fluoview software. Cells were scored as positive if the overlap coefficient {R) was greater than 
0.5. The error bars represent standard deviations. (C) Western blot analysis showing the efficiency of siRNA-mediated depletion of TSG101, 
EAP20, and CHMP6. 
requirements for MHC-I downregulation are similar to the 
requirements for HIV-1 budding. 
We examined the trafficking of EGF to the lysosome in cells 
depleted of TSG101/ESCRT-I, EAP20/ESCRT-1I, orCHMP6/ 
ESCRT-III. HeLa Cells depleted of TSGIOI/ESCRT-I, 
EAP20/ESCRT-II, or CHMP6/ESCRT-II1 were incubated 
with the fluid phase marker Alexa 488-dextran for 18 h, fol-
lowed by a 4-h chase in dextran-free medium, which allows the 
fluid phase marker to accumulate in lysosomes (12, 78). As 
shown above, the unstimulated EGFR is predominantly local-
ized to the plasma membrane. Incubation of cells with EGF-
Alexa Fluor 555 streptavidin induced the internalization of the 
EGFR, and after 30 min, fluorescent EGF colocalized with 
lysosomes in 41% of the cells examined (Fig. 10, "INV,") 
(86/208 cells). In contrast, cells depleted of TSG101/ESCRT-I 
showed no colocalization of EGF with lysosomes ("TSG101") 
(0/29 cells tested). Cells depleted of either EAP20/ESCRT-II 
or CHMP6/ESCRT-III showed intermediate phenotypes, with 
7 to 10% of the cells showing EGF staining at the lysosome. To 
control for possible differences between different siRNA oli-
gonucleotides, we also tested one of the siRNA oligonucleo-
tides used to deplete EAP20 in the study by Bowers et al. This 
oligonucleotide (EAP20-2) also efficiently depleted EAP20 
levels (Fig. IOC) and again gave an intermediate EGF local-
ization phenotype (Fig. 10A and B, "EAP20-2") (19/258 cells 
positive for EAP20-2 versus 10/140 cells for EAP20-1 and 
22/213 cells for CHMP6-2). 
As will be reported elsewhere, we have also now found that 
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degradation of ferroporlin, a cell surface receptor that is down-
regulated by hepcidin binding (55), shows a strong dependence 
on TSG101, EAP20, and CHMP6 (I. De Domenico, D. M. Ward, 
C. Langelier, M. B. Vaughn, E. Nemeth, W. I. Sundquist, T. 
Ganz, G. Musci, and J. Kaplan, unpublished data). We there-
fore conclude that lysosomal targeting of different cell surface 
receptors can differ in EAP20 and CHMP6 requirements. 
Some receptors, such as MHC-I, exhibit little or no require-
ment for these proteins, while other receptors, such as ferro-
portin, exhibit strong requirements, and still others, such as 
EGFR, exhibit intermediate phenotypes. These experiments 
indicate that there are probably multiple pathways for sorting 
membrane proteins into the MVB vesicles of mammalian cells. 
DISCUSSION 
Not surprisingly, our studies have revealed that the human 
ESCRT-II complex has a number of features in common with 
its better-characterized yeast counterpart. The similarities in-
clude interactions with ESCRT-I, ESCRT-III, and ubiquitin; 
transient association with endosomal membranes; and func-
tional participation in receptor downregulation. These obser-
vations are all consistent with the idea that ESCRT-II can play 
a central role in the human ESCRT pathway, interacting with 
the upstream ESCRT-I and downstream ESCRT-III com-
plexes and with ubiquitylated cargos as they are sorted into 
MVB vesicles. Nevertheless, depletion of EAP20/ESCRT-II 
and CHMP6/ESCRT-III did not significantly reduce HIV-1 
release from cultured 293T or HeLa cells, indicating that only 
a subset of the mammalian ESCRT machinery is required for 
efficient virus release from these cell types. 
Role of EAP20/ESCRT-II in HIV-1 release. We considered 
several possible explanations for the observation that EAP20/ 
ESCRT-II depletion does not inhibit HIV-1 release. As with 
all siRNA depletion experiments, it is possible that even the 
very low levels of EAP20 remaining after depletion were still 
sufficient to function in HIV-1 release (and MHC-I downregu-
lation). While we cannot rule out this possible explanation, il 
seems unlikely because EAP20 was efficiently depleted in our 
experiments (Fig. 7 and 10), and this depletion measurably 
inhibited EGFR degradation and lysosomal targeting (Fig. 9 
and 10). Furthermore, EAP20 depletion actually produced a 
slight, but reproducible, increase in HIV-l infectivity (Fig. 7), 
which could be explained if the endogenous ESCRT-II com-
plex binds and competes for other factors essential for virus 
budding (e.g., ESCRT-I). It is also conceivable that ESCRT-II 
may remain active even without EAP20 subunits. This expla-
nation again seems unlikely, because the two copies of EAP20 
comprise half of the ESCRT-II subunits and form the only 
known link between ESCRT-II and ESCRT-III. Furthermore, 
ESCRT-II activity is blocked by deletion of EAP20/Vps25p in 
both S. cerevisiae arid Drosophila (4, 76, 77). We therefore 
conclude that the most likely explanation for our data is that 
ESCRT-II is not required for efficient HIV-1 release from 
human cells, either because the complex does not normally 
participate in virus budding or because the viral budding ma-
chinery still functions efficiently in its absence. 
Our results also imply that if HIV-1 utilizes the late-acting 
ESCRT-III and VPS4 complexes to bud from cells, then there 
must be other proteins or complexes, in addition to ESCRT-II, 
that can bridge ESCRT-I and ESCRT-III. In principle, ALIX/ 
AIP1 could be one such bridging protein, as it can bind directly 
to both TSG101 (83) and to the CHMP4 proteins (38, 41, 69, 
83), although simultaneous depletion of ALIX and EAP20 did 
not synergistically inhibit EGFR degradation (11). Similarly, 
interactions between the yeast ESCRT-I components, Vps37p 
and Vps28p, and the ESCRT-III component, Vps20p 
(CHMP6), have been reported (10), although we did not ob-
serve analogous ESCRT-I-ESCRT-III interactions between 
the isolated human proteins in two-hybrid experiments. Fi-
nally, the deubiquitylating enzyme, AMSH, binds both the 
upstream HRS-STAM complex (which binds to TSG101) (71) 
and the ESCRT-III components CHMP3 and CHMP4 (23). In 
principle, these (and other) bridging interactions could help to 
recruit ESCRT-III to sites of MVB vesicle formation and virus 
budding even in the absence of ESCRT-II. 
Role of ESCRT-III in HIV-1 release. Models for the roles of 
ESCRT-III (and VPS4) in virus budding must take into ac-
count the observation that HIV-1 release is not significantly 
inhibited by depletion of endogenous CHMP5 and CHMP6 
(reference 85 and this work), yet virus release is very potently 
inhibited by overexpression of dominant-negative CHMP5 or 
CHMP6 protein (46, 69, 70). siRNA depletion of these indi-
vidual CHMP proteins therefore imposes a less severe (or less 
general) block in the ESCRT pathway than the dominant-
negative ESCRT-III and VPS4 constructs. A likely explanation 
for this difference is that dominant-negative CHMP (and 
VPS4) constructs function by inducing the formation of aber-
rant endosomal compartments (class E compartments) that 
not only inhibit the functions of the modified CHMP proteins 
themselves, but also sequester other ESCRT complexes and 
possibly many other MVB proteins required for HIV-1 bud-
ding. Thus, we cannot rule out the possibility that wild-type 
CHMP and VPS4 proteins do not normally function in HIV-1 
release but rather affect virus budding only when present in 
dominant-negative forms. However, we favor a model in which 
at least a subset of the ESCRT-III and VPS4 proteins do 
actually participate directly in virus release but where deple-
tion of individual CHMP5 or CHMP6 proteins does not inhibit 
virus budding owing to (i) functional redundancy within the 
MVB pathway arising from the presence of 10 different CHMP 
proteins, (ii) the possibility that CHMP5 (and possibly other 
CHMP proteins) may function at a step following MVB vesicle 
formation (7, 66), and/or (iii) the presence of multiple distinct 
ESCRT pathways in human cells. It therefore continues to be 
important to determine precisely which subset of different 
ESCRT proteins is utilized directly by HIV-1 and other vi-
ruses. 
Complexity of MVB vesicle formation and protein sorting in 
higher eukaryotes. Genetic studies have identified the basic 
machinery required for MVB vesicle formation and protein 
sorting in S. cerevisiae. Importantly, deletion of each of the six 
known yeast ESCRT-I and ESCRT-II subunits ultimately leads 
to a strong block in protein sorting and MVB vesicle formation 
(the class E phenotype) (40). While it seems almost certain 
that the basic mechanism of MVB biogenesis is highly con-
served, because human cells have at least one ortholog of every 
known yeast class E protein (33, 51), our studies add to the 
growing number of indications that MVB protein-sorting/ves-
icle formation pathways are more complex in higher eu-
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karyotes than in yeasl. One level of increased complexity is 
suggested by the fact that unique yeast class E proteins often 
have multiple orthologs in mammalian cells. Examples include 
the 4 different human homologs of the single yeast Vps37p 
protein (6,19,70), the 10 different human homologs of the six 
yeast ESCRT-III proteins (51), and the 2 (or more) different 
human homologs of yeast Vps4p (60). Thus, unique proteins or 
complexes that are essential for MVB formation in yeast may 
play redundant or overlapping roles in higher eukaryotes. For 
example, simultaneous depletion of both VPS37B and VPS37C 
inhibits PTAP-dependenl retrovirus budding to a greater ex-
tent than depletion of either single VPS37 paralog alone (48). 
A second level of complexity is suggested by the fact thai 
even unique ESCRT-I or ESCRT-II subunits do not appear to 
be required for metazoan MVB vesicle formation in all con-
texts. For example, a knockout of the Drosophila Vps28/ 
F.SCRT-I protein has only modest effects on MVB morphology 
and no measurable effect on the downregulation of several 
different cell surface receptors in vivo, even though there is 
only a single vps28 gene in Drosophila (63). Similarly, agonist-
induced lysosomal degradation of the delta opioid receptor is 
inhibited by dominant-negative VPS4B mutants and by deple-
tion of HRS, but not by depletion of TSG101/ESCRT-I (31). 
Hence, an intact ESCRT-I complex is apparently not required 
for downregulation of all cell surface receplors via the MVB 
pathway (27, 31). Similarly, EAP20/ESCRT-1I is not required 
for MHC-I receptor downregulation induced by Kaposi's sar-
coma-associated herpesvirus KK3 (reference 11 and data not 
shown). 
Retroviruses also differ in their requirements for ESCRT-I. 
HIV-1, which binds directly to TSG101, requires all of the 
known ESCRT-I components for efficient release (19, 22, 48), 
whereas equine infectious anemia virus and Moloney murine 
leukemia virus, which bud primarily via ALIX and the Nedd4 
E3 Iigases, respectively, exhibit little or no requirement for 
TSO101/ESCRT-I (22, 48,62, 64, 72). Nevertheless, all retro-
viruses are inhibited by dominant-negative ESCRT-III and 
VPS4 proteins, suggesting a common use of these downstream 
factors (22, 46, 69, 83). This model is consistent with the idea 
that ESCRT-I and ESCRT-II may function primarily as adap-
tor complexes that help recruit cargoes into the pathway, 
whereas the F,SCRT-III/VPS4 machinery functions more di-
rectly in vesicle formation. Indeed, the genomes of Plasmo-
dium falciparum and Toxoplasma gondii reportedly lack ES-
CRT-I and ESCRT-II entirely but do encode ESCRT-III and 
VPS4 proteins and require VPS4 to create multivesicular bod-
ies (87). Finally, we note that even the ESCRT-III/VPS4 ma-
chinery appears to be dispensable in some cases, as the mela-
nosomal protein Pmell7 is sorted into MVB vesicles via an 
ESCRT-independent pathway that is also insensitive to inhibi-
tion by dominant-negative forms of VPS4 (75). The apparent 
diversity of MVB sorting pathways raises the intriguing possi-
bility that viral systems may also have evolved to utilize such 
"noncanonical" MVB pathways to escape the cell (34). 
Roles for mammalian ESCRT-1 and ESCRT-II in receptor 
downregulation. Although ESCRT-I and ESCRT-II are not 
absolutely required for the efficient downregulation of all re-
ceptors or for the release of all retroviruses, both complexes 
clearly play very important roles in downregulating certain cell 
surface receptors. Indeed, a number of recent studies indicate 
that both ESCRT-I and ESCRT-II exhibit growth/tumor sup-
pressor activities by virtue of their roles in cell surface receptor 
downregulation. For example, all three known ESCRT-I com-
ponents (TSG101, VPS28, and VPS37) have now been impli-
cated in cell growth and tumor suppression. TSG101 was ini-
tially identified in a genetic screen for genes with tumor 
suppressor activity, and depletion of TSG101 induces NIH 3T3 
cell overproliferation in culture and metastatic tumor forma-
tion in nude mice (44). Similarly, deletion of erupted, the Dro-
sophila TSG101 ortholog, inhibits Notch receptor degradation 
and activates the JAK-STAT (and possibly other) signaling 
pathway and thereby induces tissue overproliferation (50). 
Likewise, depletion of one of the four mammalian VPS37 
proteins (6,19,70), VPS37A/HCRP-1, enhances the growth of 
cultured hepatocellular carcinoma BEL-7404 cells and elevates 
their invasive ability (86). Interestingly, VPS37A/HCRP-1 is 
also downregulated in some hepatocellular carcinomas. Fi-
nally, we have observed that depletion of VPS28 can relieve 
contact-inhibited growth in cultured 293T cells (J. Garrus, per-
sonal communication). ESCRT-II also appears to play an im-
portant role in growth receptor downregulation, as deletion of 
the Drosophila vps25 gene leads to tissue overproliferation 
through aberrant stabilization of the Notch and DPP (and 
possibly other) receptors (76, 77). Similarly, we observed that 
depletion of EAP20 (human VPS25) reduces the degradation 
rates of EGFR (Fig. 9 and 10), ferroportin (De Domenico, et 
al., unpublished), and presumably other cell surface receptors 
following ligand stimulation. Thus, just as the proteasome 
functions to degrade soluble proteins, the mammalian ESCRT 
pathway, including ESCRT-II, can play a critical role in medi-
ating both homeostatic and regulated lysosomal degradation of 
integral membrane proteins. 
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The ESCRT-I and ESCRT-II complexes help sort ubiquitinated 
proteins into vesicles that accumulate within multivesicular 
bodies (MVBs). Crystallographic and biochemical analyses 
reveal that the GLUE domain of the human ESCRT-II EAP45 
(also called VPS36) subunit is a split pleckstrin-homology 
domain that binds ubiquitin along one edge of the (^-sandwich. 
The structure suggests how human ESCRT-II can couple 
recognition of ubiquitinated cargoes and endosomal 
phospholipids during MVB protein sorting. 
Late endosomal compartments called multivesicular bodies serve as 
primary sorting sites for cell-surface receptors and other membrane 
proteins that are ultimately downregulated through lysosomal degra-
dation. Ubiquitinated cargoes are sorted into MVB vesicles through 
the sequential action of three multiprotein complexes called ESCRT-I, 
ESCRT-n and ESCRT-III1. Both human and yeast ESCRT-I complexes 
bind ubiquitin (Ub) through ubiquitin E2 variant domains of the 
TSG101 (yeast Vps23p) subunit2'3. In contrast, the human and yeast 
ESCRT-II complexes must recognize ubiquitin differently, because 
yeast ESCRT-II binds Ub through the second of two Npl4 zinc finger 
(NZF) modules embedded within the 'GRAM-like Ub binding in 
EAP45* (GLUE) domain of the Vps36p subunit4, whereas the mam-
malian homolog, EAP45 (or VPS36), binds Ub directly through its 
GLUE domain5. 
To leam how human ESCRT-II recognizes ubiquitinated protein 
cargoes, we determined crystal structures of the EAP45 GLUE-Ub 
complex (Fig. 1, Supplementary Methods and Supplementary Table 1 
online). Like its yeast counterpart6, EAP45 GLUE adopts a pleckstrin-
homology (PH) domain fold, with a seven-stranded P-sandwich 
capped by a C-terminal cc-helix (Fig. la). The EAP45 and Vps36p 
GLUE domains are both 'split' by insertions within the S6-S7 loop. 
Split PH domains have been characterized previously7-9, but these are 
the first examples in which the insertion occurs at this position. The 
16-residue insertion of EAP45 GLUE forms an exposed loop that 
buttresses the base of the bound Ub molecule and then extends into 
solution, whereas the larger insertion within Vps36p ( ~ 150 residues) 
contains two NZF modules that bind ESCRT-I and Ub4'6, respectively. 
The structures of the human EAP45 and yeast Vps36p GLUE domains 
are otherwise very similar (r.m.s. deviation of 0.77 A over secondary 
structure regions), despite sharing just 14% sequence identity (see 
Supplementary Figs. 1 and 2 online). 
In the complex, the S5 edge of the second sheet of the EAP45 GLUE 
fi-sandwich binds the exposed Ub fS-sheet. The Ub interface is 
centered about Val70 and spans an extended hydrophobic patch 
b ^ 
Figure 1 Structure of the EAP45 GLUE-Ub complex, (a) Ribbon and space-filling model of the complex, with the EAP45 GLUE molecule shown in cyan, 
(b) Expanded view of the Ub Ile44-EAP45 binding interface (orientation is similar to a), (c) Expanded view showing the approximate locations of the 
canonical (PIA, orange) and noncanonical (Pig, magenta) Pl-binding sites. To identify the different Pl-binding sites, the EAP45 GLUE structure was overlaid 
onto the PH domain complexes DAPP1/PHISH-I(l,3,4,5)p4 (PDB 1FA0, secondary structure r.m.s. deviation = 2.8 A, canonical Pl-binding site)14 and 
P-spectrin-l(1.4,5)p3 (PDB 1BTN, secondary structure r.m.s. deviation =: 3.4 A, noncanonical Pl-binding site)15. The DAPP1 and p-spectrin backbones 
were then removed for clarity. Basic side chains in the binding site are shown explicitly, and the translucent space-filling model is color coded according 
to electrostatic potential (dark blue to red, +5 t o - 5 keTei1). 
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Ubiquitin (M) 
Figure 2 Biosensor binding analyses of the EAP45 GLUE-Ub interaction. 
Isotherms show Ub binding to wild-type and mutant EAP45 GLUE proteins 
(see inset for color coding). Measured K& values (uM) were as follows: wild-
type protein = 105 \M; L10D = 133; V67A > 1,000; F68A > 1,000; 
E70A > 1,000. Error bars from triplicate measurements were smaller than 
the data points. 
including Ile44, Leu73 and Leu8, whereas the EAJP45 GLUE binding 
interface is centered about Phe68 and is comprised of residues from 
S5, S6, H2 and the S6-S7 loop (Fig. lb). The interface core is 
hydrophobic on both sides, with peripheral hydrophilic side chain 
interactions, including Ub Arg42-EAP45 Glu70 (salt bridge) and 
possibly Ub Lys4&-EAP45 Thrl27 (hydrogen bond). Several key 
interacting residues are not conserved in yeast Vps36p, consistent 
with the idea that yeast ESCRT-H instead binds Ub through an NZF 
domain (Supplementary Figs. 1 and 2). 
In the two crystal forms examined, each EAP45 GLUE domain 
makes similar contacts with two different ubiquitin molecules, one 
through the primary binding site described above and a second 
through an interface centered about EAP45 residue LeulO. Several 
Ub-binding domains (UBDs) have recently been shown to bind two 
Ub molecules10, ]1, and we therefore tested the relevance of both 
crystaUographic EAP45 GLUE interfaces for Ub binding in solution. 
Ub bound the immobilized wild-type EAP45 GLUE domain with a 
dissociation constant of ~ 100 uM, which matches the binding energies 
of many other UBD-Ub interactions (see Fig. 2 and Supplementary 
Table 2 online for full details)12. Mutation of any of the three key 
residues in the primary EAP45 GLUE binding interface (V67A, F68A or 
E70A) reduced the Ub-binding affinity more than ten-fold (Fig. 2). 
Similarly, a single point mutation in the primary Ub-binding surface 
(144A) also reduced EAP45 GLUE binding affinity up to 
20-fold (Supplementary Table 2). In contrast, a mutation in the center 
of the second EAP45 GLUE-Ub crystaUographic interface (L10D) did 
not reduce the Ub-binding affinity appreciably. These data all support 
the idea that the primary interface seen in the EAP45 GLUE-Ub crystal 
structure forms in solution, whereas the second interface does not. 
Like many other PH domains, the GLUE domains from EAP45 
and Vps36p also bind inositol phosphates/phosphatidylinositides 
(abbreviated PI)5,6, and the yeast protein binds preferentially to 
liposomes containing PI(3)P (ref. 6), which is the predominant 
endosomal PI13. PH domains can bind PI ligands at two distinct 
sites: a canonical site located between the S1-S2 and S3-S4 loops 
(PIA in Fig. lc) and a noncanonical site located on the other side of 
the S1-S2 loop, in a pocket between the S1-S2 and S5-S6 loops (PIB in 
Fig. lc). An overlay of the EAP45 GLUE structure onto PH-PI 
complexes from DAPP1 (canonical PI site) and P-spectrin (noncano-
nical PI site) illustrates that the noncanonical site in EAP45 GLUE 
forms an extended groove surrounded by basic residues, whereas the 
canonical site is actually slightly acidic. The EAP45 GLUE structure 
therefore indicates that Pis probably bind in the noncanonical site 
(Pig), in good agreement with a recent mutational analysis of the 
Vps36p GLUE domain6. In vitro, the mammalian EAP45 GLUE 
domain preferentially binds phosphorylated 3-phosphoinositides 
such as PI(3,4,5)P3 (ref. 5), and this apparent difference between the 
human and yeast proteins may reflect the presence of three additional 
basic residues in the human EAP45 PIP-binding site {Arg25, Lys34 
and LysI07; see Fig. lc and Supplementary Figs. 1 and 2). 
In summary, we find that EAP45 GLUE adopts a split PH domain 
fold that couples the recognition of ubiquitinated cargoes and 
endosomal membranes. Pis appear to bind in the noncanonical site 
at the apex of the S-sandwich, whereas ubiquitin binds along the 
opposite edge of the second sheet. It appears possible that EAP45 
GLUE could bind Ub and Pis cooperatively, as the two binding sites 
are physically linked through the intervening S5-S6 B-hairpin. We 
speculate that in the absence of ligand binding, the extended insertion 
that splits the EAP45 GLUE domain between strands S6 and S7 could 
act as a hinge that allows the S5-S6 hairpin to sample both closed 
(ligand binding) and open (nonbinding) conformations. Although 
speculative, such an allosteric binding model is consistent with 
suggestions that PH domain splitting may support regulated phos-
pholipid binding in other biological systems7,8. 
Accession codes. Protein Data Bank: Coordinates and structure 
factors have been deposited with accession code 2HTH. Research 
Collaboratory for Structural Bioinformatics: 038741. 
Note: Supplementary information is c 
Biology website. 
tillable on the Nature Structural & Molecular 
ACKNOWLEDGMENTS 
Biosensor analyses, protein sequencing and mass spectrometry were performed 
at University of Utah core facilities, and we also thank 1. Jafri for technical 
assistance. This work was supported by US National Institutes of Health grants 
to CP.H. (GM66521) and WJ.S. (AI51174). The National Synchrotron Light 
Source is funded by the US National Center for Research Resources, by the US 
Department of Energy, Office of Basic Energy Sciences and by the US National 
Institutes of Health. 
COMPETING INTERESTS STATEMENT 
The authors declare that they have no competing financial interests. 
Published online at http://www.nature.com/nsmb/ 
Reprints and permissions information is available online at http://npg.nature.com/ 
reprintsandpe [missions/ 
1. Hurley, J.H. & Emr, S.D. Anna. Rev. Biophys. Biomol. Struct. 35, 277-298 (2006) 
2. Sundquist, W.I. ef al. Mol. Cell 13, 783-789 (2004). 
3. Teo, H., Veprintsev, D.B. & Williams, R.L J. Biol. Chem. 279, 28689-28696 (2004). 
4. Atam, S.L. etal. EMBOJ. 23, 1411-1421 (2004). 
5. Slagsvold, T. etal. J. Biol. Chem. 280, 19600-19606 (2005). 
6. Teo, H. etal. Cell 125, 99-111 (2006). 
7. Lemmon, MA Cell 120, 574-576 (2005). 
8. Van, J. et al. EMBO J. 24, 3985-3995 (2005). 
9. Wen, W., Yan, J. & Zhang, M. J. Biol. Chem. 281, 12060-12068 (2006). 
10. Trempe, J.F. etal. EMBOJ. 24. 3178-3189 (2005). 
11. Hirano, S. etal. Nat. Struct. Mol. Biol. 13, 272-277 (2006). 
12. Hicke, I., Schubert, H.L. & Hill, C.P. Nat Rev. Mol. Cell Biol. 6, 610-621 
(2005). 
13. Birkeland, H.C. & Stenmark, H. Curr. Top. Microbiol. Immunol. 282, 89-115 
(2004). 
14. Ferguson, K.M. etal. Mol. Cell6, 373-384 (2000). 
15. Hyvonen, M. etal. EMBOJ. 14, 4676-4685 (1995). 
VOLUME 1 3 NUMBER 11 NOVEMBER 2006 NATURE STRUCTURAL & MOLECULAR BIOLOGY 
CHAPTER 5 
THE MOLECULAR MECHANISM OF HEPCIDIN-MEDIATED 
FERROPORTIN DOWN-REGULATION 
Molecular Biology of the Cell 
Vol. 18, 2569-2578, July 2007 
The Molecular Mechanism of Hepcidin-mediated 
Ferroportin Down-Regulation 
Ivana De Domenico,* Diane McVey Ward,* Charles Langelier/ 
Michael B. Vaughn/ Elizabeta Nemeth,* Wesley I. Sundquist / Tomas Ganz,* 
Giovanni Musci,§ and Jerry Kaplan* 
Depar tments of 4Pathology and b iochemis t ry , School of Medicine, University of Utah, Salt Lake City, U T 84132; 
•Depar tment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, 
C A 90095; and §Dipart imento di Scienze e Tecnologie Agroa l imenta r i , Ambiental i e Microbiologiche, University 
del Molise, Campobasso, Italy 86100 
Submitted January 26, 2007; Revised April 10, 2007; Accepted Apri ! 19, 2007 
Monitoring Edi tor Sandra Schmid 
Ferroportin (Fpn) is the only known iron exporter in vertebrates. Hepcidin, a peptide secreted by the liver in response to 
iron or inflammation, binds to Fpn, inducing its internalization and degradation. We show that after binding of hepcidin, 
Fpn is tyrosine phosphorylated at the plasma membrane. Mutants of human Fpn that do not get internalized or that are 
internalized slowly show either absent or impaired phosphorylation. We identify adjacent tyrosines as the phosphory-
lation sites and show that mutation of both tyrosines prevents hepcidin-mediated Fpn internalization. Once internalized, 
Fpn is dephosphorylated and subsequently ubiquitinated. An inability to ubiquitinate Fpn does not prevent hepcidin-
induced internalization, but it inhibits the degradation of Fpn. Ubiquitinated Fpn is trafficked through the multivesicular 
body pathway en route to degradation in the late endosorne/tysosome. Depletion of proteins involved in multivesicular 
body trafficking (Endosome Sorting Complex Required for Transport proteins), by small-interfering RNA, reduces the 
trafficking of Fpn-green fluorescent to the lysosome. 
INTRODUCTION 
Iron homeostasis in vertebrates is dominated by the lack of 
an excretory route for excess iron. Plasma iron level is reg-
ulated by the rate of iron entry through the duodenal mu-
cosa, which affects net iron absorption, and by the rate of 
iron release from macrophages recycling iron from aged or 
damaged erythrocytes (Hentze et al., 2004; Camaschella, 
2005; Donovan et al, 2006). Export of iron from duodenal 
enterocytes and macrophages into plasma is regulated by 
the plasma membrane transporter ferroportin (Fpn) (Abboud 
and Haile, 2000; Donovan et al., 2000; McKie et al,, 2000). Fpn 
is the receptor for hepcidin, a peptide of 25 amino acids 
synthesized by the liver in response to inflammation and 
increased iron stores (Ganz and Nemeth, 2006). Binding of 
hepcidin to Fpn results in the internalization and degrada-
tion of Fpn, leading to a decrease in iron export (Nemeth et 
al., 2004). Decreased plasma iron leads to a reduction in 
hepcidin synthesis, resulting in increased plasma membrane 
Fpn and increased iron delivery into plasma. 
Inadequate hepcidin production can explain many of the 
genetic forms of iron overload disease, whereas high levels 
of hepcidin produced by prolonged inflammatory stimuli 
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can account for hypoferremia and anemia of chronic disease 
(Weiss and Goodnough, 2005; Pietrangelo, 2006). There is 
one form of genetic iron overload disease, however, that is 
not caused by abnormal hepcidin production. This disease, 
referred to as ferroportin disease or hereditary hemochro-
matosis type 4, results from mutations in the Fpn gene 
(Pietrangelo, 2004). Characterization of mutant alleles of Fpn 
showed that some Fpn mutant proteins are not appropri-
ately targeted to the cell surface, whereas other mutant 
proteins are appropriately targeted to the plasma mem-
brane, but they have impaired internalization in response to 
hepcidin (De Domenico et al, 2005; Drakesmith et al, 2005; 
Liu et al, 2005; Goncalves et al, 2006). To understand the 
molecular basis of the defect in hepcidin-resistant Fpn mu-
tants, we examined the mechanism of hepcidin-induced in-
ternalization and degradation. We show that in response to 
hepcidin, Fpn is phosphorylated and that phosphorylation is 
required for internalization. Once internalized, Fpn is ubi-
quitinated and trafficked through the multivesicular body 
(MVB) for degradation in the lysosome. 
MATERIALS AND METHODS 
Cells and Media 
Mouse Fpn was expressed in a cytomegalovirus (CMV)-containing vector 
(pECFP-Nl, Clontech, Mountain View, CA; or pCMV-Tag4 (FLAG], Strat-
agene. La Jolla, CA) as described previously (De Domenico et al., 2005). 
Human embryonic kidney (HEK)293T cells were maintained in DMEM with 
10% fetal bovine serum and transfected with pFpn-enhanced green fluores-
cent protein (EGFP)-Nl, pFpn{mutations>-EGFP-Nl, pCMV-Fpn-FLAG, pDy-
namin-EGFP, or pDynaminK44A-EGFP by using Nucleofector technology 
(Amaxa, Gaithersburg, MD), according to die manufacturer's directions. 
FM3A and ts85 cells were maintained in RPMI 1640 medium with 5% fetal 
bovine serum and transfected using Nucleofector technology. HEK293T Fpn, 
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a stable cell line in which Fpn-green fluorescent protein (GFP) expression is 
regulated by the ecdysbne promoter, has been described previously (Nemeth 
el al, 2004; De Domenico et al., 2005). 
Generation ofFpn Constructs 
All Fpn mutations were generated in pFpn-EGFP-Nl by using the 
QuikChange site-directed mutagenesis kit (Stratagene), amplified in Esche-
richia coli, and sequence-verified before transfecting into mammalian cells. 
Small Interfering RNA (siRNA) Transfection 
siRNA oligonucleotide or siRNA pools matching selected regions of TSC101, 
L1P5, and CHMP5 were as described previously (Garrus el al., 2001, Ward et 
al., 2005). siRNA oligonucleotides for CHMP6 and EAP20 were as described 
in Langelier et al. (2006). siRNA oligonucleotide pools matching selected 
regions of epsin were obtained from Dhaimacon RNA Technologies (Lafay-
ette, CO). HEK293T Fpn-GFP cells were transfected with siRNA oligonucle-
otides at a final concentration of 50-100 nM by using OligofectAMINE 
reagent (Invitrogen, Carlsbad, CA). Twenty-four to 48 h after transfection, the 
cells were trypsinized and plated onto 60-mm plates with or without cover-
slips. Twenty-four hours after plating, the cells were induced to express 
Fpn-GFP, incubated in the presence or absence of 1 fig/ml hepcidin, and then 
processed for fluorescence microscopy or Western analysis. 
Other Procedures 
Biotinylation of the plasma membrane of HEK293T cells was performed using 
sulfosuccin im idyl-2-(biotinarnido)ethy 1-1,3-d ithiopropinate (s u Ifo- NHS-SS-
biotin) (Pierce Chemical, Rockford, IL) according to the manufacturer's in-
structions Immunoprecipitation of Fpn-GFP or Fpn-FLAG was performed as 
described previously (De Domenico et al., 2005) using either protein A/G 
resin (Santa Cruz Biotechnology, Santa Cruz, CA) and rabbit anti-GFP 
(ab65561; Abeam, Cambridge, MA), anti-FLAG M2 affinity gel (Sigma-AJ-
drich, St. Louis, MO), or immobilized streptavidin affinity gel (Pierce Chem-
ical). Immunoprecipitation of phosphotyrosine was performed using mouse 
anti-phosphotyrosine antibody (1:500) (Calbiochem, San Diego, CA) and pro-
tein A/G resin (Santa Cruz Biotechnology). Samples were analyzed by SD5-
polyacryiamide gel electrophoresis under nonreducing conditions. Samples 
were heated at 37°C for 10 min before being applied to the SDS-PACE. 
Western analysis was performed using either mouse anti-FLAG antibody 
(1:10,000; Sigma-Aldrich); rabbit anti-GFP (1:10,000, ab6556; Abeam); goat 
anti-human actin (1:1000; Santa Cruz Biotechnology); mouse anti-tubulin 
(1:1000; GeneTex, San Antonio, TX); mouse anti-phosphotyrosine clone 16F4 
(1:500; Calbiochem), mouse anti-ubiquitin (1:1000; Covance, Berkeley, CA); 
mouse anti-TSGlOl (1:1000; GeneTex), rabbit anti-UP5 (1:500), rabbit anti-
CHMP5 (1:500), rabbit anti-CHMP6 (1:1000), rabbit anti-EAP20 (1:10001, or 
rabbit anti-epsin (1:1000; Santa Cruz Biotechnology) followed by either per-
oxidase-conjugated goat anti-mouse immunoglobulin (Ig)G (1:10,000; Jackson 
ImmunoResearch Laboratories, West Grove, PA), peroxidase-conjugated goat 
anti-rabbit IgG (1:10,000; Jackson ImmunoResearch Labs, West Grove, PA) or 
peroxidase-conjugated donkey anti-goat IgG (1:5000; Santa Cruz Biotechnol-
ogy). All Westerns were normalized for the total protein concentration using 
the bicinchoninic acid assay (Pierce Chemical). Immunofluorescence and 
ferritin analysis were performed as described previously (De Domenico et al., 
2005). All experiments Were performed a minimum of three times, and error 
bars represent the SD. Analysis of fluorescent images was performed as 
described previously (Langelier et al., 2006). The calf intestinal phosphatase 
was obtained from New England Biolabs (Ipswich, MA), and it was used 
according to the manufacturer's instructions. 
RESULTS 
Fpn Is Ubiquitinated and Phosphorylated in Response to 
Hepcidin 
Ubiquitination and phosphorylation are two protein modi-
fications known to signal the internalization of plasma mem-
brane proteins (Bonifacino and Traub, 2003). We examined 
whether hepcidin binding to Fpn induces either of these 
modifications. Hepcidin was added to cells, and Fpn-GFP 
was immunoprecipitated and examined for Fpn modifica-
tions by Western blot analysis using specific antibodies. As 
shown previously, Fpn-GFP is fully active for iron export 
and is hepcidin responsive (Nemeth et al., 2004). A 15-min . 
incubation of Fpn-GFP-expressing cells with hepcidin led to 
both ubiquitination and tyrosine phosphorylation of Fpn-
GFP (Figure 1A). Both modifications were independent of the 
epitope tag on Fpn, and tyrosine phosphorylation was detected 
using four different monoclonal antibodies (data not shown). 
Both ubiquitination and phosphorylation changed the appar-
ent molecular mass of Fpn-GFP. Although the change in mo-
lecular mass of the ubiquitinated species was consistent with 
addition of multiple ubiquitins, a polyubiquitin "ladder" was 
not seen. The change in the molecular mass of the phosphor-
ylated species was also unexpectedly large. The samples are 
run under nonreducing conditions because reduction and heat 
treatment result in an inability to detect Fpn. In the Western 
blot, the high-molecular-mass Fpn-GFP species are a small 
fraction of the total Fpn-GFP, suggesting that phosphorylation 
and ubiquitination are brief transient events. 
Phosphorylation of fpn Occurs at the Cell Surface 
We next examined whether ubiquitination and phosphory-
lation were required for internalization. To determine 
whether these events occur at the cell surface, we used the 
membrane-impermeable biotinylation reagent suIfo-NHS-
SS-biotin to distinguish between cell surface and internal-
ized Fpn. Cells were treated with sulfo-NHS-SS-biotin at 
specific times after incubation with hepcidin to distinguish 
cell surface Fpn-GFP from internalized Fpn-GFP. Biotinyl-
ated proteins were purified using streptavidin beads, and 
the affinity-purified samples were examined for Fpn-GFP by 
Western blot analysis using antibodies against GFP. Treat-
ment of cells with the sulfo-NHS-SS-biotin resulted in bioti-
nylation of Fpn-GFP (Figure IB, bottom). In the absence of 
ponasterone A (no Fpn^CJFP expression), there was no de-
tectable biotinylated Fpn-GFP. No Fpn-GFP was detected in 
the absence of sulfo-NHS-SS-biotin. The amount of biotin-
ylated Fpn-GFP decreased upon addition of hepcidin. The 
disappearance of total cellular Fpn-GFP closely parallels the 
disappearance of cell surface Fpn-GFP, indicating that inter-
nalized Fpn-GFP is rapidly degraded. We note that Fpn-GFP 
often occurs as a doublet (De Domenico et al., 2005). Biotin-
ylated Fpn-GFP was examined for protein modifications. 
Cell surface Fpn-GFP was phosphorylated within 15 min of 
hepcidin addition (Figure 1C, lane 5, top) but not ubiquiti-
nated (Figure 1C, lane 5, middle). In contrast, internalized 
Fpn-GFP, which was not biotinylated and did not bind to 
streptavidin beads ("flow-through"), was ubiquitinated (Fig-
ure 1C, lane 6, middle), but phosphorylation was no longer 
detected (Figure 1C, lane 6, top). These results suggest that 
phosphorylation is the primary event in response to hepcidin 
and that it occurs on the cell surface followed by ubiquitina-
tion, which occurs once Fpn-GFP has been internalized. 
A dominant-negative mutant of dynamin 1, unable to 
hydrolyze GTP, inhibits both clathrin- and caveolin-medi-
ated internalization (Damke et ah, 1994). We took advantage 
of this dynamin mutant to confirm that phosphorylation is a 
proximal effect of hepcidin binding to Fpn. Transfection of 
HEK293T cells with plasmids expressing wild-type dy-
namin-GFP and Fpn-FLAG did not prevent hepcidin-in-
duced Fpn-FLAG internalization (Figure 2A). In contrast, 
transfection with a dominant-negative dynamin(K44A)-GFP 
inhibited hepcidin-induced internalization of Fpn-FLAG. 
Likewise, Western blot analysis showed that cells trans-
fected with the dynamin(K44A)-GFP and treated with hep-
cidin had higher levels of Fpn-FLAG compared with hepci-
din-treated cells expressing wild-type dynamin-GFP (Figure 
2B). Immunoprecipitation of Fpn-FLAG followed by West-
em blot analysis showed that Fpn was phosphorylated at the 
plasma membrane; however, it was not ubiquitinated in 
cells expressing the dynamin mutant (Figure 2B). These 
results confirm that phosphorylation is an early event that 
occurs at the cell surface and that ubiquitination occurs after 
Fpn is internalized. We note that the migration pattern of 
ubiquitinated Fpn-FLAG does not increase as would be 
predicted. Ubiquitination of Fpn-FLAG is not detected in the 
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Figure 1. Fpn-GFP is ubiquitinated and phosphorylated. (A) HE1C293T cells (stably transfected with an inducible Fpn-GFP) induced to 
express Fpn-GFP (+ponasterone) were incubated in the presence or absence of 1 /ig/ml hepcidin for 15 min. Cells were placed at 0°C and 
solubilized in 1.0% Triton X-100, 150 mM NaCl, 10 mM EDTA, 10 mM Tris, pH 7.4, protease inhibitor mixture, 50 mM iV-ethylmaleimide, 
and protein phosphatase inhibitor set. Samples were irnmunoprecipitated with rabbit anti-GFP antibodies as described in Materials and 
Methods. Immunoprecipitated samples were analyzed by Western blots probing for ubiquitin by using mouse anti-ubiquirin or for 
phosphotyrosine by using mouse anri-phosphotyrosine followed by a peroxidase-conjugated goat anti-mouse IgG as secondary antibody. 
Blots were also probed for Fpn-GFP by using rabbit anti-GFP followed by peroxidase-conjugated goat anti-rabbit IgG as secondary. (B) 
HEK293T cells were induced to express Fpn-GFP with ponasterone for 18 h. Cells were incubated in the presence or absence of 1 /xg/ml 
hepcidin for the indicated rimes, placed at 0°C, and the cell surface was biotinylated using sulfo-NHS-SS-biotin. After biorinylation, cells were 
solubilized as described in A, and the biotinylated proteins were affinity purified using streptavidin affinity gel. The affinity-purified samples 
were analyzed by Western blot using a rabbit anti-GFP followed by peroxidase-conjugated goat anti-rabbit IgG. (C) HEK293T Fpn-GFP cells 
were induced to express Fpn-GFP as described in B. Cells were incubated in the presence or absence of 1 /ig/ml hepcidin for 15 min, placed 
at 0°C, and the cell surface was biotinylated. Biotinylated samples were purified using streptavidin beads as described in B. Affinity-purified 
samples were analyzed by Western blot with mouse anri-phosphotyrosine, mouse anti-ubiquitin followed by a peroxidase-conjugated goat 
anti-mouse IgG as secondary, or Fpn-GFP by using rabbit anti-GFP followed by peroxidase-conjugated goat anti-rabbit IgG as secondary. 
"Control" in the top panel is a mixture of tyrosine-modified proteins purchased from Calbiochem as a control for the anti-phosphotyrosine 
antibody. Flow-through is the sample that did not bind the streptavidin affinity gel (nonbiotinylated Fpn-GFP) but that was subsequently 
immunopurified using rabbit anti-GFP and the immunopurified sample analyzed by Western blot to test for the presence of phosphotyrosine 
or ubiquitin modifications on Fpn-GFP. 
absence of hepcidin, suggesting that this Fpn-FLAG modi-
fication is specific to hepcidin incubation. To determine 
whether Fpn is internalized through clathrin-coated pits, we 
silenced epsin, a protein required for clathrin-mediated en-
docytosis (Chen et at., 1998). Cells expressing Fpn-GFP were 
transfected with nonspecific oligonucleotide pools or pools 
specific to epsin. Depletion of epsin, as shown by Western 
blot analysis (Figure 2C), inhibited hepdicin-mediated Fpn-
GFP internalization and degradation (Figure 2D). These re-
sults indicate that hepcidin-mediated internalization of Fpn-
GFP occurs through clathrin-coated pits. 
Tyrosine phosphorylation of Fpn is a rapid response to 
hepcidin binding, occurring within 15 min of hepcidin ad-
dition (Figure 3A). Phosphorylation of Fpn-GFP was inde-
pendent of the mode of Fpn expression (inducible vs. tran-
sient/CMV) or epitope. Critically, mutants of Fpn that are 
expressed at the cell surface at similar levels to wild type 
bind hepcidin, but they are not internalized [Fpn(N144H)-
GFP] or are internalized at a slower rate than wild type 
[Fpn(Q182H)-GFPJ (De Domenico et al, 2005) showed either 
no phosphorylation or delayed phosphorylation, respec-
tively, supporting the hypothesis that phosphorylation is the 
signal for internalization. There is a large difference in the 
mobility of the protein detected by the anti-phosphotyrosine 
antibody and that of Fpn-GFP, raising the possibility mat the 
phosphoprotein might not be Fpn. Alternatively, phosphor-
ylation might affect Fpn conformation, because the samples 
of Fpn applied to SDS-PAGE are not boiled nor do they 
contain reducing agents; boiling or reducing agents results 
in an inability to detect Fpn. To examine this issue, we 
immunoprecipitated extracts with anti-phosphotyrosine an-
tibody and then probed the immunoprecipitate for Fpn-
GFP. After hepcidin addition, the anti-phosphotyrosine an-
tibody precipitated a high-molecular-mass Fpn-GFP, as 
shown by Western blotting (Figure 3B). The immunoprecipi-
tate was treated with calf intestinal phosphatase, which 
resulted in the detection of Fpn-GFP at a lower molecular 
mass, similar to cells not incubated with hepcidin. Based on 
these results, we conclude that Fpn-GFP is phosphorylated 
after hepcidin treatment. 
Although the topology of Fpn has not been conclusively 
resolved, a working model was proposed by Haile and 
colleagues (Liu et al., 2005). This model suggests that there 
are four tyrosine residues that face the cytosolic surface. We 
mutated each of these residues (227, 302, 303, and 537) 
individually to phenylalanine. The mutated proteins local-
Vol. 18, July 2007 2571 
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Figure 2. Fpn is phosphorylated at the plasma membrane. (A) HEK293T cells were transiently transfected with Fpn-FLAG and either 
Dynamin-GFP or DynaminK44A-GFP. Cells were incubated in the presence or absence of 1 jjg/ml hepcidin for 60 min and processed for 
immunofluorescence using mouse anti-FLAG followed by Alexa 594-conjugated goat anti-mouse IgG (1:750) as secondary antibody. (B) 
HEK293T cells were transiently transfected as described in A. Cells were incubated in the presence or absence of 1 Mg/ml hepcidin as in A, 
extracts obtained as described in Figure 1 and Western blotted for Fpn-FLAG, Dynamin-GFP, and actin (loading control). Extracts were 
immunoprecipitated using anti-FLAG resin (M2), and the immunoprecipitates were examined for the presence of tyrosine phosphorylated 
Fpn-FLAG or ubiquitinated Fpn-FLAG by using mouse anti-phosphotyrosine or mouse anti-ubiquitin antibodies followed by peroxidase-
conjugated goat anti-mouse IgG. (C and D) HEK293T Fpn-GFP cells were transfected with nonspecific (NS) or epsin-specific siRNA 
oligonucleotide pools. After 48 h of incubation, cells were induced to express Fpn-GFP and then 18 h later 1 jig/ml hepcidin was added for 
1 h. The efficiency of epsin depletion was assessed by Western blot analysis using antibodies to epsin. The presence of Fpn-GFP was assessed 
by epifluorescence (C) and Western blot analysis (D). 
ized to the plasma membrane, and they were internalized 
similarly to wild-type Fpn in response to hepcidin (data not 
shown). This result suggests that either the topological 
model is wrong and other tyrosines are cytosolic or that 
multiple tyrosines can be phosphorylated. We then mutated 
multiple tyrosines. We mutated two adjacent tyrosines con-
tained within a putative cytosolic peptide located between 
transmembrane regions VI and VII. The mutant protein 
Fpn(Y302-303F)-GFP, expressed in HEK293T cells, was tar-
geted appropriately to the plasma membrane, but it was not 
internalized in response to hepcidin/ even after 24 h (Figure 
3C). To determine whether the mutant protein was phos-
phorylated, Fpn-GFP or Fpn(Y302-303F)-GFP expressed us-
ing the CMV promoter was immunoprecipitated from cells 
after a brief (15-min) exposure to hepcidin. This brief expo-
sure to hepcidin is not long enough to see significant loss of 
Fpn-GFP. Western blot analysis of the immunoprecipitate 
confirmed the absence of the high-molecular-weight phos-
phorylated species (Figure 3D). Sequence analysis of Fpn 
does not suggest that it is a kinase. A number of potassium 
and chloride channels are tyrosine phosphorylated by a 
nonreceptor tyrosine kinase, usually belonging to the src 
kinase family (Davis et al., 2001). Cells expressing Fpn-GFP 
were incubated with PP2, a src kinase inhibitor. The inhib-
itor did not affect the expression of Fpn-GFP, but it pre-
vented hepcidin-mediated tyrosine phosphorylation, irtter-
2572 Molecular Biology of the Cell 
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Figure 3. Phosphorylation, location, and function of human Fpn mutations. (A) HEK293T cells were transiently transfected with Fpn-GFP, 
Fpn(N144H)-GFP, or Fpn(Q182H)-GFP expressed under a CMV promoter. Cells were incubated in the presence or absence of 1 jxg/ml hepcidin 
for indicated times, solubilized, and immunoprecipitated with rabbit anti-GFP antibodies. Immunoprecipitated samples were analyzed on 
nonreducing 10% SDS-PAGE, and Western blots were probed for either phosphotyrosine by using mouse anti-phosphotyrosine followed by a 
peroxidase-conjugated goat anti-mouse IgG as secondar)' or Fpn-GFP by using rabbit anti-GFP followed by peroxidase-conjugated goat anti-rabbit 
IgG as secondary. (B) HEK293T cells expressing wild-type Fpn-GFP were incubated with and without 1 /xg/ml hepcidin for 15 min. Cell extracts 
were immunoprecipitated with anti-phosphotyrosine antibodies, and the immunoprecipitate was incubated in the presence or absence of calf 
intestinal phosphatase (CIP) for 60 min at 37*>C. The samples were analyzed by SDS-PAGE and Western blot probing for Fpn-GFP. (C) HEK293T 
cells transfected with Fpn-GFP or Fpn(Y302-303F)-GFP were incubated in the presence of 1 ng/ml hepcidin for up to 24 h. Fpn-GFP localization 
was examined by fluorescence microscopy after 4 h of hepcidin incubation, and Fpn-GFP levels were measured by Western blot analysis after 24 h 
of hepcidin incubation. (D) HEK293T cells transfected with Fpn-GFP or Fpn(Y302-303F)-GFP were incubated with hepcidin for 15 min. The cells 
were solubilized, and Fpn-GFP was immunoprecipitated and analyzed by Western blots as described in A. 
nalization, and degradation of Fpn-GFP (Figure 4A). These 
data indicate that phosphorylation of Fpn is required for its 
internalization. Fpn(Y302-303F)-GFP is a functional iron ex-
porter, because expression in iron-loaded cells resulted in 
decreased levels of the iron storage protein ferritin similar to 
wild-type Fpn-GFP (Figure 4B). Addition of hepcidin does 
not, however, prevent iron export as shown by the low level 
of ferritin in Fpn(Y302-303F)-GFP- expressing cells. This re-
sult confirms the conclusion based on human Fpn mutants 
that hepcidin regulates Fpn iron export activity by facilitat-
ing Fpn removal. 
Ubiquitination of Fpn Is Required for Trafficking 
and Degradation 
Once internalized, Fpn is targeted to the lysosome where it 
is degraded (Nemeth et al., 2004). Most membrane proteins 
degraded in the lysosome are trafficked through the MVB 
pathway en route to lysosomes, and entry into the MVB 
typically requires ubiquitination of target proteins (Hurley 
and Emr, 2006). To determine whether ubiquitination is a 
requirement for internalized Fpn to enter the MVB, we took 
advantage of the cell line ts85 that has a temperature-sensi-
tive El-ubiquitin ligase. This cell line cannot add ubiquitin 
to target proteins at the restrictive temperature of 39°C 
(Ikehata et al, 1997). Both wild-type (FM3A) and mutant 
cells (ts85) were transformed with a plasmid containing a 
CMV-regulated Fpn-GFP. Fpn-GFP was found on the cell 
surface at the permissive (Figure 5A) and restrictive temper-
atures (data not shown). Addition of hepcidin to either 
wild-type or ts85 cells led to the internalization of Fpn-GFP 
at both permissive and restrictive temperatures. Fpn was 
degraded in both cell types at the permissive temperature; 
Vol. 18, July 2007 2573 




(TM-VI and -VII), because this loop also contains tyrosines 
302 and 303. Mutation of lysine residues 253, 258, or 269 to 
alanine had no effect on the plasma membrane localization 
of Fpn-GFP or on the ability of the mutated Fpn to be 
internalized and degraded in response to hepcidin (data not 
shown). Mutation of lysine residue 253 resulted in a protein 
that targeted to the cell surface and could be internalized by 
hepcidin (Figure 5B). The mutant protein Fpn(K253A)-GFP 
was degraded at a much slower rate than wild-type protein 
and was found in intracellular vesicles. Fpn(K253A)-GFP 
was phosphoryfated in response to hepcidin, but it was no 
longer ubiquitinated, suggesting that residue 253 is a site for 
ubiquitination (Figure 5C). These results show that ubiquiti-
nation is not required for internalization but that it is re-
quired for degradation. There was a difference in the ap-
pearance of internalized Fpn-GFP in ts85 cells and in 
Fpn(K253A)-GFP in HEK293T cells. We feel that this differ-
ence can be ascribed to the difference in morphology be-
tween the nonadherent ts85 cells and the adherent HEK293T 
cells. 
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Figure 4. Effect of sre kinase inhibitor PP2 on hepcidin-induced 
phosphorylation and internalization of Fpn-GFP. (A) HEK293T Fpn-
GFP-expressing cells were incubated with 100 fjM PP2 for 15 min. 
Hepcidin was added for an additional 20 min, and Fpn-GFP local-
ization was examined by fluorescence microscopy, and tyrosine 
phosphorylation was assayed as on immunoprecipitated Fpn-GFP 
as described in Figure 3. (B) HEK293T cells, transfected with either 
pEGP vector, Fpn-GFP, or Fpn(Y302-303F)-GFP, were incubated 
with or without ferric ammonium citrate (FAC) (10 fjM Fe) for 16 h, 
and the amount of cell-associated ferritin was determined. Iron-
loaded cells expressing Fpn-GFP or Fpn(Y302-303F)-GFP were in-
cubated in the presence of 1 jxg/ml hepcidin for 24 h, and the 
amount of cell-associated ferritin was determined. 
however, at the restrictive temperature Fpn-GFP was de-
graded in wild-type cells, but it was not degraded in ts85 
cells. In ts85 cells, at the restrictive temperature, Fpn-GFP 
accumulated in intracellular vesicles with some present on 
the plasma membrane. 
Haile's model of Fpn topology (Liu et al, 2005) suggests 
that there are 11 lysine residues on the cytosolic surface of 
Fpn that may be sites for ubiquitin addition. We focused our 
attention on the lysines present in the large cytoplasmic loop 
that is between two putative transmembrane (TM) domains 
Fpn Traffics through the MVB En Route to the Lysosome 
Trafficking of plasma membrane proteins to the lysosome is 
dependent on sorting through the MVB (Raiborg et al, 2003; 
Hurley and Emr, 2006). Many proteins involved in sorting 
through the MVB have been identified, and most are asso-
ciated with three complexes that are sequentially recruited 
to the endosomal membrane during MVB formation, endo-
some sorting complex required for transport (ESCRT) I—III 
(Babst et al, 2002a,b; Katzmann et al, 2002). We used RNA 
interference oligonucleotide pools specific to different pro-
teins in the MVB pathway to determine whether degradation 
of Fpn requires trafficking through the MVB. TSG101(Vps23p) is 
a component of the ESCRT-I complex, which is required for 
recognition of ubiquitinated cargos destined for the MVB 
(Garrus et al, 2001; Katzmann et al, 2001). Depletion of 
TSG101 in mammalian cells results in the accumulation of 
epidermal growth factor-epidermal growth factor receptor 
(EGFR) in endocytic compartments (Bishop et al, 2002), and 
deletion of the yeast homologue results in the missorting of 
the vacuolar peptidase carboxypeptidase S (CPS) and the 
formation of a vesicle termed the "class E compartment" 
(Babst et al., 2000). EAP20(Vps25p) is a component of ESCRT-II, 
and ESCRT-II has been shown to bridge ESCRT-I and ES-
CRT-III (Babst et al, 2002b; Teo et al, 2004,2006; Yorikawa et 
al, 2005; Langelier et al., 2006). The absence of ESCRT-II 
components in yeast results in the accumulation of CPS and 
a class E or enlarged MVB compartment (Babst et al, 2002b). 
CHMP6(Vps20p) binds EAP20 and is part of the ESCRT-III 
complex (Teo et al, 2004; Langelier et al, 2006). The absence 
of Vps20p also results in the missorting and accumulation 
of CPS in a class E compartment (Babst et al, 2002a). 
CHMP5(Vps60p) is thought to be a part of the ESCRT-III 
complex, and it has been shown to be involved in trafficking 
EGFR through the MVB/lysosomal pathway (Ward et al, 
2005). Finally, LIP5(Vtalp) is thought to act after ESCRT-III, 
binding and activating the MVB ATPase Vps4 (Scott et al, 
2005; Azmi et al., 2006; Lottridge et al., 2006). LIP5 is in-
volved in trafficking EGFR through the MVB/lysosomal 
pathway (Fujita et al, 2004). siRNA transfection by using 
oligonucleotide pools directed against specific ESCRT pro-
teins did not affect the cell surface localization of Fpn-GFP 
nor hepcidin-mediated internalization (Figure 6A). Deple-
tion of ESCRT-I, ESCRT-II, and ESCRT-III proteins or ESCRT 
III accessory proteins (CHMP5 or LIP5), however, did lead 
to a delay in the degradation of Fpn-GFP, as assessed by 
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ts86 Fpn-GFP DIG 
Figure 5. Ubiquitinatton is required for Fpn-
GFP trafficking to the lysosome. (A) Wild-type 
(FM3A) or mutant cells (ts85) were transfected 
with Fpn-GFP. Cells were then incubated at 
the permissive (33°C) or restrictive (39°C) 
temperature in the presence or absence of 1 
jig/ml hepcidin for 60 min. Cells were exam-
ined by epifluorescence microscopy for the 
localization of Fpn-GFP. (B) HEK293T cells 
were transiently transfected with Fpn-GFP or 
Fpn(K253A)-GFP and grown for 12 h. Cells 
were incubated in the presence or absence of 1 
Mg/ml hepcidin for 60 min at 37°C, and then 
they were examined for the localization of 
Fpn-GFP, and protein levels were assessed by 
Western blot. (C) Cells expressing wild-type 
or Fpn(K253A)-GFP were incubated in the 
presence of 1 /ig/ml hepcidin for 15 min. The 
cells were solubilized, and Fpn-GFP was im-
munoprecipitated as in Figure 1. Immunopre-
cipitates were analyzed by SDS-PAGE and 
Western blot for the presence of Fpn-GFP by 
using rabbit anti-GFP followed by peroxidase-
conjugated goat anti-rabbit IgG or for ubiqui-
tinated or tyrosifte-phosphorylated Fpn-GFP 
by using mouse anti-ubiquitin or mouse anti-
phosphotyrosine antibodies followed by per-
oxidase-conjugated goat anti-mouse IgG. anti-ubiquJtin anti-phosphotyrosine 
Western blot analysis (Figure 6B) with Fpn-GFP accumula-
tion in endocylic vesicles (Figure 6A). The relative amounts 
of Fpn-GFP after hepcidin addition was quantified (Figure 
6C). Protein depletion by specific siRNA oligonucleotide 
pools was assessed by Western analysis using protein-spe-
cific antibodies (Figure 6D). These data demonstrate that 
upon internalization, Fpn-GFP is trafficked through the 
MVB in route to the lysosomes for degradation and that 
efficient degradation requires all three ESCRT complexes as 
well as late-acting accessory factors. 
DISCUSSION 
The relationship between hepcidin and Fpn provides insight 
into mammalian iron homeostasis and its dysregulation. 
Hepcidin-mediated internalization of Fpn results in reduced 
cellular iron export and provides an explanation for the 
regulation of iron absorption and for malregulation of iron 
absorption leading to both iron deficiency and excessive iron 
accumulation (Ganz and Nemeth, 2006). In this study, we 
examined the initial events after the binding of hepcidin to 
Fpn. Our results show that hepcidin induces Fpn phosphor-
ylation, which is critical for internalization (Figure 7A). The 
data that support this conclusion are as follows: 1) Fpn 
tyrosine phosphorylation occurs at the cell surface; 2) Fpn 
tyrosine phosphorylation is not blocked by inhibitors of 
endocytosis; 3) Fpn tyrosine phosphorylation is defective in 
human Fpn mutants N144H and Q182H that are not inter-
nalized or that are internalized slowly; 4) mutation of Fpn 
Y302 and Y303 prevents phosphorylation, and thus Fpn endo-
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Figure 6. Depletion of MVB proteins affects the trafficking and degradation of Fpn-GFP. (A) HEK293T Fpn-GFP cells were transfected with 
siRNA oligonucleotide pools specific for TSG101 (ESCRT I), EAP20 (ESCRT II), CHMP6 (ESCRT III), CHMP5 (ESCRT in), LIP5, nonspecific 
(N.S.), or inverted TSG101 (TNV) by using OligofectAMTNE. Forty-eight hours later, cells were induced to express Fpn-GFP, and after 18 h, 
the cells were incubated in the presence or absence of hepcidin. Cells were examined by confocal microscopy, and the localization of Fpn-GFP 
was determined. (B) Cells treated as described in A were solubilized as in Figure 1, analyzed on SDS-PAGE under nonreducing conditions, 
and VVestem blotted for either Fpn-GFP or actin. (C) Images from A were analyzed using National Institutes of Health ImageJ, and the 
amount of relative fluorescence per cell was determined. The data are expressed as arbitrary fluorescence units per cell, and error bars 
represent the analysis of greater than five fields per sample. (D) To assess silencing, samples from A were applied to SDS-PAGE under 
reducing conditions and analyzed by Western blot by using mouse or rabbit antibodies against TSG101 (T101), EAP20 (E20), CHMP6 (C6), 
CHMP5 (C5), or LIP5 followed by peroxidase-conjugared goat anti-mouse/rabbit IgG. 
cytosis; and 5) inhibitors of sre kinases prevent Fpn-GFP phos-
phorylation and also prevent Fpn-GFP internalization. 
These results show that phosphorylation of either Fpn 
Y302 or Fpn Y303 is an early event after hepcidin binding 
and that it is required for internalization. Phosphorylation of 
Fpn can occur on either of these adjacent tyrosines, because 
mutation of either tyrosine alone has little effect on internal-
ization. This result suggests that only one of the two ty-
rosines needs to be phosphorylated for Fpn internalization. 
We note that phosphorylation of Fpn leads to a decreased 
mobility on SDS-PAGE that is discrepant with the additional 
mass of either one or two phosphates. We feel confident that 
it is Fpn that is phosphorylated and hypothesize that the 
nonboiled protein retains some conformation that is affected 
by phosphorylation. We cannot, however, rule out the pos-
sibility that the migration on SDS-PAGE is due to a protein 
that binds to the phosphorylated residues. The Y302 and 
Y303 residues are adjacent to a potential transmembrane 
segment (Figure 7B), and it is possible that phosphorylation 
results in a significant structural alteration in the protein-
lipid interaction. Furthermore, sequence analysis (ExPASy-
prosite database) suggests that the amino acids surrounding 
the two tyrosines 302-303 may be a src homology 2 domain, 
indicating that the phosphorylated protein could interact 
with a variety of adaptor proteins to effect internalization. 
There is a precedent for tyrosine phosphorylation of mem-
brane transporters/channels leading to either internaliza-
tion or modification of channel function (for review, see 
Davis et ah, 2001). Our data suggest that Fpn, like other ion 
transporters such as potassium and chloride channels, is 
tyrosine phosphorylated by a src kinase. It remains to be 
determined what conformational features in Fpn are altered 
upon binding of hepcidin and how these features recruit a 
nonreceptor tyrosine kinase. Similarly, the nature of the 
structural changes resulting from N144H and Q182H, which 
are predicted to be on a cytoplasmic loop but not the loop 
containing the phosphorylation site are also unknown. Fpn 
is a dimer, and these mutations might affect the conforma-
tion of the multimeric protein (De Domenico et al., 2007; 
Zohn et al., 2007). 
Our data show that ubiquitinarion of Fpn occurs subse-
quently to internalization (Figure 7A). Inhibition of ubiquiti-
nation, through the use of cells with a temperature-sensitive 
El ligase or through site-directed mutagenesis of lysine 
residue K253, leads to the accumulation of Fpn-GFP in in-
tracellular vesicles as well as at the plasma membrane. The 
presence of Fpn-GFP at the plasma membrane may reflect a 
decrease in the internalization of Fpn-GFP, or it may repre-
sent the recycling of Fpn-GFP when it is not ubiquitinated. 
The recycling of membrane proteins back to the plasma 
membrane, if not ubiquitinated, has been demonstrated for 
the EGFR (Grovdal et al., 2004), and it may indicate specific 
sorting of membrane proteins that have been internalized 
but not ubiquitinated. It is of interest that the ubiquitination 
site is on the same large cytosolic loop as the phosphoryla-
tion sites (Figure 72), suggesting that a ubiquitin ligase may 
respond to alterations in Fpn structure or binding partners 
induced by phosphorylation. 
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Figure 7. Model for Fpn internalization and 
degradation. (A) Hepcidin binds Fpn at the 
plasma membrane where Fpn is tyrosine 
phosphorylated. Once Fpn is internalized, the 
phosphates are removed, and Fpn is ubiquiti-
nated, which targets it to the MVB for degra-
dation in the lysosomes. (B) Topology of Fpn 
showing the potential transmembrane domain 
containing the phosphorylation (Y302 and 
Y303) and ubiquitination (K253) sites. 
cytoplasm 
Targeting of most membrane proteins to the lysosome is 
accomplished by their entry into the MVB. Data suggest, 
however, that not all ESCRT subunits are required for 
trafficking through the mammalian MVB. Depletion of 
HRS by siRNA prevents the agonist induced lysosomal 
degradation of 8 opiod receptors, whereas depletion of 
TSG101/ESCRT-I does not prevent 8 opioid receptor 
lysosomal degradation (Hislop et al, 2004). Similarly, 
TSG101/ESCRT I depletion inhibits MHC class I degra-
dation, whereas EAP20/ESCRT-II is not required for ma-
jor histocompatibility complex (MHC)-I receptor down-
regulation (Bowers et al., 2006), although this complex is 
required for efficient degradation of internalized epider-
mal growth factor-receptors (Langelier et ah, 2006). Our 
data demonstrate that trafficking of Fpn-GFP to the lyso-
some goes through the MVB pathway and requires par-
ticipation of all of the ESCRT complexes. Depletion of 
members of ESCRT I, ESCRT II, or ESCRT III complexes 
leads to the accumulation of Fpn-GFP in intracellular 
vesicles and reduced degradation. We note that the block 
on degradation is not absolute, as Fpn-GFP levels do 
decrease with time. Whether the lack of a complete block 
is due to incomplete silencing or to redundancy in ESCRT 
proteins is unresolved. Nevertheless, our studies demon-
strate a role for the MVB pathway in hepcidin-mediated 
degradation of Fpn. 
Many mutations in Fpn cause iron overload disease, 
which has two distinct presentations (Pietrangelo, 2006). 
One form of the disease results from Fpn mutants that are 
unable to reach the plasma membrane (De Domenico et al., 
2005; Schimanski et al, 2005). Cells expressing these Fpn 
mutations are compromised in their ability to export iron 
and show excessive iron accumulation. A second form of the 
disease results from Fpn mutants that are targeted to the 
plasma membrane but do not bind hepcidin or bind hepci-
din and are not internalized (De Domenico et al., 2005; 
Drakesmith et al., 2005). These results confirm that hepcidin 
regulates Fpn-mediated iron export by regulating the con-
centration of Fpn at the plasma membrane and not by af-
fecting the transport activity of Fpn. 
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Structural basis for ESCRT-III protein autoinhibition 
Monika Bajorek1,2, Heidi L Schubert1,2, John McCullough1,2, Charles Langelier1, Debra M Eckert1, 
William-May B Stubblefield1, Nathan T Uter1, David G Myszka1, Christopher P Hill1 & Wesley I Sundquist1 
Endosomal sorting complexes required for transport-Ill (ESCRT-III) subunits cycle between two states: soluble monomers and 
higher-order assemblies that bind and remodel membranes during endosomal vesicle formation, midbody abscission and 
enveloped virus budding. Here we show that the N-termina! core domains of increased sodium tolerance-1 (IST1) and charged 
multivesicular body protein-3 (CHMP3) form equivalent four-helix bundles, revealing that IST1 is a previously unrecognized 
ESCRT-III family member. IST1 and its ESCRT-III binding partner, CHMP1B, both form higher-order helical structures in vitro, and 
IST1-CHMP1 interactions are required for abscission. The IST1 and CHMP3 structures also reveal that equivalent downstream a5 
helices can fold back against the core domains. Mutations within the CHMP3 core-ot5 interface stimulate the protein's in vitro 
assembly and HIV-inhibition activities, indicating that dissociation of the autoinhibitory oc5 helix from the core activates ESCRT-III 
proteins for assembly at membranes. 
The endosomal sorting complexes required for transport (ESCRT) 
pathway functions in a series of important membrane-remodeling 
processes, including multivesicular body vesicle formation at endo-
somal membranes, enveloped virus budding from the plasma mem-
brane and midbody abscission during cytokinesis (reviewed in reft. 1-
4). In performing these functions, ESCRT components cycle between 
two different states: an inactive state, in which they are dispersed 
throughout the cytoplasm, and an active state, in which they are 
recruited to specific membranes by upstream adaptor proteins that 
induce tight membrane binding and component assembly. ESCRT' 
recruitment and assembly ultimately lead to membrane fission, 
producing endosomal vesicles, budded viruses or daughter cells. The 
ESCRT pathway is therefore apparently a mobile machine that can be 
recruited to different membranes to help mediate membrane remo-
deling and fission. 
Most of the approximately 30 proteins of the human ESCRT' 
pathway function as components of one of five different complexes 
(termed the ESCRT-O-III and VPS4 complexes). These complexes are 
recruited sequentially to sites of action, with each successive complex 
recruiting and activating downstream complexes for membrane asso-
ciation and assembly1"4. Recent studies have revealed that subunits of 
the late-acting ESCRT-III complex can form rings, helical filaments 
and tubes in vifro and in vivo. Thus, ESCRT-III complexes may form 
'collars' within the cytoplasm-filled necks of membrane vesicles and 
tubules that can constrict the neck and promote membrane fission5"10. 
Variants of this general model suggest that one specific subset of 
ESCRT-III proteins, those of the CHMP4/Snf7p (Snf7p is a yeast 
CHMP4 homolog) family, may create an encircling ring or spiral, and 
the other ESCRT-III proteins serve primarily to nucleate and cap the 
CHMP4 filament8"10. ESCRT-III proteins also recruit VPS4 ATPases 
and induce them to assemble into active complexes. Enzyme recruit-
ment and activation are further promoted by the accessory factors 
I S T ] i i-i4 a n d L I P 5 ( V t a l p m yeasty^ b o t h o f w h i c h c a n b i n d 
ESCRT-III and VPS4 proteins. Once assembled, VPS4 uses the energy 
of ATP hydrolysis to release the assembled ESCRT-III machinery back 
into the cytoplasm, thereby allowing multiple rounds of membrane 
deformation and fission10. 
The 11 known human ESCRT-M-like proteins can be divided into 
seven different families, six of which (CHMP1-6) correspond to the 
six ESCRT-IH-like proteins of Saccharomyces cerevisiae. Most ESCRT-
III proteins can form both homo- and hetero-oligomers and can pair 
preferentially at membrane sites of action (for example, CHMP4-
CHMP6 and CHMP2-CHMP3)6'15. ESCRT-III proteins vary consi-
derably in primary sequence, but all share common N-terminal core 
domains of ~150 residues. The core domain of one ESCRT-III 
protein, CHMP3a^183, has been crystallized and shown to form a 
four-helix bundle15. The longer first two helices form an extended 
hairpin, and the shorter two helices pack at the open end of the 
hairpin. Sequences located beyond the helical core have autoinhibitory 
activities, and there is now considerable biochemical and genetic 
evidence that these downstream sequences prevent premature mem-
brane binding and assembly6,16*21. Downstream sequence elements 
also bind various late-acting ESCRT factors, including ALIX22 and a 
series of microtubule-interacting and transport (MITJ domain-
containing proteins and enzymes such as ubiquitin hydrolases (for 
example, AMSH and UBPY)23,24, proteases (calpain 7)25,26, ATPases 
(Spastin and VPS4 proteins)21,27"30 and ATPase activators (UP5 
(Vtalp))31"33. Different ESCRT-III subunits have distinct binding 
partner specificities, helping to explain the need for so many different 
ESCRT-III proteins. 
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Figure 1 CHMP3, CHMP3s-222 and IST1NTD 
are monomers in solution, (a-c) Equilibrium 
sedimentation distributions of recombinant 
CHMP3 (a), CHMP38-222 <b) and IST1N TD (C) 
(above), and residual differences (below), with 
data points shown in open symbols and the single 
species models shown as solid lines. Rotor 
speeds were 20,000 r.p.m. and the initial subunit 
protein concentrations are shown. Data sets were 
also collected at 24,000 r.p.m. (not shown) and 
all ot the data were globally fit to single species 
models in which the molecular weights were 
allowed to float during the refinement. Estimated 
. — molecular weights were: CHMP3, 25,840 Da 
Msgg&afta&^^etf1 (molecular weight of the monomer (MWrronomer) = 
J 25,267 Da, / l W * t * c = 1.02); CHMP38-222. 
24,390 Da (MWmonomef = 24,663 Da, J IWMdc 
= 0.99); IST1NTD, 20,520 Da (MWm, 
5.95 6 6.05 6.1 21,791 Da, AW*«feae = 0.94). 
ISTl is a recently identified, late-acting ESCRT pathway factor that 
binds LIP5, VPS4 and CHMP1 (Did2p in yeast)11-14. The precise 
function(s) of ISTl are not well understood and, indeed, ISTl can 
exert both positive11"14 and negative12 effects on ESCRT pathway 
functions. Yeast Istlp has synthetic interactions with the Vtalp--
Vps60p (UP5-CHMP5) complex in endosomal protein-sorting reac-
tions, implying that Istlp functions in the formation of multivesicular 
bodies (MVB), albeit in a non-essential role12,13. Human ISTl 
localizes to midbodies, and its depletion inhibits abscission but not 
HIV budding11,14. ISTl proteins therefore seem to have important 
roles in cytokinesis, auxiliary roles in endosomal protein sorting and 
no essential role in HIV budding. Biochemical and secondary-
structure analyses indicate that ISTl is composed of a helical 
N-terminal domain (residues 1-189, here termed ISTIKTD, but also 
called the 'ELYC domain after a conserved tetrapeptide sequence12), 
C-terminal MIT-interacting motifs (MIM) (residues 321-366) that 
can bind cooperatively to the MIT domains ofVPS4 (refs. 11,14) and 
a central linker region that is predicted to lack persistent secondary 
structure (residues ~190-320)11,14 
Extensive structural and biochemical analyses have revealed many 
of the relevant molecular interactions that allow different ESCRT' 
components to associate with one another, with phosphatidylinositol-
3-phosphate (PI (3)P)-containing membranes and with ubiquitylated 
protein cargoes1-4. In contrast, the mechanisms that regulate ESCRT 
pathway assembly and disassembly are much less well understood. 
Here we have determined crystal structures of the human ISTl and 
CHMP3 proteins. Furthermore, we have performed complementary 
biochemical analyses that characterize the functional importance of 
the IST1-CHMP1 binding interaction in cytokinesis, and we suggest 
how ESCRT-III proteins can switch between their inactive, soluble 
states and their active, membrane-bound assemblies. 
RESULTS 
Characterization of recombinant CHMP3 and ISTl proteins 
We developed methods for expressing and purifying recombinant 
human ISTl and CHMP3 proteins for structural and biochemical 
studies. Full-length CHMP3 and an N-terminally truncated construct 
(CHMP3g-222) were both monomeric in solution, as analyzed 
by equilibrium sedimentation (Fig. la,b), in good agreement with a 
previous report16. Full-length ISTl was also monomeric under high-
ionic-strength conditions (>300 mM NaQ)11, but aggregated at 
lower ionic strength. The purified N-terminal domain of ISTJ 
(ISTINTD) behaved similarly to the full-length protein in that it was 
also monomeric under high-ionic-strength conditions (Fig. lc) and 
insoluble in lower-ionic-strength solutions. This construct was parti-
cularly amenable for structural and biochemical studies, presumably 
because it lacked the proline-rich linker region present in the full-
length protein. 
Crystal structures of I S T 1 N T D 
We crystallized ISTINTD under high-ionic-strength conditions and 
determined the structure in space groups P2X (1.8-A resolution) and 
P^2{1 (2.6-A resolution) (Table 1 and Supplementary Fig. 1). The 
structures were similar, and the higher-resolution P2\ structure is 
described here. ISTINTD is composed of eight helices that pack to 
create a flat, elongated structure, with overall dimensions of 21 x 30 x 
60 A (Fig. 2a). The two longest helices, ocl and a2, form a helical 
hairpin that packs against the smaller a3 and a4 helices to create an 
asymmetric four-helix bundle (termed the 'core'). Beyond the core, 
the segment between helices a4 and oc5 forms a flap that tracks along 
the length of the molecule, packing against the o2-<x3 edge. The flap 
contains two short helices, designated ocA and aB to maintain a 
consistent numbering scheme for conserved ESCRT-III helices. Helix 
ctS packs perpendicularly across helices a l and a2 near the closed end 
of the hairpin and is termed the 'autoinhibitory helix". A final turn 
takes the polypeptide across the hairpin loop and into cc6, which 
projects away from the core. This helix was seen in only the P2\ crystal 
form, where it is stabilized by lattice contacts. As discussed below, 
the ISTI N TD structure seems to represent a closed, autoinhibited 
ESCRT-III conformation in which the flap and autoinhibitory helix 
fold against the core to prevent higher-order interactions. 
ISTINTD bears an unexpected resemblance to the published 
CHMP3g_lfi3 structure16 (Fig. 2a-c), and the four helices of the 
ISTINTD c o r e superimpose with the first four helices of CHMP3 
with an r.m.s. deviation of 2.4 A (128 Ca positions). Muziol et al. 
noted that the al edge of CHMP3 is distinctly cationic and proposed 
that this surface binds membranes16. The equivalent ISTl surface is 
also basic, although the a3-a4 face is even more so (Fig. 2d-f). 
In addition to their similar core structures, the autoinhibitory 
oc5 helices of CHMP3ng3 and ISTINTD sit in equivalent positions 
(Fig. 2a-c oc5, orange). Thus, all of the ordered helices in the 
CHMP3g_]83 structure have analogs in ISTINTD- However, the 
assigned connectivity of the autoinhibitory helices differ between 
the two structures because this helix is connected in cis to the ISTIKTD 
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Table 1 IST l N T D and CHMP3 ciystallographic statistics 
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Native 1 
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core via the flap segment, whereas it was assigned to an adjacent 
molecule in the CHMP3s_i83 lattice10. Muziol et al noted, however, 
that the CHMP38_183 connectivity could not be defined unambigu-
ously owing to a lack of visible electron density for the flap region16. 
We therefore speculate that the CHMP3e_1g3 connectivity may actually 
match that of ISTINTD and t^31 t n e CHMP3g_]83 structure may also 
represent a closed conformation. 
Crystal structures of CHMP3 
The CHMP36_,83 construct lacked the final 39 CHMP3 residues, 
which may have favored an open conformation16. We therefore 
attempted to remove this ambiguity by crystallizing both the ifull-
length monomelic CHMP31_222 protein and a slightly truncated 
CHMP3g_222 protein. Both proteins crystallized isomorphously in 
space group Pl\, but CHMP3g_222 diffracted to slightly higher 
resolution (4.0 A), and this structure is therefore reported (Fig. 2c 
and Table I). We determined the CHMP3g_222 structure by molecular 
Figure 2 Structures of ISTINTD and CHMP3. (a) Ribbon diagram and helix-
labeling scheme for ISTINTD- (b) Overlay of the ordered regions of ISTINTD 
and CHMP38^i83. (c) Ribbon diagram of CHMP3g_222. £d) Space-filling 
model of IST1NTD, color coded to show the surface charge distribution 
(blue, basic; red, acidic; ±7 kV)35 (created using PyMOL (http:// 
pymol.sourceforge.net)). The molecule is shown in the same orientation as 
in a. (e) Same as d with the view toward a l . Figure generated from d by 
rotation about the horizontal so that the bottom edge of d faces the viewer. 
(f} Space-filling model of CHMP38_222 shown in an equivalent orientation to 
the view of IST1NT0 shown in e, emphasizing the basicity of the a l surface 
0fCHMP3(ref. 16). 
replacement, using the core of CHMP3g_ig3 as a search model, and 
then subjected the structure to rigid body refinement. Discernible 
features beyond the search model were limited, but the structure 
solution is supported by the molecular replacement statistics (see 
Online Methods) and by unbiased electron density maps (Supple-
mentary Fig. 2). In addition to the four core helices, density for the 
autoinhibitory helix was evident in unbiased electron density maps, 
particularly for one of the two independent molecules in the asym-
metric unit (Supplementary Fig. 2c,d). Although the connectivity 
between a4 and v.5 was not defined by experimental electron density, 
a « e f ^ 
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a5 seems to sit in the same position in both the CHMP38_ie3 and the 
CHMP3s-222 structures, despite different crystal packing interactions 
in the two lattices. We have connected 0(4 and oc5 in cis rather than in 
trans to create a structure with the same topology as ISTINTD. and this 
assignment is consistent with biochemical analyses described below. 
Finally, we reasoned that a construct corresponding to the CHMP3 
core alone could not adopt an auto inhibited conformation and might 
therefore reveal authentic protein-protein interactions used for 
ESCRT-I1I assembly. We crystallized the CHMP3 core construct 
(CHMP3i_150) in space group P6] and solved the structure by 
molecular replacement (3.7-A resolution; Table 1 and Supplementary 
Fig. 2b). As expected, the CHMPSj .^ core was similar to the cores of 
the other CHMP3 and ISTI^TD structures, although, as described 
below, the lattice interactions were unique. 
Figure 3 CHMP3 crystal packing interactions, 
(a) Overlay of the cores of the tip-to-tip dinners 
in the crystal lattices of CHMP38-1&3 (orange)'6 
and CHMP3s_222 (blue and green). The upper 
subunits were aligned, and the lower subunits 
diverge owing to smalt differences in their tip-to-
tip interfaces, (b) Detailed expansion of the boxed 
region of CHMP38_222 shown in a. Most side 
chains conformations are shown as defined in the 
CHMP3e-i83 search model, with some minor 
adjustments to avoid clashes. Precise description 
of these side chain conformations is not possible 
at current resolutions, (c) Subunit packing down 
the 3] screw axis of the CHMP3i-iso crystal 
lattice, with a single CHMP3]_j50 molecule 
highlighted in blue, (d) Same assembly as in c 
but viewed perpendicularly to the 3i screw axis. 
(e) Detailed expansion of the boxed area shown 
in d. As in b, most side chains conformations are 
shown as defined in the CHMP38-183 search 
model, with some minor adjustments to 
avoid clashes. 
Crystal packing interactions 
We analyzed lattice contacts in the different 
1ST1 and CHMP3 crystal structures to deter-
mine whether they were strong candidates for 
authentic interactions used in ESCRT-OI pro-
tein assembly (see Supplementary Figure 3 for a complete catalog of 
the different lattice interactions). Overall, there are no compelling 
reasons to believe that any of the various crystal contacts re-
present authentic assembly interfaces. Moreover, both of our CHMP3 
structures lacked the 'side-to-side' dimer interface seen in die 
CHMP38_i83 structure16 and postulated as a possible ESCRT-III 
assembly interface6,7. 
Two of the new CHMP3 interfaces merit comment because they are 
mediated by a conserved, exposed hydrophobic surface on the closed 
'tip' of the al-a2 hairpin. In the CHMPg.^ structure, two adjacent 
molecules associate through a small (359 A2) two-fold symmetric 'tip-
to-tip' dimer interface (Fig. 3a,b). A similar tip-to-tip interface was 
also present in the CHMP38_183 lattice16, and this is the only interface 
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• WT = 22±2 
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Figure 4 Mutational analyses of IST1-CHMP1B interactions, (a) Sensorgrams showing different concentrations of purified CHMP1B binding to immobifoed 
GST-IST1NTD. Triplicate measurements in response units (RU) are shown for each CHMP1B concentration, (b) Representative biosensor binding isotherms 
showing CHMPIB binding to wild-type (WT) and mutant GST-IST1NTD proteins with strong (S), intermediate (I) and weak (W) binding affinities. IST1NTD 
mutations and estimated dissociation constants are given in the inset. Errors represent either s.d. from multiple independent measurements {n > 3) or s.d. 
derived from single isotherms measured in triplicate (values in parentheses report the s.d. in the final digit of the measurement), (c) Ribbon diagram showing 
the location of all IST1NTD mutations tested for CHMPIB binding. Mutated residues are shown explicitly, and the binding affinities of the mutant proteins 
are color coded as follows: blue, strong (S) binding (binding affinities within 1.5-fold of wild-type IST1NT0); green, intermediate (I) binding (binding affinity 
reduced 1.5-fold to 8-fold); magenta, weak (W) binding (binding affinity reduced >8-fold). 
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A different type of tip-to-tip interaction is present in the CHMP3n5(, 
lattice. In this case, the interaction lacks two-fold rotational symmetry 
and instead follows a crystallographic 3i screw axis that creates an 
infinite CHMP3]_iso filament with interfaces on both sides of the dp 
(Fig. 3c-e). The yeast homolog of CHMP3 (Vps24p) can assemble 
into three-stranded filaments in vitro7, although the relationship 
between the Vps24p filaments and the crystallographic CHMP3 
filaments remains to be determined. In summary, the crystal packing 
interactions in our IST1 and CHMP3 structures do not obviously 
correspond to authentic biological interfaces, but do reinforce the idea 
that the exposed hydrophobic surface located at the tip of the helix 1-
helix 2 loop is a preferred site for protein-protein interactions6,7,1*. 
I S T I N T D binds CHMP1 proteins 
Many ESCRT-III proteins bind one another, and previous studies have 
shown that the N-terminal domain of IST1 binds preferentially to the 
C-terminal region of the CHMPl subset of ESCRT-III proteins11-". 
To map the IST1 binding surface more precisely, we created an 
ensemble of ISTl proteins with point mutations at conserved, sur-
face-exposed residues and tested them for CHMPlA and CHMPIB 
interactions using: (i) immunoprecipitation reactions in 293T cells 
(not shown), (ii) glutathione S-transterase (GST) pull-down experi-
ments with recombinant proteins (not shown) and (iii) biosensor 
binding experiments in which pure recombinant CHMPlB bound 
immobilized GST-ISTINTD (Fig. 4). 
Figure 5 Requirement for IST1-CHMP1 interactions during abscission. 
(a) Above, quantified abscission defects as reflected in the percentages of 
He La M cells with visible midbodies following siRNA treatment to deplete 
endogenous ISTl (lanes 2-9) and rescue with an empty vector control (lane 
2, negative control) or with vectors expressing wild-type ISTl (lane 3, 
positive control) or the designated ISTl mutants (lanes 4-9). Untreated 
cells are shown in lane 1. Error bars show s.d. from three independent 
repetitions of the experiment. Middle, western blot (anti-ISTl) showing 
levels of soluble endogenous ISTl (lanes 1 and 2) or exogenously expressed 
ISTl proteins (lanes 3-9). Below, a western blot (anti-a-tubulin) showing 
expression levels of endogenous a-tubulin (loading control). CHMPIB 
binding phenotypes of the different ISTl proteins are shown below: strong 
(S), intermediate (I) or weak (W). (b) Immunofluorescence images showing 
the mid body phenotypes of cells from a designated subset of the 
experiments from a. Microtubules (anti-a-tubulin, gray) and nuclei (SYTOX 
Green) were stained for reference, and yellow arrowheads highlight 
midbodies. Scale bars, 10 jim. 
CHMPIB bound wild-type ISTI^TD with an estimated dissociation 
constant of 22 + 2 uM (Fig. 4a,b). CHMPl B binding was unaltered by 
most mutations tested, including mutations within the closed tip of 
the otl-ot2 hairpin (for example, E39A, Y43D, K48D, R51D, I54D and 
R55D) and in the ISTINTD surface that corresponded to the side-to-
side dimer interface seen in the crystal structure of CHMP38_iB3 and 
included the signature 73-ELYCEL278 motif (for example, E70A, 
I.74R, Y75A and L78R). However, one mutation along helix 2 
(E67A) reduced CHMPIB binding in the immunoprecipitation and 
pull-down experiments and lowered the CHMPIB binding affinity 
six-fold in the biosensor binding assay, suggesting that this residue 
contributed to the CHMPlB binding site. We therefore tested muta-
tions in adjacent surface-exposed residues to identify the CHMPlB 
binding site more precisely. Three ISTl mutants bound CHMPlB 
weakly (reductions in affinity of more than eight-fold; IST1Y6«> 
ISTlyjesA and IST1E168R), three bound CHMPlB with intermediate 
affinities (two- to eight-fold reductions; ISTlr^A* I S T I J ^ and 
IST1RI M D ) and one still bound strongly to CHMPIB (IST1EI63R; 
data not shown). 
Given the proximity of the apparent CHMPlB binding site to the 
ISTl autoinhibitory helix a5, we also tested the effects of a series of 
ISTl mutations predicted to destabilize the oc5-core interface (V56D, 
I60D, L166D and I169D). All of these ISTl mutations blocked 
CHMPlB binding entirely (data not shown), indicating that 
CHMPIB binds the closed conformation of ISTl^-rc seen in the 
crystal structures. As summarized in Figure 4c, mutations that 
inhibited CHMPlB binding clustered within or near a groove created 
by packing of autoinhibitory helix oc5 against core helix a2. The 
groove features a pair of exposed tyrosine residues (Tyr64 and Tyrl65) 
that probably contribute to CHMPlB binding. 
The 1ST1-CHMP1B interactions function in cytokinesis 
To determine whether CHMPl binding was necessary for ISTl 
cytokinesis function(s), we tested whether ISTl mutations that 
impaired CHMPlB binding also inhibited abscission. Depletion of 
endogenous ISTl increased the percentage of HeLa cells with visible 
midbodies from 4 ± 1% to 20 ± 3% (Fig. 5a, compare lanes 1 and 2, 
and Fig. 5b, compare image above left with image above middle), 
and this midbody arrest defect was largely (but not entirely) rescued 
by re-expression of a wild-type, small interfering RNA (siRNA)-
resistant ISTl construct (8 ± 2%; Fig. 5a, lane 3, and Fig- 5b, 
above right)11. Midbody arrest was also corrected by an ISTl protein 
with a mutation in the tip of the al-a2 hairpin that retained 
strong (S) CHMPIB binding (ISTlRSir> 8 ± ]%; Fig. 5a, lane 4, 
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OT 350 mM NaCI Y43D 100 mM NaCl Figure 6 IST1NT0 and CHMP1B tube assembly. 
(a) Assembly of wild-type (WT) IST1MTD or three 
different ISTlNTo mutants with the designated 
amino acid substitutions at the tip of the al-a2 
hairpin (mutated residues are underlined in 
Figure 4c). ISTlNTo proteins were diluted from 
concentrated protein stocks in high-salt buffers 
to final concentrations of 62 nM. Salt 
concentrations in the assembly buffers are 
provided in the inset key and protein assembly 
was followed by light scattering at 330 nm. 
(b) TEM images of a subset of the wild-type and 
mutant IST1NTD assembly reactions from a. Note 
that ISTINTD assembled only under low-salt 
conditions (compare upper and middle left 
images) and that IST1NTD proteins with different 
point mutations at the tip of the al-a2 hairpin 
did not assemble in either high-salt (not shown) 
or low-salt conditions (right). An expanded view 
of a single IST1NTD tube is shown in the lower left image. Scale bars. 500 rm. (c) TEM images of CHMP1B tubes assembled under low-salt conditions. 
A field of tubes is shown at left and an expanded view of a single CHMP1B tube is shown at right. Scale bars, 500 nm. 
too mM NaCt 
WT 350 mM NaCI 
Y43D 100 mM NaCI 
Y43D 350 mM NaCI 
R51D 100 mM NaCI 
R51D 350 mM NaCI 
I54D 100 mM NaCI 
I54D 350 mM NaCI 
and Fig. 5b, below left). In contrast, three weakly binding ISTl 
mutants failed to rescue midbody arrest (1R-21%; Fig. 5a, lanes 7-9, 
and Fig. 5b, images below middle and below right). Point mutations 
within the a5-core interface that blocked CHMPlB binding also 
blocked rescue of the midbody arrest defect. However, these 
mutant proteins partitioned almost exclusively into the insoluble, 
membrane-bound cellular fractions, and their failure to support 
abscission may therefore reflect either aberrant CHMP1 binding 
or ISTl protein mislocalization (Supplementary Fig. 4 and Supple-
mentary Discussion). Finally, two ISTl mutants with intermediate (I) 
CHMPlB binding affinities rescued midbody arrest to an inter-
mediate extent (12-13%; Fig. 5a, lanes 5 and 6). Hence, there 
was an excellent correlation between the ability of different ISTll 
constructs to bind CHMPlB in vitro and to function in abscis-
sion, indicating that CHMP1 binding is required for ISTll 
abscission function(s). 
• S T I N T D and C H M P l B form homoporymeric helices in vitro 
CHMP3 can co-polymerize with truncated CHMP2A proteins to form 
helical tubes 50 nm in diameter in vitro6. As noted above, both ISTl 
and ISTINTD became insoluble under low-ionic-strength conditions, 
and we therefore tested whether these proteins assembled into regular 
structures. We initially surveyed assembly conditions using light 
scattering to follow complex formation. Monomelic ISTINTD sponta-
neously polymerized into high-molecular-weight complexes that 
strongly scattered light at 330 nm when the protein was diluted 
from a high-salt buffer (350 mM NaCI) into a low-salt buffer (100 
mM NaCI) (Fig. 6a). In contrast, ISTINTD <"d not scatter light when 
diluted into an otherwise equivalent high-salt buffer (350 mM NaCI). 
EM analyses revealed that the light-scattering ISTINTD assem-
blies were large tubular structures with diameters of ~700 nm 
(Fig. 6b, lower left images). The tubes seemed to be open along one 
edge and may therefore be curled sheets rather than fully closed 
• • < # 5 % ^ 
r& 
Figure 7 CHMP3 activation in vitro, (a) Ribbon 
diagram showing the locations of mutated 
CHMP3 residues at the tip of the ecl-a2 hairpin 
(purple) and activating mutations on either side 
of the interface between the core a2 helix (cyan) 
and the autoinhibitory a5 helix (magenta). The 
red arrow suggests how the closed CHMP3 
conformation might convert into an open 
conformation by dissociation of the autoinhibitory 
a5 helix from the core, (b) GST pull-down 
analyses of the binary CHMP3-CHMP2A 
interaction. Pure recombinant CHMP2A (below, 
anti-CHMP2A) was tested for binding to a 
glutathione-Sepharose matrix (lane 2, negative 
control) or to immobilized wild-type (lane 3) or 
mutant GST-CHMP3 proteins (lanes 4-S). Both 
proteins were detected by western bfotting, and 
input CHMP2A (0.3%) is shown in lane 1 for _ _ _ _ - ^ ^ 
reference, (c) EM analyses of helical CHMP3- % 1 & t ^ S ^ & 3 JBKtH^ - H ^ $ * e ^ ! ! ^ M H H R E i £ I S ^ S P ^ I S S S S t S E I 
CHMP2A assembly. Different panels show 
assemblies formed by 1:1 mixtures of CHMP2A 
with: full length, wild-type CHMP3 (i, negative 
control, no assembly), CHMP3].]5o core domain ' " "' ™ v 
(ii, positive control), activated CHMP3V48D A64D ('"). activated CHMP3|)6BO LI69D (iv), and activated and tip mutant CHMP3V59D V62D neso Li690 (V, no 
assemblies). Arrows highlight rings (1), tubes (2) and cones, or tapered tubes (3). Scale bars, 100 nm. 
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helices. Lattice lines were evident in some assemblies, and the 
clearest lattice spacing was — 440 A, which presumably represents 
a supermolecular spacing because the maximal length of a single 
IST1NTD molecule is only ~60 A. As noted above, CHMP3 
interactions can be mediated by various different kinds of tip-to-
tip interactions6'7 (Fig. 3). A series of three point mutations in the 
analogous ISTl surface (Y43D, R51D and I54D) also inhibited 
ISTINTD polymerization (Fig. 6a,b, right) (see Supplementary 
Fig. 5 for ESCRT-III protein alignments). IST1NTD assembly there-
fore probably also requires some type of tip-to-tip interaction. 
We also attempted to test whether ISTINTD and CHMP1B could co-
polymerize in a manner similar to the CHMP2A9_]6i-CHMP3 pair6. 
However, controls for these experiments revealed that pure recombinant 
CHMP1B alone polymerized into helical tubes when diluted into low-
salt buffers, even in the absence of I S T I ^ - D (Fig. 6c). CHMP1B tubes 
were of intermediate size (~230 nm in diameter), seemed to be fully 
closed and had visible lattice spacing of ~420 A, similar to the lattice 
spacing in the ISTINTD ™bes. Thus, both ISTINTD and CHMP1B, as for 
CHMP2A-CHMP3 (ref. 6), form tubular structures in vitro, and the 
ability to assemble into helical tubes therefore seems to be a property 
common to many ESCRT-III core domains. However, the ISTl and 
CHMP1B tubes were homopolymeric, and they were substantially 
larger than those formed by CHMP2A-CHMP3 heteropolymers6. 
CHMP3 a1-a2 hairpin tip binds CHMP2A 
As with the 1ST1-CHMP1 pair, CHMP2A and CHMP3 bind one 
another preferentially. To investigate this interaction further, we used 
GST pull-down assays to test for binary interactions between 
CHMP2A and GST-CHMP3 (Fig. 7a,b). We performed these experi-
ments at low protein concentrations where higher-order assemblies 
Figure 8 CHMP3 activation in vivo. Hlv-1 vector expression and release 
upon co-expression with an empty vector {negative control, lane 1), or with 
vectors expressing wild-type CHMP3 (negative control, lane 2), a CHMP3]^]5o 
protein lacking the entire autoinhibitory region (positive control, lane 3), 
proteins with activating mutations in the o5-core interface: CHMP3Q68O L169D 
(lane 4) and CHMP3V48D leao L]69D ( |ane 5). The two uppermost western 
blots show cellular expression levels of CHMP3-Myc proteins (panel 1, 
anti-Myc) and of the viral Gag protein and its p4l and CA-processing 
products (panel 2, anti-CA). The western blot below shows levels of released, 
virion-associated CA proteins. The graph shows the infectious titers of HfV-1 
vectors released under the different conditions (infectious units (IU) per ml: 
error bars show s.d. in multiple titer measurements, n > 4). 
were not detectable (35 u.M CHMP2A, ~ 7 uM GST-CHMP3). 
CHMP2A protein bound GST-CHMP3 (Fig. 7b, lane 3) but did not 
bind a matrix control (lane 2). CHMP2A also bound the truncated 
GST-CHMP3,_I50 protein (lane 4), indicating that CHMP2A inter-
acted with the CHMP3 core and that the binary interaction was not 
strongly affected by removal of the terminal CHMP3 autoinhibitory 
sequences. In contrast, a double point mutation (V59D V62D) that 
disrupted the exposed hydrophobic surface on one side of the tip of 
the CHMP3 a l - a2 hairpin eliminated CHMP2A binding (lane 5). 
These data suggest that CHMP2A and CHMP3 interact through a tip-
to-tip interaction and demonstrate that the binary CHMP2A-CHMP3 
and IST1-CHMP1B pain interact via different binding surfaces, and 
therefore form structurally distinct complexes. 
Autoinhibitory helix inhibits CHMP3 polymerization 
Comparative analyses of the IST1NTD> CHMP3g_ie3 and CHMP38_222 
structures suggested a model for ESCRT-III autoinhibition in which 
the a5 helix and flap elements fold back against the protein core to 
prevent higher-order assembly. We tested this idea by introducing 
destabilizing mutations within the a5-core interface of the full-length 
CHMP3 protein and testing their effects on CHMP2A co-assembly. 
Although the full-length CHMP2A and CHMP3 proteins bind one 
another, these two proteins do not readily form higher-order 
helical assemblies6 (Fig. 7cj). In contrast, a CHMP3i_15o protein 
that lacked the flap and autoinhibitory helix readily co-polymerized 
with CHMP2A to form long, regular helical tubes (Fig. 7c4i, positive 
control). As CHMP2A forms binary complexes with both CHMP3 
and CHMPSJ.JSO, these experiments imply that CHMP3 residues 
151-222 inhibit additional interaction(s) required for higher-
order assembly. 
To examine the mechanism of CHMP3 autoinhibition, we mixed 
full-length CHMP2A with full-length CHMP3 proteins that contained 
mutations on either side of the core-o5 interface (CHMP3V4SD A64D 
and CHMP3n68D LI69D> Fig. 7 a ) - Both sets of mutations activated 
CHMP3 for assembly, as reflected in the formation of numerous rings, 
tubes and cones (Fig. 7c,ui,iv). The tubes were similar in diameter 
to those formed in the CHMP2A-CHMP31_150 control reaction 
(~50 nm) but were typically shorter, possibly because the point 
mutations activated CHMP3 proteins less fully than removal of the 
entire autoinhibitory region. 
We also tested whether the binary CHMP2A-CHMP3 interface 
detected at low protein concentrations was required for higher-order 
assembly. As expected, mutations on either side of the CHMP3 
autoinhibitory interface did not substantially affect CHMP2A binding 
to GST-CHMP3 (CHMP3V48D A64D and CHMP3n68D Li69D; Fig. 7b, 
lanes 6 and 7). However, a CHMP3 protein carrying mutations in both 
the tip and autoinhibitory interfaces (CHMP3vs9D V62D H68D H69D) 
could neither bind CHMP2A in the GST pull-down assay (Fig. 7b, 
lane 8) nor assemble into helical tubes (Fig. 7c,v). These experiments 
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imply that tip-to-tip interactions contribute to CHMP2-CHMP3 
co-assembly, in good agreement with a previous study6. 
Mutations in the autoinhibitory helix activate CHMP3 in vivo 
Although co-expression of full-length CHMP3 has only minimal 
effects on HIV-1 budding, truncated CHMP3 constructs lacking the 
C-terminal autoinhibitory elements potently inhibit vims budding, 
presumably because the activated protein sequesters itself and other 
ESCRT-III proteins on cellular membranes20. Inhibition of HrV release 
therefore provides a sensitive assay for CHMP3 activation in vivo. We 
used this system to examine whether mutations in the a5-core 
interface also activate CHMP3 in vivo. Overexpression of full-length 
CHMP3 together with an HIV-1 vector system in 293T cells had little 
effect on the release of viral particles, as measured by the levels of 
virion-associated CA proteins released (Fig. 8, image 3, compare lanes 
1 and 2) or by viral titers (Fig. 8, image 4, compare lanes 1 and 2). In 
contrast, HIV release and infectivity were potently inhibited by co-
expression of a CHMP3 protein that lacked the autoinhibitory region 
entirely (CHMPS^so, positive control, compare lanes 2 and 3, 
"g showing a > 250-fold infectivity reduction). In the actual experiment, 
£ two different CHMP3 proteins with point mutations within the 
« a5-core interface (CHMP3fI68D L169D and CHMP3V48D H6SD u s e ) 
"" reduced HIV vector release and infectivity by 1.7-fold and 3-fold, 
£ respectively (compare lanes 4 and 5 to lane 2). Western blots 
—• confirmed that the full-length CHMP3 proteins and viral Gag proteins 
= and proteolytic processing products were expressed at similar levels 
(images 1 and 2, respectively). Thus, point mutations in the a5-core 
c interface enhanced the ability of CHMP3 proteins to inhibit HTV-D 
aj- budding in vivo, although this enhancement was much weaker than 
~ that seen upon deletion of the entire autoinhibitory region. We 
c presume that die weaker effects seen for die point mutants reflects 
< either incomplete activation and/or their ability to interact with VPS4, 
£ which will reduce their propensity to become 'trapped' on mem-
*g branes, as compared to CHMP31_150 (which lacks a terminal VPS4 




® Our studies have unexpectedly revealed that the N-terminal domain of 
IST1 contains an asymmetric four-helix bundle that closely resembles 
the core of the ESCRT-III protein CHMP3 (Fig. 2). As is true for other 
ESCRT-III proteins, ISTl (i) localizes to midbodies and functions in 
cytokinesis11'14 and MVB vesicle sorting12,13, (ii) binds preferentially 
to another subset of ESCRT-III proteins (the CHMPl proteins)11-14, 
(iii) contains MIM elements near its C terminus that can bind VPS4 
and LIP5 MIT domains11,14 and (iv) can self-assemble into tubular 
structures in vitro (Fig. 6). Thus, despite its larger size and primary 
sequence divergence, ISTl is an ESCRT-III protein family member. 
Despite these similarities, there are also important differences 
between ISTl and CHMP3, particularly in the binary interactions 
that they make with their CHMPl and CHMP2 binding partners. Our 
mutational analyses mapped the CHMPl binding site to a groove 
formed by the autoinhibitory <x5 helix and the core a2 helix of 
ISTINTD (Fig. 4). CHMP1B binding was also inhibited by mutations; 
expected to favor the (hypothetical) open ISTINTD conformation, 
implying that CHMPl binds the closed conformation seen in OUT 
ISTINTD crystal structures (Fig. 2). ISTl mutations that blocked 
CHMP1B binding also prevented ISTl from functioning in abscission, 
implying that these two proteins must act together during this final 
stage of cytokinesis (Fig. 5). In contrast, binary interactions between 
CHMP2 and CHMP3 were not inhibited by mutations that displaced 
or even removed the oc5 helix entirely (Fig. 7). This interaction was 
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sensitive to mutations at the tip of the al-a2 hairpin, however, 
suggesting that, unlike ISTl and CHMPlB, CHMP2 and CHMP3 
probably interact through some sort of a tip-to-tip interaction 
(Kg- 7). 
In vitro assemblies formed by ESCRT-III proteins include filaments, 
rings, cones, curled sheets and tubes6,7 (Figs. 6b,c and 7c). At present, 
we do not know which (if any) of these different in vitro assemblies 
mimic different ESCRT-III assemblies formed in vivo. As noted 
previously5-7, however, filaments, rings and/or tubes could correspond 
to 'collars' within the necks of budding particles, and tapered tubes or 
spiraling cones could provide a mechanism for closing the neck during 
budding6 (Fig. 7c, structure type 3). Although the precise molecular 
interactions that mediate higher-order ESCRT-III assembly remain to 
be determined, both ISTINTD and CHMP2-CHMP3 assemblies are 
inhibited by point mutations within the conserved, exposed hydro-
phobic surface located at the tip of the al-oc2 hairpin (Figs. 6b and 
7c), suggesting that some type of tip-mediated interface forms within 
both assemblies. Two distinct types of homopolymeric ESCRT-III tip-
to-tip interactions have now been seen crystallographically16 (Fig. 3), 
and a third type was inferred from cryo-EM studies of helical yeast 
Vps24 (CHMP3) assemblies7. Thus, the conserved hydrophobic sur-
face at the tip of ESCRT-III proteins is a preferred interaction site, 
although it is not yet clear which, if any, of the tip-to-tip interactions 
characterized to date represent biologically relevant interactions. We 
also note that, although the ISTIRSID tip mutation inhibits ISTl 
assembly (Fig. 6a,b) it does not block the ability of ISTl to function in 
cytokinesis (Fig. 5), implying that there are different requirements for 
ISTl assembly in vitro and abscission function in vivo. Finally, in 
addition to tip contacts, at least one more protein-protein interface is 
required to create two-dimensional surfaces in helices or sheets. These 
secondary interaction(s) are disfavored by C-terminal autoinhibitory 
interactions (ref. 6 and this work) and may correspond to one of the 
several different kinds of higher-order packing interactions that have 
been proposed on the basis of cryo-EM analyses of helical ESCRT-III 
protein assemblies6,7. 
Our ISTINTD structure revealed that the downstream flap and 
autoinhibitory helix can fold back against the ESCRT-III core, and 
this topology was unambiguously established by high-quality electron 
density throughout the flap region (Fig. 2 and Supplementary Fig. 1). 
Analogous models can be built for the CHMP3g_i83 and CHMP3a-222 
structures, although in those cases the connectivity has not been 
established unambiguously. Nevertheless, we suggest that all of these 
structures probably correspond to the closed, autoinhibited ESCRT-III 
conformation, for several reasons: (i) both ISTINTD and CHMP3g_222 
are monomers in solution under the conditions used for crystal-
lization (although IST1NTD polymerizes under low-salt conditions) 
(Fig. 1); (ii) ISTl is redistributed into the insoluble membrane-bound, 
assembled fractions of cellular extracts by mutations that disrupt core 
packing of the autoinhibitory elements (Supplementary Fig. 4); 
(iii) CHMP3 and CHMP2A can be activated for co-assembly by 
deletions that remove the autoinhibitory helices from CHMP2A° or 
CHMP3, or by point mutations that destabilize packing of the 
CHMP3 autoinhibitory helix against the core (Fig. 7); (iv) mutations 
that remove the autoinhibitory helix or destabilize its core packing 
interactions render CHMP3 a dominant inhibitor of HIV-l bud-
ding17,20 (Fig. 8). Nevertheless, there is also good evidence that 
additional contacts beyond those visualized in our ISTINTD o r 
CHMP3 structures help to stabilize the closed CHMP3 conformation 
even further, because point mutations in the autoinhibitory helix-core 
interface do not activate CHMP3 to the same extent as does deletion 
of the entire autoinhibitory region (Figs. 7c and 8), and because short 
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C-terminal deletions downstream of the autoinhibitory o5 helix can 
also enhance ESCRT-III membrane binding and inhibition of HIV-11 
budding, albeit to a lesser extent than deletions that include a5 
{refs. 17,20). These observations indicate that the terminal ESCRT-III 
helix 6 (and possibly also flap sequences) make energetically impor-
tant contacts that favor the closed ESCRT-III conformation. 
In summary, many ESCRT-III proteins can adopt two distinct 
conformational states6,16"21, and our studies provide a molecular 
model for the closed, monomeric state adopted by ESCRT-III proteins 
when they are distributed throughout the cytoplasm (or loosely 
associated with nonspecific membranes)34. Primary sequence and 
secondary-structure analyses indicate that all ESCRT-III proteins 
have analogous a5 helices in equivalent positions, and the mechanism 
of autoinhibition described here is probably quite general (Supple-
mentary Fig. 5a). Surrounding elements can vary substantially in 
sequence, length and secondary structure, however, and they probably 
mediate various protein-protein interactions33. Notably, these differ-
ent protein-protein interactions can be enhanced, inhibited or 
unchanged by mutations that favor the open states of various. 
ESCRT-III proteins (for example, reft. 21,22,28,33). Thus, changes, 
in protein-protein and protein-membrane interactions that accom-
pany ESCRT-III activation and assembly are likely to reflect the 
conformational changes described here, coupled with avidity effects 
created by the assembly of oligomeric ESCRT-III protein arrays. 
METHODS 
Methods and any associated references are available in the online 
version of the paper at http://www.nature.com/nsmb/. 
Accession Codes. Protein Data Bank: Coordinates and structure factor 
amplitudes have been deposited for the two ISTINTO crystal forms 
(3FRR and 3FRS), CHMPs_222 (3FRT) and CHMP3,_]5o (3FRV). 
Note: Supplementary information is available on the Nature Structural & Molecular 
Biology website. 
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ONLINE METHODS 
Expression vectors and antibodies. Vectors and antibodies are summarized m 
Supplementary Tables 1 and 2. 
Protein expression and purification. We expressed 1ST! and CHMP proteins 
in Escherichia coli with N-terminal GST-affinity tags. Protein expression, 
purification and tag removal are described in the Supplementary Methods. 
Equilibrium sedimentation analyses. We centrifuged purified CHMP3, 
CHMP38_222 and ISTINTO in 10 mM Tris-HCl pH 8.0, 100 mM NaCl (CHMP3 
proteins) or 50 mM Tris-HCl pH 7.0, 350 mM NaCl and 1 mM DTT 
(ISTINTD) at 4 °C in an Optima XL-A centrifuge (Beckman). Initial protein 
concentrations are given in Figure la—c Data were collected after equilibrium 
was reached at two speeds (20,000 r.p.m. and 24,000 r.p.m.) in a Beckman An-
60 Ti rotor, and the molecular masses were determined from the resulting sis 
data sets for each protein by globally fitting to single ideal species models using 
the nonlinear least-squares algorithms in the Heteroanah/sis software36. Protein 
partial specific volumes and solvent densities were calculated with the program 
SEDNTERP (version I.09)37. 
Protein crystallization and data collection. We crystallized IST1NTG» 
CHMP3ft_222 and CHMP3i_150 by vapor diffusion at 13 °C IST1NTD crystals 
grew from a 12 mg ml - 1 solution in gel filtration buffer. Crystal form 1 
(diamond-shaped morphology, P432j2, 1 molecule per asymmetric unit) grew 
in 1-3 d by simple dehydration of a 2-ul drop. Crystals were cryoprotected by 
passage through silica oil, suspended in a nylon loop and plunged into liquid! 
nitrogen. Crystal form II (rods and plates, P2j, 1 molecule per asymmetric 
unit) grew from a 1:1 (v/v) mixture of protein and well solution (180 mM KCI, 
50 mM HEPES pH 7.6, 35% pentaethritol propexylate and 7% (v/v) ethylene 
glycol). Crystals were cryo-cooled directly without solution modification. 
Native data for both crystal forms were collected on a Rigaku Micromax 
007HF rotating anode generator equipped with VeriMax-HR optics. 
CHMP3g_222 crystals (flat plates, P2is 2 molecules per asymmetric unit) grew 
from a 1:2 (v/v) mixture of protein (30 m g m r 1 in gel filtration buffer) and well 
solution (10-22% PEG 6000 and 0.1M Na-HEPES pH 7.0-8.0). Data were 
collected at SSRL beamline 11-1. CHMP3,_1So crystals (hexagonal rods, P6t) 
grewfroma 1:1 (v/v) mixture of protein (22 mg ml" J in gel nitration buffer J 
and well solution (16% (v/v) PEG 3350,0.1 M Na HEPES pH 7.0-8.0,200 mM 
proline). Data were collected on a rotating anode generator. Despite extensive 
effort, we were unable to collect better data at the synchronon. Data were 
indexed and scaled with the program HKL2000 (ref. 38) (Table 1). 
Structure determinations. We collected three-wavelength MAD data from 
sdenomethionine-substituted ISTINTD a t SSRL beamline 9-1 to 3.4 A. Three of 
the six potential selenium sites were identified using SOLVE39, and the resulting 
4.0-A phases were solvent flattened and extended to 2.6-A resolution using the 
native data and the program DM40. The four core helices (ctl-ct4) were built 
using O41, and this partial model was used for molecular replacement 
determination of the higher-resolution form II crystal structure using PHA-
SER42. The models were completed with COOT43, refined with REFMAC5 (ref. 
44) and analyzed using programs within the CCP4 suite45. The similar ISTINTD 
structures in the two crystal forms overlapped with an r.m.s. deviation of 1.25 A 
on Ca atoms 12-170. 
We determined both CHMP3 structures by molecular replacement using the 
published CHMP3n 8 3 structure (PDB 2GD5}16 as the search model. The 
correctness of the solutions is supported by PHASER42 Z-scores of 9.1 
(CHMP3e_222) and 8.6 (CHMP3i_iso) and by the appearance of electron 
density when portions of the search model were omitted from the molecular 
replacement calculation (Supplementary Fig. 2). Both structures are hampered 
by low resolution and a correspondingly low number of unique reflections. R(ia. 
sets of 5% contain too few reflections (-~120) to be statistically useful. Aw 
optimal strategy was therefore determined by considering R{m values from 
multiple refinement runs, each starting from the same molecular replacement 
solution and with a different small number ( ~ 200) of reflections in the test set. 
This indicated that the best results were obtained using rigid-body refinement 
in PHENDC46 with each helix treated as a rigid unit. This approach was 
therefore applied to the starting molecular replacement solution but using all of 
the reflections in the calculation (no test set). 
Biosensor binding assays. We used BIACORE2000 and BIACORE3000 instru-
ments (GE Healthcare) to measure the binding of pure recombinant CHMP1B 
to immobilized GST-ISTlt^TD proteins captured from £. coli extracts28, as 
described in Supplementary Methods. 
ISTI depletion and rescue experiments. We transfected HeLa-M cells with 
IST1 expression vectors (1 ug per well, using Lipofectamine 2000, Invitrogen) 
and siRNA (20nM, Lipofectamin RNAi MAX, Invitrogen) following the time 
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CHAPTER 7 
CONCLUSIONS AND FUTURE DIRECTIONS 
The global HIV/AIDS pandemic represents one of the most significant 
afflictions to confront humanity during the past century. Moreover, although very 
significant progress has been made in developing effective combination 
chemotherapies that inhibit viral replication and dramatically extend life 
expectancies, drug resistance is a very significant (and growing) problem (3, 18) 
and little progress has been made in developing an effective preventative 
vaccine against HIV (5). Thus, there remains a need to understand and 
investigate the molecular mechanisms of retroviral pathogenesis, both to identify 
potential new targets for therapeutic intervention and to understand how and why 
immune responses to the virus succeed and fail. Toward this end, the work 
described in this dissertation focused on examining early events in retroviral 
replication and on the mechanisms by which these events can be inhibited by the 
restriction factor TRIM5a. 
TRIM5a Restriction 
Intrinsic immune systems help vertebrates defend against viral infections 
by producing interferon-inducible proteins that can target and disrupt many 
different stages of viral replication (1, 15, 25). The restriction factor, TRIM5a, is 
one such central mediator of intrinsic antiretroviral immunity in primates. TRIM5a 
was identified in 2004 and has been intensively studied in the ensuing past five 
years (2, 9, 10, 16, 17, 22, 23). Nevertheless, several key mechanistic aspects 
of TRIM5cc restriction are still not well understood, and these gaps in our 
understanding provided the motivation for much of my dissertation research. 
A general model for TRIM5oc restriction that encompasses available data 
(including results from this dissertation) is that: 1) dimeric TRIM5oc proteins 
initially recognize incoming viral capsids, 2) capsid recognition leads to higher-
order TRIM5cc assembly, thereby creating more stable complexes through avidity 
effects, 3) capsid binding and assembly induce TRIM5oc auto-ubiquitylation, 
which creates signals that recruit proteasomes, and 4) proteasomal extraction 
and degradation of bound TRIM5cc proteins may destabilize the capsid and 
induce premature capsid dissociation/thereby inhibiting accumulation of reverse 
transcripts (2, 9, 10, 16, 17, 22, 23). 
I have employed biochemical approaches to examine the mechanism of 
TRIM5a restriction. Chapter 2 describes the development of methods for 
expressing and purifying recombinant TRIM5oc proteins, and their biochemical 
characterization. Previous attempts to purify full-length TRIM5oc proteins had 
been hampered by low expression levels and by their tendency to form insoluble 
complexes in both mammalian and E.coli cells. I overcame these problems by 
using an insect cell/baculovirus system to express TRIM5-21R, a chimeric TRIM5 
protein composed primarily of the rhesus TRIM5cc protein, but with the RING 
domain of human TRIM21 protein replacing rhesus TRIM5oc RING domain. This 
substitution increased the cellular half-life of the protein (leading to higher protein 
expression levels), and also increased protein solubility (making the protein 
easier to purify) (4, 8, 9). Importantly, TRIM5-21R retained good restriction 
activity against HIV-1 and other retroviruses that are normally restricted by the 
wild type rhesus TRIM5oc protein (4, 9). TRIM5-21R (and related) proteins were 
purified using a three-stage chromatography scheme, which led to the isolation of 
milligram quantities of highly pure recombinant protein suitable for biochemical 
and structural analyses. 
The oligomeric states of recombinant and native TRIM5-21R and rhesus 
TRIM5oc proteins were characterized using a combination of gel filtration 
chromatography, analytical ultracentrifugation, and chemical crosslinking. These 
studies led to the discovery that TRIM5 proteins are dimers (8, 9), not trimers as 
had been initially reported (14). Our recombinant TRIM5-21R proteins also 
exhibited several additional functional attributes, including ubiquitin E3 ligase 
activity and retroviral capsid recognition. TRIM5-21R bound directly and 
specifically both to purified EIAV cores and to synthetic CA-NC capsid 
assemblies, as analyzed by sedimentation-based in vitro binding assays and by 
electron microscopy. However, interactions between TRIM5-21R proteins and 
isolated CA subunits were not observed in several different types of binding 
assays, implying that tight TRIM5-21R binding requires an intact hexameric 
capsid lattice. High affinity binding appears to involve recognition of the 
conserved lattice spacing found in all mature retroviral capsids, together with 
templated higher order TRIM5a assembly. These properties explain how 
individual TRIM5a isoforms can interact with a variety of different retroviral 
capsids, in spite of the fact that their CA subunits often differ considerably in 
primary sequence. Experimental evidence in support of this capsid recognition 
mode comes from the recent discovery that the B-Box-2 domain mediates 
TRIM5a higher order assembly (10) and from 2D electron crystallography-based 
structural studies, discussed below (Ganser-Pomillos et al., unpublished). 
The development of TRIM5a expression and purification methods was 
undertaken in part to facilitate structural studies of TRIM5oc proteins and their 
complexes with retroviral capsid assemblies. Electron crystallographic analyses 
of 2D crystals formed from TRIM5-21R/CA complexes are now underway in a 
collaborative effort led by Barbie Ganser-Pornillos (University of Virginia, Yeager 
laboratory), Vish Chandrasekaran (Sundquist laboratory), and Owen Pornillos 
(University of Virginia). Our initial findings indicate that TRIM5a proteins can 
assemble into hexameric superlattices upon capsid templates. Intriguingly, the 
unit cell spacing of the hexameric TRIM5-21R lattice (assembled from hexameric 
subunits of TRIM5oc dimers) is four times larger than that of the hexameric CA 
lattice. These results imply that there is a size and symmetry match between the 
TRIM5-21R and CA lattices that may help to nucleate assembly of a TRIM5oc 
cage that entraps cytoplasmic retroviral core particles. TRIM5oc binding and 
assembly then lead to a series of events that likely include TRIM5cc 
autouiquitylation, proteasomal degradation, disruption of capsid integrity and 
inhibition of reverse transcription. 
While the electron crystallographic reconstructions of 2D crystals of 
TRIM5-21R are exciting, resolution is currently limited by the low intrinsic order of 
the crystals. Higher resolution structural studies of TRIM5a: capsid complexes 
will also be important for understanding the details of capsid recognition and for 
explaining how substitution of a single charged amino acid at SPRY domain 
residue 332 can confer HIV-1 restriction ability upon the human TRIM5a isoform 
(20, 24, 26). Conceivably, this understanding could facilitate the design of small 
molecules capable of stabilizing the human TRIM5cc: capsid-binding interface, 
perhaps by mimicking a residue 332 substitution. We note that TRIM5a 
expression and in vitro capsid binding systems like those described in Chapter 2 
could prove useful for screening the efficacy of such compounds. 
Early Events in Lentiviral Replication and the Development 
of Cell-Free Uncoatinq and Restriction Assays 
The early events of uncoating, reverse transcription, and preintegration 
complex formation are critical for viral replication and are targets of restriction, 
but are not yet understood in mechanistic detail. To help remedy this deficiency, 
a cell free assay to study these processes is in development, but not described in 
detail here because the data have not yet been published. In brief, this assay 
involves incubation of purified EIAV core particles with soluble cell extracts, 
dNTPs and an ATP regeneration system, followed by analysis of reverse 
transcription and capsid dissociation. This cell free retroviral replication assay 
will provide a potentially valuable tool for second-generation studies aimed at 
dissecting the processes of reverse transcription, capsid uncoating and retroviral 
restriction in greater detail. For example, the system could provide an assay for 
identifying and characterizing new cellular factors that influence retroviral 
replication and restriction as they are purified by fractionation of cell extracts. 
Candidate factors purified in this fashion could then be verified functionally using 
IP and siRNA depletion experiments performed in vitro and in vivo. 
We also envision that the assay can form the basis for reconstitution of 
additional stages of the retroviral life cycle in vitro. For example, it is possible that 
this assay could be adapted to reconstitute the activity of APOBEC3G, a cytidine 
deaminase that also functions as a potent retroviral restriction factor. In this case, 
restricting APOBEC3G proteins would need to be expressed in the cells used to 
produce the EIAV core particles because APOBEC3G is incorporated into virions 
as they assemble, but then exerts its effects when the genome is reverse 
transcribed in the new host cell (11-13, 19, 21). It will also be of interest to 
determine whether or not full length reverse transcripts produced in vitro form 
integration-competent PICs. Gaining the ability to study these processes in vitro 
would also be a significant step forward because we currently lack a 
comprehensive understanding of PIC composition, activity and nuclear 
targeting/import. 
Finally, it would be of interest to modify this cell free system to examine 
the early lifecycle events of other retroviruses, particularly HIV-1. Such studies 
would, of course, have more direct relevance to human pathology, and would 
also allow us to take advantage of the large body of information and reagents 
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available for HIV-1, including well characterized CA mutants, known HIV-specific 
host replication factors like cyclophilin-A, and specific inhibitors of early stages of 
the HIV life cycle including reverse transcription and integration (6, 7). In 
principle, an HIV assay could also be used to screen for new pharmaceutical 
inhibitors capable of targeting additional steps in the HIV-1 lifecycle, including 
uncoating, reverse transcription or PIC formation. In short, the development of a 
new system for studying lentiviral replication and restriction in a cell free system 
has opened up new research opportunities whose ultimate impact will depend, in 
large part, on just how expandable and general this system proves to be. 
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